WO2022031736A1 - Substituted pyridine derivatives as sarm1 inhibitors - Google Patents

Substituted pyridine derivatives as sarm1 inhibitors Download PDF

Info

Publication number
WO2022031736A1
WO2022031736A1 PCT/US2021/044389 US2021044389W WO2022031736A1 WO 2022031736 A1 WO2022031736 A1 WO 2022031736A1 US 2021044389 W US2021044389 W US 2021044389W WO 2022031736 A1 WO2022031736 A1 WO 2022031736A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazol
pyridin
methyl
propanamide
chlorophenyl
Prior art date
Application number
PCT/US2021/044389
Other languages
French (fr)
Inventor
Jennifer Aiden Kozak
Sean Pomeroy BROWN
Christopher Michael Tegley
Alexander Wayne Schammel
Liusheng Zhu
Maximiliano DE LA HIGUERA MACIAS
Shilpa SAMBASHIVAN
Original Assignee
Nura Bio, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nura Bio, Inc. filed Critical Nura Bio, Inc.
Priority to US18/019,452 priority Critical patent/US20230339913A1/en
Priority to EP21763435.1A priority patent/EP4192828A1/en
Publication of WO2022031736A1 publication Critical patent/WO2022031736A1/en
Priority to US18/481,173 priority patent/US11970481B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS FIELD OF THE INVENTION This disclosure is drawn to compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing a neurological disorder.
  • BACKGOUND OF THE INVENTION Aging constitutes the main risk factor for the development of neurodegenerative diseases. Axonal degeneration is an important pathological event in many neurodegenerative and neurological disorders, including peripheral neuropathy and traumatic brain injury (Gerdts, J. et al., Neuron, 2016, 89, 449–60).
  • Axonal degeneration has also been implicated in, for example, Alzheimer’s disease, Parkinson’s disease and Amyotrophic Lateral Sclerosis, where degeneration precedes symptom onset and widespread neuronal loss (Kurowska, Z. et al., J. Parkinson’s Dis., 2016, 6, 703–07). While these neurological conditions have unique underlying etiologies, inhibition of axonal degeneration in the conditions’ early stages may slow or prevent their progression by preventing the loss of functional synapses and maintaining neuronal connectivity (Essuman, K. et al., Neuron, 2017 Mar.22, 93(6), 1334-43).
  • Wallerian degeneration after injury occurs both toward the proximal cell body (termed retrograde degeneration) and toward the distal axon terminal (termed Wallerian or orthograde degeneration) (Kanamori A. et al., Am. J. Pathol. 2012 Jul; 181(1):62-73).
  • Wallerian degeneration which occurs in that section of the axon that is distal to the site of injury, occurs after axonal injury in both the peripheral nervous system (PNS) and the central nervous system (CNS). Wallerian degeneration usually begins within 24–36 hours of a lesion.
  • axonal degeneration constitutes an early event in pathological processes and provides a potential therapeutic target to treat neurodegeneration prior to neuronal cell death (Salvadores, N. et al., Front. Neurosci., 2017, 11, 451).
  • the present invention is directed to inhibitors of SARM1 such as a compound of Formula Ia, Ib, Ic, or Id: Ic Id or a pharmaceutically acceptable salt thereof, wherein constituent members are defined herein.
  • the present invention is further directed to a pharmaceutical composition comprising a compound of Formula Ia, Ib, Ic, or Id, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
  • the present invention is further directed to a method of inhibiting SARM1 comprising contacting the SARM1 with a compound of Formula Ia, Ib, Ic, or Id, or a pharmaceutically acceptable salt thereof.
  • the present invention is further directed to a method of inhibiting axonal degeneration in a patient in need thereof comprising administering to the patient an inhibiting amount of a compound of Formula Ia, Ib, Ic, or Id, or a pharmaceutically acceptable salt thereof.
  • the present invention is further directed to a method of treating or preventing a neurological disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Formula Ia, Ib, Ic, or Id, or a pharmaceutically acceptable salt thereof.
  • the present invention is further directed to use of a compound of Formula Ia, Ib, Ic, or Id, or a pharmaceutically acceptable salt thereof, in treating or preventing a neurological disorder in a patient in need thereof.
  • the present invention is further directed to a compound of Formula Ia, Ib, Ic, or Id, or a pharmaceutically acceptable salt thereof, for use in the preparation of a medicament for treating or preventing a neurological disorder in a patient in need thereof.
  • DETAILED DESCRIPTION Similar to programmed cell death pathways (e.g., apoptosis), axonal degeneration in response to injury or disease stimulates a local signaling cascade that causes destruction of the injured axon segment (Summers D.
  • SARM1 sterile alpha and TIR motif-containing 1 protein (NP_055892) is a 724 amino acid protein involved in axon degeneration.
  • the SARM1 protein also known as FLJ36296, KIAA0524, MyD88-5, SAM domain-containing protein 2, and SAMD2, comprises four domains, i) a mitochondrial localization signal, ii) an auto-inhibitory N-terminus region consisting of armadillo/HEAT motifs, iii) two sterile alpha motifs responsible for multimerization, and iv) a C-terminus Toll/Interleukin-1 receptor that possesses enzymatic activity (Essuman K., et al., Neuron 2017 Mar., 93(6):1334- 43.e5). SARM1 protein plays a critical role in the Wallerian degeneration pathway.
  • SARM1 Activation of SARM1 triggers a rapid collapse of NAD + levels in the distal section of the injured axon, which then undergoes degeneration (Gerdts J. et al., Science 2015 Apr.348(6233):453-57). Promoting dimerization of the Toll/interleukin receptor (TIR) domain of SARM1 has been shown to be sufficient to promote NAD + loss and axon degeneration. SARM1’s activity is responsible for, at least in part, the protective nature of the survival factor NMNAT2, as NMKNAT enzymes have found to prevent SARM1- mediated depletion of NAD + .
  • TIR Toll/interleukin receptor
  • SARM1 pro-degeneration signaling pathways
  • MAPK signaling has been shown to promote the loss of NMNAT2, which promotes SARM1 activation (See, e.g., Yang J. et al., Cell 2015 Jan 160(1-2):161-76).
  • SARM1 is involved in the innate immune response. It promotes neuronal cell death in response to stress and other stimuli.
  • SARM1 acts as a negative regulator of TICAM1/TRIF-dependent Toll-like receptor signaling by inhibiting induction of TLR3- and TLR4-dependent genes, which play a pivotal role in activating axonal degeneration following injury.
  • SARM1 specifically blocks TICAM1/TRIF-dependent transcription factor activation and gene induction, without affecting the MYD88- dependent pathway or non-TLR signaling. It is also a negative regulator of NF- kappa-B and IRF activation. (See, e.g., Summers, D.W. et al., J Neurosci., 2014 Jul 9, 34(28):9338-50).
  • the present invention provides inhibitors (e.g., small molecules) of SARM1.
  • SARM1 activation is known to cause a rapid reduction in NAD + levels in injured axons, which then undergo degeneration.
  • the compounds inhibit axonal degeneration, including axonal degeneration that results from reduction or depletion of NAD + (e.g., inhibition of SARM1 NADase).
  • SARM1 such as a compound of Formula Ia, Ib, Ic, or Id: Ic Id or a pharmaceutically acceptable salt thereof, wherein: A is N or N + -O-; Q 1 and Q 2 are each independently selected from CH and N; W is O, S, or NR N ; is a single, double, or triple bond; wherein when the bond between X and Y is a single bond, then: X is CR 5 R 6 , NR 7 , or O and Y is CR 8 R 9 , NR 10 , O, S, SO, or SO 2 , wherein when X is NR 7 or O, then Y is CR 8 R 9 ; wherein when the bond between X and Y is a double bond, then: X is CR
  • the compound of Formula Ia, Ib, Ic, or Id is other than or .
  • the compound has a structure according to Formula Ia.
  • the compound has a structure according to Formula Ib.
  • the compound has a structure according to Formula Ic.
  • the compound has a structure according to Formula Id.
  • A is N.
  • A is N + -O-.
  • one of Q 1 and Q 2 is CH and the other is N.
  • Q 1 is CH and Q 2 is N.
  • Q 1 is N and Q 2 is CH.
  • Q 1 is CH and Q 2 is N.
  • both Q 1 and Q 2 are CH. In some embodiments, both Q 1 and Q 2 are N.
  • W is O or S. In some embodiments, W is O. In some embodiments, W is S. In some embodiments, is a single bond. In some embodiments, is a double bond. In some embodiments, is a triple bond.
  • X is CR 5 R 6 . In some embodiments, X is NR 7 . In some embodiments, X is O. In some embodiments, Y is CR 8 R 9 . In some embodiments, Y is NR 10 . In some embodiments, Y is O. In some embodiments, Y is S, SO, or SO 2 .
  • Ring Z is C 6-10 aryl or 5-10 membered heteroaryl. In some embodiments, Ring Z is C 6-10 aryl. In some embodiments, Ring Z is phenyl. In some embodiments, Ring Z is 5-10 membered heteroaryl. In some embodiments, Ring Z is 5-6 membered heteroaryl. In some embodiments, Ring Z is pyridyl, pyrimidinyl, thienyl, thiazolyl, isoxazolyl, or pyrrazolyl. In some embodiments, Ring Z is C 3-7 cycloalkyl. In some embodiments, Ring Z is cyclohexyl or cyclopentyl.
  • Ring Z is selected from the following (a)-(k): ( ( .
  • m is 0 or 1.
  • m is 0.
  • m is 1.
  • R 1 is halo, C 1-4 alkyl, or C 1-4 alkoxy.
  • R 1 is halo, C 1-4 alkyl, or C 1-4 alkoxy.
  • R 1 is F, methyl, or methoxy.
  • R 2 , R 2A , and R 2B are each independently selected from H, halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxy, and C 3-7 cycloalkyl.
  • R 2 and R 2A are each independently selected from halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxy, and C 3-7 cycloalkyl.
  • R 2 , R 2A , and R 2B are each independently selected from H, Cl, Br, methyl, ethyl, trifluoromethyl, methoxy, cyclopropyl, and hydroxymethyl. In some embodiments, R 2 , R 2A , and R 2B are each independently selected from Cl, Br, methyl, ethyl, trifluoromethyl, methoxy, cyclopropyl, and hydroxymethyl. In some embodiments, R 2 and R 2A are each independently selected from H, Cl, Br, methyl, ethyl, trifluoromethyl, methoxy, cyclopropyl, and hydroxymethyl. In some embodiments, R 2B is H.
  • n is 0, 1, or 2. In some embodiments, n is 0 or 1. In some embodiments, n is 0. In some embodiments, each R 4 is independently halo, nitro, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, or C 1-4 haloalkoxy. In some embodiments, each R 4 is independently F, Cl, Br, I, CN, NO 2 , methyl, ethyl, CF 3 , CHF 2 , OCF 3 , or OCHF 2 . In some embodiments, each R 4 is independently halo. In some embodiments, each R 4 is independently F or Cl.
  • two adjacent R 4 together with the atoms to which they are attached form a fused phenyl ring, C 3-7 cycloalkyl ring, 5-7 membered heteroaryl ring, or 4-7 membered heterocycloalkyl ring, each optionally substituted with 1, 2, or 3 substituents independently selected from oxo, halo, nitro, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl, C 1-4 alkoxy, and C 1-4 haloalkoxy.
  • two adjacent R 4 together with the atoms to which they are attached form a fused phenyl ring or 4-7 membered heterocycloalkyl ring. In some embodiments, two adjacent R 4 together with the atoms to which they are attached form a fused phenyl ring or 5-6 membered heterocycloalkyl ring. In some embodiments, two adjacent R 4 together with the atoms to which they are attached form a fused phenyl ring. In some embodiments, two adjacent R 4 together with the atoms to which they are attached form a fused 4-7 membered heterocycloalkyl ring.
  • R 5 and R 6 are each independently selected from H, F, NH 2 , and OH. In some embodiments, one of R 5 and R 6 is H and the other is selected from H, F, NH 2 , and OH. In some embodiments, R 5 and R 6 are both H. In some embodiments, each R 7 is independently selected from H and C 1-4 alkyl. In some embodiments, each R 7 is independently selected from H and methyl. In some embodiments, R 7 is H. In some embodiments, R 8 and R 9 are each independently selected from H and methyl.
  • R 8 and R 9 are both H.
  • R 3 and R 5 together with the atoms to which they are attached and together with any intervening atoms, form a C 5-7 membered cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, and C 1-4 haloalkoxy.
  • R 3 and R 7 together with the atoms to which they are attached and together with any intervening atoms, form a C 5-7 membered cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, and C 1-4 haloalkoxy.
  • R 3 and R 8 together with the atoms to which they are attached and together with any intervening atoms, form a C 5-7 membered cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, and C 1-4 haloalkoxy.
  • R 3 and R 10 together with the atoms to which they are attached and together with any intervening atoms, form a C 5-7 membered cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, and C 1-4 haloalkoxy.
  • R 4 and R 9 together with the atoms to which they are attached and together with any intervening atoms, form a C 5-7 membered cycloalkyl ring fused with ring Z or a 5-7 membered heterocycloalkyl ring fused with ring Z, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, and C 1-4 haloalkoxy.
  • R 5 and R 9 together with the atoms to which they are attached form a C 3-7 cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted with 1, 2 or 3 substituents independently selected from oxo, halo, NH 2 , OH, CN, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, and C 1-4 haloalkoxy.
  • R 5 and R 10 together with the atoms to which they are attached form a 5-7 membered heterocycloalkyl ring optionally substituted with 1, 2 or 3 substituents independently selected from oxo, halo, NH 2 , OH, CN, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, and C 1-4 haloalkoxy.
  • R 8 , R 9 , and R 10 are each independently selected from H and C 1-4 alkyl.
  • R 10 is selected from H and C 1-4 alkyl.
  • R 10 is H.
  • the compound has Formula IIa: IIa.
  • the compound has Formula IIb: .
  • the compound has Formula IIIa: IIIa.
  • the compound has Formula IIIb: IIIb.
  • C 1-6 alkyl is specifically intended to individually disclose methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl.
  • aryl, heteroaryl, cycloalkyl, and heterocycloalkyl rings are described. Unless otherwise specified, these rings can be attached to the rest of the molecule at any ring member as permitted by valency.
  • pyridinyl “pyridyl,” or “a pyridine ring” may refer to a pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl ring.
  • n-membered typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is “n”.
  • piperidinyl is an example of a 6-membered heterocycloalkyl ring
  • pyrazolyl is an example of a 5-membered heteroaryl ring
  • pyridyl is an example of a 6-membered heteroaryl ring
  • 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
  • each variable can be a different moiety independently selected from the group defining the variable.
  • the two R groups can represent different moieties independently selected from the group defined for R.
  • the phrase “optionally substituted” means unsubstituted or substituted.
  • substituted means that a hydrogen atom is replaced by a non-hydrogen group. It is to be understood that substitution at a given atom is limited by valency.
  • Ci-j where i and j are integers, employed in combination with a chemical group, designates a range of the number of carbon atoms in the chemical group with i-j defining the range.
  • C1-6 alkyl refers to an alkyl group having 1, 2, 3, 4, 5, or 6 carbon atoms.
  • alkyl employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chain or branched. In some embodiments, the alkyl group contains 1 to 7, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n- pentyl, 2-methyl-1-butyl, 3-pentyl, n-hexyl, 1,2,2-trimethylpropyl, n-heptyl, and the like.
  • the alkyl group is methyl, ethyl, or propyl.
  • alkenyl employed alone or in combination with other terms, refers to an alkyl group having one or more carbon-carbon double bonds.
  • the alkenyl moiety contains 2 to 6 or 2 to 4 carbon atoms.
  • Example alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n- butenyl, sec-butenyl, and the like.
  • alkynyl employed alone or in combination with other terms, refers to an alkyl group having one or more carbon-carbon triple bonds.
  • Example alkynyl groups include, but are not limited to, ethynyl, propyn-1-yl, propyn-2-yl, and the like.
  • the alkynyl moiety contains 2 to 6 or 2 to 4 carbon atoms.
  • halo or “halogen”, employed alone or in combination with other terms, includes fluoro, chloro, bromo, and iodo. In some embodiments, halo is F or Cl.
  • haloalkyl employed alone or in combination with other terms, refers to an alkyl group having up to the full valency of halogen atom substituents, which may either be the same or different. In some embodiments, the halogen atoms are fluoro atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
  • Example haloalkyl groups include CF 3 , C 2 F 5 , CHF 2 , CCl 3 , CHCl 2 , C 2 Cl 5 , and the like.
  • alkoxy employed alone or in combination with other terms, refers to a group of formula -O-alkyl.
  • Example alkoxy groups include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy, and the like.
  • the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
  • haloalkoxy employed alone or in combination with other terms, refers to a group of formula -O-(haloalkyl).
  • the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
  • An example haloalkoxy group is -OCF 3 .
  • amino employed alone or in combination with other terms, refers to NH 2 .
  • cycloalkyl employed alone or in combination with other terms, refers to a non-aromatic cyclic hydrocarbon including cyclized alkyl and alkenyl groups. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3, or 4 fused, bridged, or spiro rings) ring systems.
  • cycloalkyl moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane, cyclohexene, cyclohexane, and the like, or pyrido derivatives of cyclopentane or cyclohexane. Ring-forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo. Cycloalkyl groups also include cycloalkylidenes.
  • cycloalkyl also includes bridgehead cycloalkyl groups (e.g., non-aromatic cyclic hydrocarbon moieties containing at least one bridgehead carbon, such as admantan-1-yl) and spirocycloalkyl groups (e.g., non- aromatic hydrocarbon moieties containing at least two rings fused at a single carbon atom, such as spiro[2.5]octane and the like).
  • the cycloalkyl group has 3 to 10 ring members, or 3 to 7 ring members.
  • the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is monocyclic.
  • the cycloalkyl group is a C 3-7 monocyclic cycloalkyl group.
  • Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, tetrahydronaphthalenyl, octahydronaphthalenyl, indanyl, and the like.
  • the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • heterocycloalkyl employed alone or in combination with other terms, refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene or alkynylene groups as part of the ring structure, which has at least one heteroatom ring member independently selected from nitrogen, sulfur, oxygen, and phosphorus.
  • Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused, bridged, or spiro rings) ring systems.
  • the heterocycloalkyl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen.
  • moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the non-aromatic heterocycloalkyl ring, for example, 1,2,3,4- tetrahydro-quinoline and the like.
  • Heterocycloalkyl groups can also include bridgehead heterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least one bridgehead atom, such as azaadmantan-1-yl and the like) and spiroheterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least two rings fused at a single atom, such as [1,4-dioxa-8-aza-spiro[4.5]decan-N-yl] and the like).
  • the heterocycloalkyl group has 3 to 10 ring-forming atoms, 4 to 10 ring-forming atoms, or about 3 to 8 ring forming atoms.
  • the heterocycloalkyl group has 2 to 20 carbon atoms, 2 to 15 carbon atoms, 2 to 10 carbon atoms, or about 2 to 8 carbon atoms. In some embodiments, the heterocycloalkyl group has 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 heteroatoms, or 1 to 2 heteroatoms.
  • the carbon atoms or heteroatoms in the ring(s) of the heterocycloalkyl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized.
  • the heterocycloalkyl portion is a C 2-7 monocyclic heterocycloalkyl group.
  • the heterocycloalkyl group is a morpholine ring, pyrrolidine ring, piperazine ring, piperidine ring, tetrahydropyran ring, tetrahydropyridine, azetidine ring, or tetrahydrofuran ring.
  • aryl refers to a monocyclic or polycyclic (e.g., a fused ring system) aromatic hydrocarbon moiety, such as, but not limited to, phenyl, 1-naphthyl, 2-naphthyl, and the like. In some embodiments, aryl groups have from 6 to 10 carbon atoms or 6 carbon atoms. In some embodiments, the aryl group is a monocyclic or bicyclic group. In some embodiments, the aryl group is phenyl or naphthyl. In some embodiments, the aryl group is phenyl.
  • heteroaryl refers to a monocyclic or polycyclic (e.g., a fused ring system) aromatic hydrocarbon moiety, having one or more heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
  • the heteroaryl group is a monocyclic or a bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen.
  • Example heteroaryl groups include, but are not limited to, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, pyrrolyl, azolyl, quinolinyl, isoquinolinyl, benzisoxazolyl, imidazo[1,2-b]thiazolyl or the like.
  • the carbon atoms or heteroatoms in the ring(s) of the heteroaryl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized, provided the aromatic nature of the ring is preserved.
  • the heteroaryl group has from 3 to 10 carbon atoms, from 3 to 8 carbon atoms, from 3 to 5 carbon atoms, from 1 to 5 carbon atoms, or from 5 to 10 carbon atoms.
  • the heteroaryl group contains 3 to 14, 4 to 12, 4 to 8, 9 to 10, or 5 to 6 ring-forming atoms.
  • the heteroaryl group has 1 to 4, 1 to 3, or 1 to 2 heteroatoms.
  • the compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated.
  • Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis.
  • Cis and trans geometric isomers of the compounds of the present invention may be isolated as a mixture of isomers or as separated isomeric forms.
  • Compounds of the invention also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge.
  • Example prototropic tautomers include ketone – enol pairs, amide - imidic acid pairs, lactam – lactim pairs, enamine – imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole.
  • Compounds of the invention also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include tritium and deuterium.
  • the compounds of the invention include at least one deuterium atom.
  • the term, “compound,” as used herein is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted, unless otherwise specified.
  • the term “compound” is also not limited by the way in which it was made.
  • a compound of the invention includes molecules that were made by a synthetic process or by a biological process (such as through enzyme conversion or metabolism), or combinations thereof. All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g., in the form of hydrates and solvates) or can be isolated.
  • the compounds of the invention, or salts thereof are substantially isolated.
  • substantially isolated is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected.
  • Partial separation can include, for example, a composition enriched in the compounds of the invention.
  • Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of a compound of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
  • phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • the present invention also includes pharmaceutically acceptable salts of the compounds described herein.
  • pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
  • Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts of the present invention include the non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two.
  • compositions of the invention can inhibit the activity of SARM1.
  • the compounds of the invention can be used to inhibit activity or a function of SARM1 in a cell or in an individual or patient in need of inhibition of the enzyme by administering an inhibiting amount of a compound of the invention to the cell, individual, or patient.
  • the term “in a cell” includes both inside the cell membrane and on the surface of the cell membrane.
  • Compounds of the invention can increase levels of NAD+ in a cell. Accordingly, the present invention is further directed to a method of increasing the level of NAD+ in a sample or in a patient, comprising contacting the sample or administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the increased level of NAD+ is relative to the level of NAD+ prior to the contacting or administering.
  • Compounds of the invention, as SARM1 inhibitors can inhibit axonal degeneration.
  • the present invention is further directed to a method of inhibiting axonal degeneration in a sample or in a patient, comprising contacting the sample or administering to the patient an inhibiting amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
  • the compounds of the invention are useful in the treatment and prevention of various diseases associated with abnormal expression or activity of SARM1.
  • the compounds of the invention are useful in the treatment and prevention of neurological disorders.
  • the term "neurological disorder” generally refers to a disorder affecting the nervous system, including the central nervous system or the peripheral nervous system.
  • the term “neurological disorder” also includes ocular indications having a nexus to the nervous system.
  • the neurological disorder treatable or preventable by administration of a compound of the invention includes neurodegenerative diseases.
  • Neurodegenerative diseases are characterized by damage to the central nervous system and can be identified by progressive dysfunction, degeneration and death of specific populations of neurons which are often synaptically interconnected. Examples of neurodegenerative diseases include Parkinson’s disease (PD), Alzheimer’s disease (AD), Huntington’s disease (HD), prion disease, motor neuron diseases (MND), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), and epilepsy.
  • Parkinson’s disease PD
  • AD Alzheimer’s disease
  • HD Huntington’s disease
  • MND motor neuron diseases
  • SCA spinocerebellar ataxia
  • SMA spinal muscular atrophy
  • ALS amyotrophic lateral sclerosis
  • Examples of neurological disorders treatable or preventable according to the methods of the invention include spinal muscular atrophy (SMA), Chemotherapy Induced Peripheral Neuropathy (representative chemotherapeutic agents include vinca-alkaloids, taxols and platins), multiple sclerosis (MS), traumatic brain injury (TBI), spinal cord injury, stroke, Parkinson’ disease, glaucoma, Huntington’s disease, Alzheimer’s disease, Charcot-Marie-Tooth disease (CMT), retinitis pigmentosa (RP), age-related macular degeneration (AMD), small fiber neuropathies, peripheral neuropathy (e.g., viral neuropathy), spinocerebellar ataxias, cystic fibrosis, familial amyloidotic polyneuropathy, spongiform encephalopathies, spinal and bulbar muscular atrophy, hereditary dentatorubral-pallidoluysian atrophy, adrenoleukodystrophy, adrenomyeloneuropathy, Alexander
  • the neurological disorder treatable or preventable by administration of a compound of the invention is a neuropathy.
  • the term “neuropathy” refers broadly to diseased conditions of the nervous system, including polyneuropathy; neuropathy, ataxia, and retinosa pigmentosa (NARP); familial amyloid neuropathies; diabetic neuropathy (peripheral neuropathy due to diabetes mellitus); peripheral neuropathy (e.g., chemotherapy-induced peripheral neuropathy (CIPN), including CIPN caused by vinca alkaloids, bortezomib, lxabepilone, thalidomide and its analogs, taxanes, and platinum-based agents); and cranial neuropathy (e.g., auditory neuropathy and optic neuropathy).
  • CIPN chemotherapy-induced peripheral neuropathy
  • cranial neuropathy e.g., auditory neuropathy and optic neuropathy
  • the term also includes other neuropathies associated with genetic disorders (e.g., NMNAT2 genetic mutation disorders).
  • the neurological disorder treatable or preventable by administration of a compound of the invention is an ocular neuropathy (e.g., optic neuropathy).
  • optic neuropathy refers to damage to the optic nerve from a number of causes.
  • optic neuropathy examples include ischemic optic neuropathy (e.g., anterior and posterior ischemic optic neuropathy); optic neuritis (e.g., chronic relapsing inflammatory optic neuropathy (CRION), single isolated optic neuritis (SION), and relapsing isolated optic neuritis); compressive optic neuropathy; infiltrative optic neuropathy; traumatic optic neuropathy; mitochondrial optic neuropathies; and hereditary optic neuropathies (e.g., Leber’s hereditary optic neuropathy (LHON), hereditary neuropathy with liability to pressure palsy (HNPP), and dominant optic atrophy).
  • ischemic optic neuropathy e.g., anterior and posterior ischemic optic neuropathy
  • optic neuritis e.g., chronic relapsing inflammatory optic neuropathy (CRION), single isolated optic neuritis (SION), and relapsing isolated optic neuritis
  • compressive optic neuropathy e.g., infiltrative optic neuropathy; traumatic optic neuropathy; mitochondrial optic
  • the neurological disorder treatable or preventable by administration of a compound of the invention is multiple sclerosis (MS), chemotherapy-induced peripheral neuropathy (CIPN), amyotrophic lateral sclerosis (ALS), glaucoma, traumatic brain injury (TBI), or stroke.
  • MS multiple sclerosis
  • CIPN chemotherapy-induced peripheral neuropathy
  • ALS amyotrophic lateral sclerosis
  • TBI traumatic brain injury
  • the term “cell” is meant to refer to a cell that is in vitro, ex vivo or in vivo.
  • an ex vivo cell can be part of a tissue sample excised from an organism such as a mammal.
  • an in vitro cell can be a cell in a cell culture.
  • an in vivo cell is a cell living in an organism such as a mammal.
  • the term “contacting” refers to the bringing together of indicated moieties in an in vitro system or an in vivo system.
  • “contacting” SARM1 or “contacting” a cell with a compound of the invention includes the administration of a compound of the present invention to an individual or patient, such as a human, having SARM1, as well as, for example, introducing a compound of the invention into a sample containing a cellular or purified preparation containing SARM1.
  • the phrase “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
  • the phrase “inhibiting amount” refers to the amount of active compound or pharmaceutical agent that elicits a measurable SARM1 inhibition or axonal degeneration in a tissue, system, animal, individual or human.
  • treating refers to 1) inhibiting the disease in an individual who is experiencing or displaying the pathology or symptomatology of the disease (i.e., arresting further development of the pathology and/or symptomatology), or 2) ameliorating the disease in an individual who is experiencing or displaying the pathology or symptomatology of the disease (i.e., reversing the pathology and/or symptomatology).
  • preventing or “prevention” refers to preventing the disease in an individual who may be predisposed to the disease but does not yet experience or display the pathology or symptomatology of the disease.
  • the invention is directed to a method of preventing a disease in a patient, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
  • Combination Therapy One or more additional pharmaceutical agents or treatment methods can be used in combination with the compounds of the present invention.
  • the agents can be combined with the present compounds in a single dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.
  • additional agents include acamprosate, agomelatine, almotriptan, amantadine, amisulpride, amitriptyline, apomorphine, aripiprazole, asenapine, atomoxetine, baclofen, botulinum toxin type A, bromocriptine, buccal midazolam, buprenorphine, buspirone, cabergoline, carbamazepine, chlordiazepoxide, chlorpromazine, citalopram, clobazam, clomethiazole, clomipramine, clonazepam, clozapine, denzapine, co-beneldopa, co-careldopa, dantrolene, dexamfetamine, diazepam, divalproex sodium, donepezil, doxepin, duloxetine, eletriptan, entacapone, epinephrine, escita
  • compositions When employed as pharmaceuticals, the compounds of the invention can be administered in the form of pharmaceutical compositions.
  • a pharmaceutical composition refers to a combination of a compound of the invention, or its pharmaceutically acceptable salt, and at least one pharmaceutically acceptable carrier. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated.
  • Administration may be oral, topical (including ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), ocular, or parenteral.
  • This invention also includes pharmaceutical compositions which contain, as the active ingredient, one or more of the compounds of the invention above in combination with one or more pharmaceutically acceptable carriers.
  • the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container.
  • the excipient when it serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
  • the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10 % by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
  • the compositions can be formulated in a unit dosage form.
  • unit dosage form refers to a physically discrete unit suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
  • the active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
  • the principal active ingredient is mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention.
  • a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention.
  • the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • This solid pre-formulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of the present invention.
  • the tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
  • compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
  • the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • compositions can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.
  • the amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications.
  • compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
  • the therapeutic dosage of the compounds of the present invention can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician.
  • the proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration.
  • the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration.
  • Some typical dose ranges are from about 1 ⁇ g/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day.
  • the dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration.
  • Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
  • the invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of non-critical parameters which can be changed or modified to yield essentially the same results.
  • the compounds of the Examples were found to be inhibitors of SARM1 according to one or more of the assays provided herein.
  • Step 1 Dimethyl 2-(4-chlorobenzyl)-2-fluoromalonate.
  • a solution of dimethyl 2-fluoromalonate (2.0 g, 9.7 mmol, 1.2 equiv) in anhydrous DMF (12 mL, 0.68 M) was cooled to 0 °C and was treated with sodium hydride (60 wt % dispersion in mineral oil, 320 mg, 8.1 mmol, 1.0 equiv). The resulting suspension was stirred at 0 °C for 1 h.
  • Step 2 Methyl 3-(4-chlorophenyl)-2-fluoropropanoate.
  • Step 2 5-Methyl-1-(pyridin-4-yl)-1H-pyrazol-4-amine: A mixture of 4-(5- methyl-4-nitro-1H-pyrazol-1-yl)pyridine (170 mg, 0.83 mmol), iron powder (70 mg, 1.3 mmol, 1.5 equiv), and ammonium chloride (130 mg, 2.5 mmol, 3.0 equiv) in ethanol–water (5:1, 6.0 mL, 0.14 M) was stirred at reflux for 3 h. The mixture was cooled to rt and then filtered.
  • Step 1 4-(4-Nitro-1H-pyrazol-1-yl)pyridine: A mixture of 4-bromopyridine (1.0 g, 6.4 mmol, 1.0 equiv), 4-nitro-1H-pyrazole (720 mg, 6.4 mmol, 1.0 equiv), copper(I) iodide (120 mg, 0.64 mmol, 1.0 equiv), and potassium carbonate (1.8 g, 13 mmol, 2.0 equiv) in DMF (20 mL, 0.32 M) was stirred at 110 °C for 16 h. The reaction mixture was cooled to rt and filtered.
  • Step 2 4-(5-Chloro-4-nitro-1H-pyrazol-1-yl)pyridine: To a stirred solution of 4-(4-nitro-1H-pyrazol-1-yl)pyridine (500 mg, 2.6 mmol, 1.0 equiv) in anhydrous THF (10 mL, 0.26 M) was added LiHMDS (1 M in THF, 3.0 mL, 3.0 mmol, 1.1 equiv) at –70 °C. After the addition, the mixture stirred at rt for 30 min, then hexachloroethane (450 ⁇ L, 4.0 mmol, 1.5 equiv) was added dropwise at –70 °C.
  • Step 3 5-Chloro-1-(pyridin-4-yl)-1H-pyrazol-4-amine: A mixture of 4-(5- chloro-4-nitro-1H-pyrazol-1-yl)pyridine (290 mg, 1.3 mmol, 1.0 equiv), iron powder (360 mg, 6.5 mmol, 5.0 equiv), and ammonium chloride (700 mg, 13 mmol, 10 equiv) in EtOH (20 mL, 0.065 M) was heated at 80 °C for 5 h. The reaction mixture was cooled to rt and filtered.
  • Step 2 tert-Butyl 3-(4-cyano-3,5-difluorophenyl)propanoate: To a mixture of tert-butyl (E)-3-(4-cyano-3,5-difluorophenyl)acrylate (3.2 g, 12 mmol) and cobalt(II) chloride hexahydrate (300 mg, 1.3 mmol, 10 mol %) in methanol (50 mL, 0.24 M) was added sodium borohydride (2.3 g, 60 mmol, 5.0 equiv) slowly at 0 °C. After the addition, the suspension stirred at 0 °C for 2 h.
  • Step 3 3-(4-Cyano-3,5-difluorophenyl)propanoic Acid: To a solution of tert-butyl 3-(4-cyano-3,5-difluorophenyl)propanoate (1.9 g, 7.1 mmol) in DCM (20 mL) was added TFA (4.2 g, 37 mmol, 5.2 equiv) dropwise at 0 °C. After the addition, the solution was stirred for 2 h at 0 °C. The mixture was concentrated in vacuo and the resulting residue was treated with ammonia in methanol (7 M) to adjust to pH 8, then concentrated in vacuo.
  • TFA 4.2 g, 37 mmol, 5.2 equiv
  • Step 1 tert-Butyl (E)-3-(4-chloro-3,5-difluorophenyl)acrylate.
  • Step 1 5-(5-Chloro-2,3-dihydro-1H-inden-1-ylidene)-2,2-dimethyl-1,3- dioxane-4,6-dione.
  • An oven-dried flask was charged with titanium(IV) tetrachloride (230 mg, 1.2 mmol 2.0 equiv) and was dissolved in THF (3.0 mL, 0.20 M).
  • Step 3.2-(5-Chloro-2,3-dihydro-1H-inden-1-yl)acetic acid A solution of 5- (5-chloro-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1,3-dioxane-4,6-dione (7.0 mg, 0.020 mmol, 1.0 equiv) in 1,4-dioxane (250 ⁇ L, 0.080 M) was treated with 6 M HCl (60 ⁇ L) and the resulting mixture was heated to 100 °C for 12 h. The reaction mixture was then cooled to rt and extracted with EtOAc (3 x 10 mL).
  • Step 2 3-(Pyridin-4-yl)-1H-pyrazol-5-amine.
  • methyl 3-methylisonicotinate 500 mg, 3.3 mmol, 1.0 equiv
  • anhydrous THF 40 mL, 0.083 M
  • n- butyllithium 2.5 M in hexanes, 2.0 mL, 5.0 mmol, 1.5 equiv
  • Step 2 4-Methyl-3-(3-methylpyridin-4-yl)-1H-pyrazol-5-amine
  • 2-methyl-3-(3-methylpyridin-4-yl)-3-oxopropanenitrile 1.9 g, 11 mmol, 1.0 equiv
  • hydrazine hydrate 85% w/w in water, 3.7 g, 63 mmol, 5.7 equiv
  • ethanol 20 mL, 0.55 M
  • Step 1 4-(4-Nitro-1H-pyrazol-1-yl)pyridine: A mixture of 4-bromopyridine (1.0 g, 6.4 mmol, 1.0 equiv), 4-nitro-1H-pyrazole (0.72 g, 6.4 mmol, 1.0 equiv), CuI (120 mg, 0.64 mmol, 0.10 equiv), and potassium carbonate (1.8 g, 13 mmol, 2.0 equiv) in anhydrous DMF (20 mL, 0.30 M) was stirred at 110 °C under nitrogen gas for 16 h. The reaction was then cooled to rt and filtered.
  • 4-bromopyridine 1.0 g, 6.4 mmol, 1.0 equiv
  • 4-nitro-1H-pyrazole (0.72 g, 6.4 mmol, 1.0 equiv
  • CuI 120 mg, 0.64 mmol, 0.10 equiv
  • potassium carbonate 1.8 g, 13 mmol, 2.0 equiv
  • Step 2 1-(Pyridin-4-yl)-1H-pyrazol-4-amine: A mixture of 4-(4-nitro-1H- pyrazol-1-yl)pyridine (600 mg, 3.1 mmol, 1.0 equiv), iron powder (960 mg, 17 mmol, 5.4 equiv), and ammonium chloride (930 mg, 17 mmol, 5.4 equiv) in ethanol (10 mL, 0.30 M) was stirred at 100 °C. After 2 h, the mixture was filtered and the filtrated was concentrated in vacuo to give 1-(pyridin-4-yl)-1H-pyrazol-4-amine (500 mg, 99 % yield) as a yellow solid.
  • 4-(4-nitro-1H- pyrazol-1-yl)pyridine 600 mg, 3.1 mmol, 1.0 equiv
  • iron powder 960 mg, 17 mmol, 5.4 equiv
  • ammonium chloride 930 mg, 17 mmol, 5.4 e
  • Step 2 Ethyl 5-amino-3-(pyridin-4-yl)-1H-pyrazole-4-carboxylate.
  • ethanol 500 mL, 0.20 M
  • hydrazine hydrate 5.7 g, 110 mmol, 1.1 equiv
  • triethylamine 11 g, 100 mmol, 1.0 equiv
  • reaction mixture was quenched carefully by adding 1.0 mL of water dropwise, followed by 3.0 M aqueous NaOH (1.0 mL), and another 1.0 mL of water.
  • the mixture was filtered and the solid was washed a 1:5 solution of MeOH:DCM (3 ⁇ 60 mL).
  • the filtrate was collected and concentrated in vacuo, then purified directly by silica gel column chromatography (10% MeOH in DCM + 5% ammonia) to obtain (5- amino-3-(pyridin-4-yl)-1H-pyrazol-4-yl)methanol (300 mg, 61 % yield) as a light yellow solid.
  • Step 1 Ethyl 3-(4-chlorophenyl)-2,2-difluoro-3-hydroxypropanoate.
  • the reaction mixture was then cooled to rt, and an aqueous solution of HCl (2.0 M, 4.0 mL, 2.0 equiv) was added.
  • Step 1 4-Chloro-3,5-difluorobenzaldehyde.
  • 5- bromo-2-chloro-1,3-difluorobenzene 4.5 g, 20 mmol, 1.0 equiv
  • LiCl 850 mg, 20 mmol, 1.0 equiv
  • isopropylmagnesium chloride 1.0 M solution in THF, 22 mL, 22 mmol, 1.1 equiv
  • Step 2 (4-Chloro-3,5-difluorophenyl)methanol.
  • 4- chloro-3,5-difluorobenzaldehyde 3.4 g, 13 mmol, 1.0 equiv
  • methanol 40 mL, 0.33 M
  • sodium borohydride 1.1 g, 30 mmol, 2.3 equiv
  • Step 5 (rac)-Methyl 3-(4-chloro-3,5-difluorophenyl)-2-fluoropropanoate.
  • DMSO dimethyl 2-(4-chloro-3,5-difluorobenzyl)-2-fluoromalonate
  • LiCl 650 mg, 15 mmol, 4.8 equiv
  • water 10 mL
  • the appropriate amine (A, R2’ is H or an amino protecting group like Boc) (1.0 equiv) (neat or in a DMF solution (1.0– 1.8 M) is added and the reaction was warmed to rt (if at 0 °C) and was stirred for 5 min–16 h.
  • reaction mixture is concentrated and purified directly by silica gel column chromatography or RP-HPLC (either Method A: MeCN in H 2 O + 0.1% TFA, or Method C: MeCN in H 2 O + 10 mM NH 4 HCO 3 + 0.025% NH 3 ⁇ H 2 O) to afford the desired amides (C) as either trifluoroacetic acid salts (Method A) or as the parent compound (silica gel column chromatography or Method C).
  • Method A MeCN in H 2 O + 0.1% TFA
  • Method C MeCN in H 2 O + 10 mM NH 4 HCO 3 + 0.025% NH 3 ⁇ H 2 O
  • GENERAL PROCEDURE #2 Step 1: A solution of amine (e.g., see Intermediate #3) (1.0 equiv) in anhydrous DMF (0.21 M) is treated with NaH (60 wt % dispersion in mineral oil, 1.2 equiv) for 0.5 h at 0 °C. Subsequently, acid chloride (A) (1.2 equiv) is added to the mixture. After stirring for 1 h at rt, a saturated aqueous solution of NH 4 Cl is added. The mixture is extracted with EtOAc (2 ⁇ 10 mL). The organic fractions are filtered over Na2SO4 and concentrated in vacuo to afford the desired compound (B) as a crude product.
  • amine e.g., see Intermediate #3
  • NaH 60 wt % dispersion in mineral oil, 1.2 equiv
  • acid chloride (A) 1.2 equiv
  • a saturated aqueous solution of NH 4 Cl is added.
  • the mixture
  • Step 2 A mixture of N-SEM protected pyrazole (B) (1.0 equiv) and TFA (2.0 mL) in DCM (0.07 M) are stirred at rt for 5 min to 1 h. The reaction mixture is concentrated in vacuo. The crude material is purified by RP-HPLC (Method A or Method C). Fractions containing the desired mass are combined and concentrated by lyophilization to afford pyrazole (C) as the desired product.
  • GENERAL PROCEDURE #4 To a mixture of carboxylic acid A (1.0 equiv) in anhydrous DCM (x-x M) is added oxalyl chloride (1.5–3.0 equiv) and one drop of anhydrous DMF at 0 °C. After the addition, the mixture is warmed to rt and stirred for 1 h. The solution is then concentrated in vacuo to afford crude product B. This material is used without further purification.
  • EXAMPLE 14 3-(4-Chlorophenyl)-N-(4-ethyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide
  • the product was prepared according to General Procedure #1 using Intermediate 4 and 3-(4-chlorophenyl)propanoic acid to give the desired product, 3- (4-chlorophenyl)-N-(4-ethyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (31 mg, 0.079 mmol, 30% yield) as a white solid.
  • Step 1 (rac)-3-(4-Chlorophenyl)-2-fluoro-N-(4-methyl-3-(pyridin-4-yl)-1- ((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)propenamide.
  • the product was prepared according to General Procedure #1 using Intermediate 2 and Intermediate 5 to give the desired product (rac)-3-(4-chlorophenyl)-2-fluoro-N-(4-methyl-3-(pyridin- 4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)propanamide (400 mg, 0.82 mmol, >95% crude yield, 65% purity) as an oil.
  • EXAMPLE 34 3-(4-Ethylphenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide
  • the product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-ethylphenyl)propanoic acid to afford 3-(4-ethylphenyl)-N-(4- methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide (20% yield).
  • EXAMPLE 38 3-(6-Chloropyridin-3-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
  • the product was prepared according to General Procedure #1 using Intermediate 1 and 3-(6-chloropyridin-3-yl)propanoic acid to afford 3-(6- chloropyridin-3-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 26% yield.
  • EXAMPLE 46 3-(4-Iodophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide
  • the product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-iodophenyl)propanoic acid to afford 3-(4-iodophenyl)-N-(4- methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 72% yield.
  • EXAMPLE 56 3-(4-(Fluoromethyl)phenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide N
  • the product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-(fluoromethyl)phenyl)propanoic acid to afford 3-(4- (fluoromethyl)phenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 26% yield.
  • EXAMPLE 60 3-(2-Fluoropyrimidin-5-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide 3
  • the product was prepared according to General Procedure #1 using Intermediate 1 and 3-(2-fluoropyrimidin-5-yl)propanoic acid to afford 3-(2- fluoropyrimidin-5-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 10% yield.
  • EXAMPLE 64 3-(4-Chloro-3-fluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
  • the product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-chloro-3-fluorophenyl)propanoic acid to afford 3-(4-chloro-3- fluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 42% yield.
  • Step 2 Ethyl N-(tert-butoxycarbonyl)-N-(4-chlorophenyl)glycinate: To a solution of tert-butyl (4-chlorophenyl)carbamate (500 mg, 2.2 mmol, 1.0 equiv) in DMF (5.0 mL, 0.44 M) was added sodium hydride (60 wt % dispersion in mineral oil, 100 mg, 2.6 mmol, 60% in mineral oil, 1.2 equiv) at 0 °C.
  • Step 3 N-(tert-Butoxycarbonyl)-N-(4-chlorophenyl)glycine: A mixture of N-(tert-butoxycarbonyl)-N-(4-chlorophenyl)glycinate (400 mg, 1.3 mmol, 1.0 equiv), lithium hydroxide monohydrate (270 mg, 6.4 mmol, 4.9 equiv) in a solution of ethanol (10 mL, 0.13 M) and water (5.0 mL, 0.26 M) was stirred at rt for 6 h.
  • the reaction was concentrated in vacuo to remove ethanol, then the residual aqueous phase was diluted with water (10 mL) and washed with ethyl acetate (2 ⁇ 10 mL). The aqueous fraction was separated, and treated with a 1.0 M aqueous solution of HCl to adjust to pH 5 ⁇ 6. This solution was then extracted with ethyl acetate (3 ⁇ 20 mL).
  • Step 1 3-(4-Chlorophenyl)-2,2-difluoro-N-(4-methyl-3-(pyridin-4-yl)-1- ((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)propanamide.
  • the product was prepared according to General Procedure #1 using Intermediate 2 and Intermediate 26 to afford 3-(4-chlorophenyl)-2,2-difluoro-N-(4-methyl-3-(pyridin-4- yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)propanamide (30 mg, 0.059 mmol, 59%) as a light yellow oil which was carried forward without further purification.
  • the product was prepared according to General Procedure #3 using 3-(4-chlorophenyl)-2,2-difluoro-N-(4-methyl-3-(pyridin-4-yl)-1- ((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)propanamide to afford 3-(4- chlorophenyl)-2,2-difluoro-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide (12 mg, 0.032 mmol, 54%) as a white solid.
  • EXAMPLE 110 3-(4-Chlorophenyl)-N-(4-methyl-3-(3-methylpyridin-4-yl)-1H-pyrazol-5- yl)propenamide
  • the product was prepared according to General Procedure #1 using Intermediate 20 and 3-(4-chlorophenyl)propanoic acid to afford 3-(4-chlorophenyl)- N-(4-methyl-3-(3-methylpyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 33% yield.
  • Step 2 4-Methoxy-3-(pyridin-4-yl)-1H-pyrazol-5-amine.
  • a mixture of crude 2-methoxy-3-oxo-3-(pyridin-4-yl)propanenitrile (200 mg, 1.1 mmol, 1.0 equiv) and hydrazine hydrate (210 mg, 3.7 mmol, 3.2 equiv) in EtOH (10 mL, 0.11 M) was stirred at 80 °C for 3 h. The mixture was concentrated in vacuo.
  • Step 4 3-(4-Chlorophenyl)-N-(4-methoxy-3-(pyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)propenamide.
  • Step 5 3-(4-chlorophenyl)-N-(4-methoxy-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide.
  • the product was prepared according to General Procedure #3 to afford 3-(4-chlorophenyl)-N-(4-methoxy-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide (12 mg, 0.034 mmol, 23% yield) as a white solid.
  • the product was prepared according to General Procedure #1 using 4-cyclopropyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine and 3-(4- chlorophenyl)propanoic acid to afford 3-(4-chlorophenyl)-N-(4-cyclopropyl-3- (pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (20 mg, 0.054 mmol, 22% yield) as a white solid.
  • reaction mixture was then cooled to rt and purified directly by silica gel column chromatography (100% EtOAc) to afford N-[5- chloro-1-(pyridin-4-yl)-1H-pyrazol-4-yl]-3-(3-chlorophenyl)propanamide (4.8 mg, 0.010 mmol, 45% yield) as a white solid.
  • reaction mixture was diluted with EtOAc (20 mL) and a saturated aqueous solution of NH 4 Cl (20 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (3 ⁇ 10 mL). The combined organic fractions were washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo.
  • Step 2 3-(4-Cyano-3,5-difluorophenyl)-N-(3-(pyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy) methyl)-1H-pyrazol-5-yl)propenamide.
  • EXAMPLE 130 4-Chlorobenzyl (4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)carbamate. Pyridine (13 mg, 0.16 mmol, 1.5 equiv) was added to a solution of Intermediate 1 (22 mg, 0.12 mmol, 1.1 equiv) and 4-chlorobenzyl carbonochloridate (22 mg, 0.11 mmol, 1.0 equiv) in anhydrous THF (5 ml, 0.022 M) and was stirred for 2 h at rt.
  • reaction mixture was then cooled to rt and treated with 1-(4-chlorophenyl)-N-methylmethanamine (45 mg, 0.29 mmol, 1.0 equiv). Heating was then resumed at 90 °C and the reaction was stirred for a subsequent 6 h.
  • the reaction mixture was cooled to rt and purified directly by RP- HPLC (Method A, 5–100% MeCN in H 2 O + 0.1% TFA) to give 1-(4-Chlorobenzyl)- 1-methyl-3-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)urea (34 mg, 25% yield) as an off-white solid, trifluoroacetic acid salt.
  • Step 1 3-(4-Chlorophenyl)-5-((4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)amino)-5-oxopentanoic acid.
  • a vial was charged with 4-methyl-3-(pyridin-4-yl)- 1H-pyrazol-5-amine (160 mg, 0.94 mmol, 1.0 equiv) and 4-(4-chlorophenyl)dihydro- 2H-pyran-2,6(3H)-dione (210 mg, 0.94 mmol, 1.0 equiv).
  • anhydrous THF 5.0 mL, 0.19 M
  • Step 2 3-(4-Chlorophenyl)-5-hydroxy-N-(4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-yl)pentanamide. A vial was charged with 3-(4-chlorophenyl)-5-((4- methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)amino)-5-oxopentanoic acid (45 mg, 0.11 mmol, 1.0 equiv).
  • Step 2 3-(4-Chlorophenyl)-N-methyl-N-(4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-yl)propenamide.
  • Step 1 3-(4-((Trimethylsilyl)ethynyl)phenyl)propanoic acid.
  • a flask was charged with 3-(4-iodophenyl)propanoic acid (400 mg, 1.5 mmol, 1.0 equiv), which was azeotroped with toluene.
  • CuI 28 mg, 0.15 mmol, 0.10 equiv
  • tetrakis(triphenylphosphine) palladium(0) 34 mg, 0.029 mmol, 0.020 equiv
  • anhydrous THF 6.0 mL, 0.25 M
  • Step 2 N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4- ((trimethylsilyl)ethynyl)phenyl) propenamide.
  • 3-(4- ((trimethylsilyl)ethynyl)phenyl)propanoic acid 55 mg, 0.22 mmol, 1.0 equiv
  • T 3 P 50 w/v % in DMF, 140 mg, 0.22 mmol, 1.0 equiv
  • triethylamine 68 mg, 0.68 mmol, 3.0 equiv).
  • Step 3 3-(4-Ethynylphenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide.
  • EXAMPLE 142 1-[(4-Fluorophenyl)methyl]-3-[4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl]urea
  • the product was prepared following the same procedure as Example #141to afford 1-[(4-fluorophenyl)methyl]-3-[4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl]urea in 10% yield (over two steps) as a white solid.
  • EXAMPLE 144 1-(4-Chlorobenzyl)-3-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)urea
  • 5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-amine (Intermediate 6, 50 mg, 0.29 mmol, 1.0 equiv), (4-chlorophenyl)methanamine (41 mg, 0.29 mmol, 1.0 equiv) CDI (50 mg, 0.31 mmol, 1.1 equiv), and DIPEA (75 mg, 0.57 mmol, 2.0 equiv) in DCM (3.0 mL, 0.10 M) was stirred at rt for 16 h.
  • Step 2 4-Chloro-N-(3-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)- 1H-pyrazol-5-yl)butanamide.
  • 3-(pyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-amine 200 mg, 0.69 mmol, 1.0 equiv) in DCM (4 mL, 0.17 M
  • 4-chlorobutanoyl chloride 120 mg, 0.83 mmol, 1.2 equiv
  • Step 5 2,6-Difluoro-4-((2-oxo-1-(3-(pyridin-4-yl)-1H-pyrazol-5- yl)pyrrolidin-3-yl)methyl)benzonitrile.
  • the product was prepared according to General Procedure #1 using 4-bromo-3-(pyridin-4-yl)-1H-pyrazol-5-amine and 3-(4- chlorophenyl)propanoic acid to afford N-(4-bromo-3-(pyridin-4-yl)-1H-pyrazol-5-yl)- 3-(4-chlorophenyl)propanamide (78 mg, 0.19 mmol, 46%) as a light yellow solid.
  • EXAMPLE 149 (5-Chlorothiophen-2-yl)methyl (5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4- yl)carbamate
  • Step 2 tert-Butyl (R)-(3-(4-chlorophenyl)-1-oxo-1-((3-(pyridin-4-yl)-1H- pyrazol-5-yl)amino)propan-2-yl)carbamate.
  • Step 3 (R)-2-Amino-3-(4-chlorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide.
  • tert-butyl (R)-(3-(4-chlorophenyl)-1-oxo-1-((3- (pyridin-4-yl)-1H-pyrazol-5-yl)amino)propan-2-yl)carbamate 100 mg, 0.23 mmol, 1.0 equiv
  • anhydrous 1,4-dioxane 1.0 mL, 0.23 M
  • Step 2 tert-Butyl (S)-(3-(4-chlorophenyl)-1-((5-methyl-1-(pyridin-4-yl)- 1H-pyrazol-4-yl)amino)-1-oxopropan-2-yl)carbamate.
  • Step 3 (S)-2-Amino-3-(4-chlorophenyl)-N-(5-methyl-1-(pyridin-4-yl)-1H- pyrazol-4-yl)propanamide.
  • tert-butyl (S)-(3-(4-chlorophenyl)-1-((5- methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)amino)-1-oxopropan-2-yl)carbamate 150 mg, 0.33 mmol, 1.0 equiv
  • anhydrous 1,4-dioxane (3.0 mL, 0.11 M) was added 4 M HCl in dioxane (0.51 mL, 1.0 mmol, 3.0 equiv).
  • Step 3 (S)-2-Amino-3-(4-chlorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide.
  • To tert-butyl (S)-(3-(4-chlorophenyl)-1-oxo-1-((3-(pyridin-4-yl)- 1H-pyrazol-5-yl)amino)propan-2-yl)carbamate 25 mg, 0.057 mmol, 1.0 equiv) was added 4 M HCl in dioxane (1.0 mL, 4.0 mmol, 70 equiv). The reaction mixture was stirred at rt for 1 h.
  • EXAMPLE 154 (rac)-3-(4-Chlorobenzyl)-1-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)pyrrolidine-2,5-dione
  • a mixture of 4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine (Intermediate 1, 100 mg, 0.57 mmol, 1.0 equiv), 3-(4-chlorobenzyl)dihydrofuran-2,5-dione (130 mg, 0.57 mmol, 1.0 equiv) and THF (4.0 mL, 0.14 M) was heated to 75 °C and stirred for 1 h.
  • EXAMPLE 156 (rac)-3-(4-Chlorobenzyl)-1-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)pyrrolidine-2,5- dione
  • a mixture of 3-(pyridin-4-yl)-1H-pyrazol-5-amine (Intermediate 13, 50 mg, 0.31 mmol, 1.0 equiv), 3-(4-chlorobenzyl)dihydrofuran-2,5-dione (70 mg, 0.31 mmol, 1.0 equiv) and THF (4.0 mL, 0.078 M) was heated to 75 °C for 1 hr. The reaction mixture was cooled to rt and a light-colored solid was filtered.
  • the crude solid was 58 taken up in DCE (4.0 mL) and treated with thionyl chloride (37 mg, 0.31 mmol, 1.0 equiv).
  • the reaction mixture was heated to 75 °C with stirring for 1 hr.
  • the reaction mixture was cooled to rt and filtered to afford (rac)-3-(4-chlorobenzyl)-1-(3-(pyridin- 4-yl)-1H-pyrazol-5-yl)pyrrolidine-2,5-dione (55 mg, 48% yield) as a tan colored solid.
  • the mixture was cooled to rt and was directly purified by RP- HPLC (Method A, 10–90% MeCN in H 2 O + 0.1% TFA) to afford a viscous, light yellow oil.
  • the purified intermediate (assume 0.57 mmol) was dissolved in DCE (4.0 mL, 0.14 M), treated with thionyl chloride (0.42 mL, 5.7 mmol, 1.0 equiv) and heated to 75 °C for 1 h.
  • Step 2 1-(4-Chlorobenzyl)-3-(1-(pyridin-4-yl)-1H-pyrazol-4- yl)imidazolidin-2-one.
  • 1-(2-chloroethyl)-3-(1-(pyridin-4-yl)-1H- pyrazol-4-yl)urea 83 mg, 0.31 mmol, 1.0 equiv
  • DMF 2.0 mL, 0.16 M
  • sodium hydride 60 wt % dispersion in mineral oil, 31 mg, 0.78 mmol, 2.5 equiv.
  • Step 2 3-(4-Chlorophenyl)-N-(5-(pyridin-4-yl)-4H-1,2,4-triazol-3- yl)propanamide.
  • a solution of 3-(4-chlorophenyl)propanoic acid (110 mg, 0.59 mmol, 1.2 equiv) in DMF (2.5 mL, 0.20 M) was treated with DIPEA (0.17 mL, 0.98 mmol, 1.7 equiv) at rt for 5 min. The mixture was cooled to 0 °C and HATU (220 mg, 0.59 mmol, 2.0 equiv) was added and the mixture was stirred for 10 min at rt.
  • tert-butyl 3-amino-5-(pyridin-4-yl)-4H-1,2,4-triazole-4-carboxylate 130 mg, 0.49 mmol, 1.0 equiv was added at 0 °C and the mixture was slowly warmed to rt and stirred for 3 h.
  • EXAMPLE 164 1-(3-(Pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5-trifluorobenzyl)urea N , 2 , , The product was prepared according to the same procedure as Example #163 to afford 1-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5-trifluorobenzyl)urea in 18% yield.
  • EXAMPLE 168 1-(4-Chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-chlorobenzyl)urea
  • the product was prepared according to the same procedure as Example #166 to afford 1-(4-chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-chlorobenzyl)urea in 45% yield.
  • EXAMPLE 170 3-(4-Chlorophenyl)-N-(3-(3-fluoropyridin-4-yl)-1H-pyrazol-5-yl)propanamide The product was prepared following the same procedure as Example #169 to afford 3-(4-chlorophenyl)-N-(3-(3-fluoropyridin-4-yl)-1H-pyrazol-5-yl)propanamide in 30% yield.
  • Example A Biological Assay Each reaction was run at a volume of 20 ⁇ L containing 50 ⁇ M compound (dissolved in DMSO; final concentration of DMSO is 1% v/v), 40 nM human SARM1 (50-724) , 0.3 mM NMN, 20 ⁇ M NAD, 1 mM TCEP, 25 mM HEPES pH 7.4, 10 mM KCl and 10 mM MgCl 2 . The reaction was incubated at room temperature for 60 minutes and quenched with 20 ⁇ L of 0.4% formic acid.
  • the samples were run on Agilent HPLC 1260 Infinity II with Synergi 2.5 ⁇ M Fusion-RP 100 ⁇ (100 x 3.0 mm) LC column from Phenomenex. Total run time for each sample was 4 minutes. The run was isocratic with 1.5% methanol in 40 mM ammonium acetate pH 6.0. Samples were run at a flow rate of 0.8 mL/min at 55 °C. Peak areas of NAD and NAM were determined using OpenLAB CDS (Chem Station edition) software. For dose- response, the compound was diluted serially 1:3 in DMSO and added to the reaction starting at a final compound concentration of 100 ⁇ M in 1% DMSO.
  • IC50 data according to the assay described above is provided in Table 1 below.
  • Table 1 68 Example B Assessment of the Protective Effect of SARM1 Inhibitors in Multiple Sclerosis To evaluate the ability of a SARM1 inhibitor to delay, prevent, or treat multiple sclerosis, a preclinical mouse model of experimental autoimmune encephalomyelitis (EAE) may be used (Lyons JA et al., Eur J of Immunology,1999 29(11):3432-9).
  • EAE experimental autoimmune encephalomyelitis
  • mice may receive 0.1 ml subcutaneous injection (s.c.) of myelin oligo glycoprotein peptide (MOG35-55) suspension in complete Freund’s adjuvant (CFA) in the upper and lower back, followed by intraperitoneal injection (i.p.) of pertussis toxin (100 ng) within 3 hours of MOG injection and again within 24 hours of MOG injection. Weight and clinical 75 score of paralysis may be recorded daily starting at day 7 until day 28 post-MOG injection.
  • a SARM1 inhibitor can be dosed orally (p.o.) daily or with the use of osmotic pumps implanted s.c. or i.p.
  • Example C Assessment of the Protective Effect of SARM1 Inhibitors in Chemotherapy- induced Peripheral Neuropathy (CIPN) To evaluate the ability of a SARM1 inhibitor to prevent CIPN, a mouse model of CIPN may be used.
  • mice may be treated with a specific chemotherapeutic known to cause peripheral neuropathy in humans (e.g., vincristine, paclitaxel, or oxaliplatin) (Geisler et al., Brain 2016, 139(Pt 12):3092- 3108; Wang MS et al., Ann. Neurol., 2002, 52(4)442-7; Sprowl et al., Proc Natl Acad Sci 2013, 110(27):11199).
  • a specific chemotherapeutic known to cause peripheral neuropathy in humans e.g., vincristine, paclitaxel, or oxaliplatin
  • Peripheral neuropathy may be assessed with behavior tests of mechanical allodynia by measuring sensitivity in the footpad by increasing applied force of Von Frey filament, cold or heat sensitivity by measuring escape/pain behavior (e.g., jumping, paw licking or paw lifts) on a thermally controlled enclosed platform. Furthermore, behavior may be correlated with biomarkers of neuropathy (e.g., plasma neurofilament light) and by histologically examining intra-epidermal nerve fiber density in hind paw pad biopsies. SARM1 inhibitors may be dosed orally (p.o.) daily, or with the use of osmotic pumps implanted s.c. or i.p. at the start of the experiment.
  • escape/pain behavior e.g., jumping, paw licking or paw lifts
  • biomarkers of neuropathy e.g., plasma neurofilament light
  • SARM1 inhibitors may be dosed orally (p.o.) daily, or with the use of
  • Effective compounds will prevent allodynia, prevent the increase of the neuropathy biomarker and/or prevent the decrease in IENF density relative to vehicle treated cohorts.
  • a genetic mouse model of the disease may be used. Transgenic mice with the mutation TDP43Q331K have been shown to develop progressive motor deficits as measured by performance on the accelerating rotarod and by progressive hind limb weakness as measured by hind paw grip strength. Furthermore, plasma NfL levels may appear to be increased in the mutants.
  • SARM1 inhibitors may be dosed with the use of osmotic pumps implanted s.c. or i.p. Effective compounds will protect from the neurodegeneration and show a decrease in plasma NfL, as well as delay and/or prevent progression of the motor deficits and hind limb weakness.
  • Example E Assessment of the Protective Effect of SARM1 Inhibitors in Glaucoma To evaluate the ability of SARM1 inhibitor to prevent glaucoma, several mouse models of the disease are utilized.
  • the optic nerve crush (ONC) model of glaucoma is generated by applying transient pressure to the optic nerve with forceps to induces retrograde retinal ganglion cell death and replicate many of the changes observed in glaucomatous retinas, excluding increased ocular pressure.
  • glaucoma mimic increased intraocular pressure and are generated by blockade of the trabecular network by injection of exogenous oil/microbeads or by laser-induced coagulation.
  • eyes and optic nerves are harvested for histology to evaluate ocular damage.
  • Retinal cross sections or flatmounts stained with markers of retinal ganglion cells, such as RBPMS or BRN2A, are used to determine the number of surviving cells.
  • Optic nerve sections stained with neuronal specific markers such as SMI32 are used to determine surviving axon number and morphology.
  • markers of neuroinflammation such as GFAP or IBA1 are used to assess injury extent.
  • SARM1 inhibitors will be dosed orally (p.o.) everyday with the use of osmotic pumps implanted s.c. or i.p. at the start of the experiment. Additionally, SARM1 inhibitors may be dosed via topical eye drops or by intravitreal, subconjunctival, subtenon, or retrobulbar injection. We expect our compounds to prevent degeneration of retinal ganglion cells and their axons in the optic nerve, attenuate neuroinflammatory responses, and preserve visual function relative to vehicle treated cohorts.
  • TBI Traumatic Brain Injury
  • Closed head TBI will be produced using a weight drop device as previously described in detail and as adapted for use in mice (Henninger et al., Brain 2016, 139(Pt 4):1094).
  • SARM1 inhibitors will be dosed orally (p.o.) everyday with the use of osmotic pumps implanted s.c. or i.p. at the start of the experiment. Effective compounds will be evaluated using multiple endpoints, primary endpoint being ⁇ APP immunohistology after TBI.

Abstract

This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing a neurological diseases.

Description

SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS FIELD OF THE INVENTION This disclosure is drawn to compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing a neurological disorder. BACKGOUND OF THE INVENTION Aging constitutes the main risk factor for the development of neurodegenerative diseases. Axonal degeneration is an important pathological event in many neurodegenerative and neurological disorders, including peripheral neuropathy and traumatic brain injury (Gerdts, J. et al., Neuron, 2016, 89, 449–60). Axonal degeneration has also been implicated in, for example, Alzheimer’s disease, Parkinson’s disease and Amyotrophic Lateral Sclerosis, where degeneration precedes symptom onset and widespread neuronal loss (Kurowska, Z. et al., J. Parkinson’s Dis., 2016, 6, 703–07). While these neurological conditions have unique underlying etiologies, inhibition of axonal degeneration in the conditions’ early stages may slow or prevent their progression by preventing the loss of functional synapses and maintaining neuronal connectivity (Essuman, K. et al., Neuron, 2017 Mar.22, 93(6), 1334-43). Axonal degeneration after injury occurs both toward the proximal cell body (termed retrograde degeneration) and toward the distal axon terminal (termed Wallerian or orthograde degeneration) (Kanamori A. et al., Am. J. Pathol. 2012 Jul; 181(1):62-73). Wallerian degeneration, which occurs in that section of the axon that is distal to the site of injury, occurs after axonal injury in both the peripheral nervous system (PNS) and the central nervous system (CNS). Wallerian degeneration usually begins within 24–36 hours of a lesion. Prior to degeneration, the distal section of the axon tends to remain electrically excitable, while after injury, the axonal skeleton disintegrates and the axonal membrane breaks apart. The processes of death of the cell body and degeneration of the axon are independent events. As alluded to above, evidence exists indicating that the degeneration of axons precedes clinical symptoms in neurodegenerative diseases and occurs before cell body loss. Thus, axonal degeneration constitutes an early event in pathological processes and provides a potential therapeutic target to treat neurodegeneration prior to neuronal cell death (Salvadores, N. et al., Front. Neurosci., 2017, 11, 451). In view of the above, new modalities are needed for the treatment of neurological disorders such as neurodegenerative disease by the prevention of axonal degeneration. SUMMARY OF THE INVENTION The present invention is directed to inhibitors of SARM1 such as a compound of Formula Ia, Ib, Ic, or Id:
Figure imgf000003_0001
Ic
Figure imgf000004_0001
Id or a pharmaceutically acceptable salt thereof, wherein constituent members are defined herein. The present invention is further directed to a pharmaceutical composition comprising a compound of Formula Ia, Ib, Ic, or Id, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. The present invention is further directed to a method of inhibiting SARM1 comprising contacting the SARM1 with a compound of Formula Ia, Ib, Ic, or Id, or a pharmaceutically acceptable salt thereof. The present invention is further directed to a method of inhibiting axonal degeneration in a patient in need thereof comprising administering to the patient an inhibiting amount of a compound of Formula Ia, Ib, Ic, or Id, or a pharmaceutically acceptable salt thereof. The present invention is further directed to a method of treating or preventing a neurological disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Formula Ia, Ib, Ic, or Id, or a pharmaceutically acceptable salt thereof. The present invention is further directed to use of a compound of Formula Ia, Ib, Ic, or Id, or a pharmaceutically acceptable salt thereof, in treating or preventing a neurological disorder in a patient in need thereof. The present invention is further directed to a compound of Formula Ia, Ib, Ic, or Id, or a pharmaceutically acceptable salt thereof, for use in the preparation of a medicament for treating or preventing a neurological disorder in a patient in need thereof. DETAILED DESCRIPTION Similar to programmed cell death pathways (e.g., apoptosis), axonal degeneration in response to injury or disease stimulates a local signaling cascade that causes destruction of the injured axon segment (Summers D. W., et al., PNAS USA, 2016 Oct 11, 113(41):E6271–E6280). Following injury, the axonal skeleton disintegrates, and the axonal membrane breaks apart. Subsequent to axonal degeneration, the myelin sheath degrades and infiltration by macrophages follows; the macrophages, along with Schwann cells, clear the cellular debris resulting from the degeneration (Coleman M.P., et al., PNAS USA, 1998 Aug, 95(17):9985-90). SARM1 (sterile alpha and TIR motif-containing 1) protein (NP_055892) is a 724 amino acid protein involved in axon degeneration. It has also been implicated in infectious and inflammatory disorders. The SARM1 protein, also known as FLJ36296, KIAA0524, MyD88-5, SAM domain-containing protein 2, and SAMD2, comprises four domains, i) a mitochondrial localization signal, ii) an auto-inhibitory N-terminus region consisting of armadillo/HEAT motifs, iii) two sterile alpha motifs responsible for multimerization, and iv) a C-terminus Toll/Interleukin-1 receptor that possesses enzymatic activity (Essuman K., et al., Neuron 2017 Mar., 93(6):1334- 43.e5). SARM1 protein plays a critical role in the Wallerian degeneration pathway. Activation of SARM1 triggers a rapid collapse of NAD+ levels in the distal section of the injured axon, which then undergoes degeneration (Gerdts J. et al., Science 2015 Apr.348(6233):453-57). Promoting dimerization of the Toll/interleukin receptor (TIR) domain of SARM1 has been shown to be sufficient to promote NAD+ loss and axon degeneration. SARM1’s activity is responsible for, at least in part, the protective nature of the survival factor NMNAT2, as NMKNAT enzymes have found to prevent SARM1- mediated depletion of NAD+. Other pro-degeneration signaling pathways, including the MAP kinase pathway, have been linked to SARM1 activation. MAPK signaling has been shown to promote the loss of NMNAT2, which promotes SARM1 activation (See, e.g., Yang J. et al., Cell 2015 Jan 160(1-2):161-76). SARM1 is involved in the innate immune response. It promotes neuronal cell death in response to stress and other stimuli. SARM1 acts as a negative regulator of TICAM1/TRIF-dependent Toll-like receptor signaling by inhibiting induction of TLR3- and TLR4-dependent genes, which play a pivotal role in activating axonal degeneration following injury. In addition, SARM1 specifically blocks TICAM1/TRIF-dependent transcription factor activation and gene induction, without affecting the MYD88- dependent pathway or non-TLR signaling. It is also a negative regulator of NF- kappa-B and IRF activation. (See, e.g., Summers, D.W. et al., J Neurosci., 2014 Jul 9, 34(28):9338-50). In some embodiments, the present invention provides inhibitors (e.g., small molecules) of SARM1. SARM1 activation is known to cause a rapid reduction in NAD+ levels in injured axons, which then undergo degeneration. In particular embodiments, the compounds inhibit axonal degeneration, including axonal degeneration that results from reduction or depletion of NAD+ (e.g., inhibition of SARM1 NADase). The present invention is directed to inhibitors of SARM1 such as a compound of Formula Ia, Ib, Ic, or Id:
Figure imgf000006_0001
Ic
Figure imgf000007_0001
Id or a pharmaceutically acceptable salt thereof, wherein: A is N or N+-O-; Q1 and Q2 are each independently selected from CH and N; W is O, S, or NRN;
Figure imgf000007_0003
is a single, double, or triple bond; wherein when the
Figure imgf000007_0004
bond between X and Y is a single bond, then: X is CR5R6, NR7, or O and Y is CR8R9, NR10, O, S, SO, or SO2, wherein when X is NR7 or O, then Y is CR8R9; wherein when the
Figure imgf000007_0005
bond between X and Y is a double bond, then: X is CR5 and Y is CR8; and wherein when the
Figure imgf000007_0006
bond between X and Y is a triple bond, then: X is C and Y is C; Ring Z is C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, or 4-10 membered heterocycloalkyl; RN is H, C1-4 alkyl, or CN; R1 is halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy; R2 , R2A, and R2B are each independently selected from H, halo, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 cyanoalkyl, C1-4 alkoxy, C1-4 alkoxy-C1-4 alkyl, C1-4 haloalkoxy, and C3-7 cycloalkyl; R2C is selected from H, C1-4 alkyl, C1-4 hydroxyalkyl, C1-4 cyanoalkyl, and C3-7 cycloalkyl; R3 is H, C1-4 alkyl, -C(=O)-(C1-6 alkyl), -S(=O)2-(C1-6 alkyl), or a group of Formula (ii):
Figure imgf000007_0002
or R3 and R5, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; or R3 and R7, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; or R3 and R8, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; or R3 and R10, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; each R4 is independently halo, nitro, cyano, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy; or two adjacent R4 together with the atoms to which they are attached form a fused phenyl ring, C3-7 cycloalkyl ring, 5-7 membered heteroaryl ring, or 4-7 membered heterocycloalkyl ring, each optionally substituted with 1, 2, or 3 substituents independently selected from oxo, halo, nitro, cyano, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; or R4 and R9, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring fused with ring Z or a 5-7 membered heterocycloalkyl ring fused with ring Z, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; R5, R6, R7, R8, R9, and R10 are each independently selected from H, halo, NH2, OH, C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; or R5 and R9 together with the atoms to which they are attached form a C3-7 cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted with 1, 2 or 3 substituents independently selected from oxo, halo, NH2, OH, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; or R5 and R10 together with the atoms to which they are attached form a 5-7 membered heterocycloalkyl ring optionally substituted with 1, 2 or 3 substituents independently selected from oxo, halo, NH2, OH, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; W1 is O, S, or NRN; wherein when the bond between X1 and Y1 is a single bond, then: X1 is CR5R6, NR7, or O and Y1 is CR8R9, NR10, O, S, SO, or SO2, wherein when X1 is NR7 or O, then Y1 is CR8R9; wherein when the bond between X1 and Y1 is a double bond, then: X1 is CR5 and Y1 is CR8; and wherein when the bond between X1 and Y1 is a triple bond, then: X1 is C and Y1 is C; Ring Z1 is C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, or 4-10 membered heterocycloalkyl; R4A is halo, nitro, cyano, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy; or two adjacent R4A together with the atoms to which they are attached form a fused phenyl ring, fused C3-7 cycloalkyl ring, fused 5-7 membered heteroaryl ring, or fused 4-7 membered heterocycloalkyl ring, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, nitro, cyano, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; m is 0, 1, or 2; n is 0, 1, 2, 3, 4, or 5; and n1 is 0, 1, 2, 3, 4, or 5. In some embodiments, the compound of Formula Ia, Ib, Ic, or Id is other than
Figure imgf000010_0001
or
Figure imgf000010_0002
. In some embodiments, the compound has a structure according to Formula Ia. In some embodiments, the compound has a structure according to Formula Ib. In some embodiments, the compound has a structure according to Formula Ic. In some embodiments, the compound has a structure according to Formula Id. In some embodiments, A is N. In some embodiments, A is N+-O-. In some embodiments, one of Q1 and Q2 is CH and the other is N. In some embodiments, Q1 is CH and Q2 is N. In some embodiments, Q1 is N and Q2 is CH. In some embodiments, Q1 is CH and Q2 is N. In some embodiments, both Q1 and Q2 are CH. In some embodiments, both Q1 and Q2 are N. In some embodiments, W is O or S. In some embodiments, W is O. In some embodiments, W is S. In some embodiments, is a single bond. In some embodiments, is a double bond. In some embodiments,
Figure imgf000010_0003
is a triple bond. In some embodiments, X is CR5R6. In some embodiments, X is NR7. In some embodiments, X is O. In some embodiments, Y is CR8R9. In some embodiments, Y is NR10. In some embodiments, Y is O. In some embodiments, Y is S, SO, or SO2. In some embodiments, Ring Z is C6-10 aryl or 5-10 membered heteroaryl. In some embodiments, Ring Z is C6-10 aryl. In some embodiments, Ring Z is phenyl. In some embodiments, Ring Z is 5-10 membered heteroaryl. In some embodiments, Ring Z is 5-6 membered heteroaryl. In some embodiments, Ring Z is pyridyl, pyrimidinyl, thienyl, thiazolyl, isoxazolyl, or pyrrazolyl. In some embodiments, Ring Z is C3-7 cycloalkyl. In some embodiments, Ring Z is cyclohexyl or cyclopentyl. In some embodiments, Ring Z is selected from the following (a)-(k): ( (
Figure imgf000011_0001
. In some embodiments, m is 0 or 1. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, R1 is halo, C1-4 alkyl, or C1-4 alkoxy. In some embodiments, R1 is halo, C1-4 alkyl, or C1-4 alkoxy. In some embodiments, R1 is F, methyl, or methoxy. In some embodiments, R2 , R2A, and R2B are each independently selected from H, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxy, and C3-7 cycloalkyl. In some embodiments, R2 and R2A are each independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxy, and C3-7 cycloalkyl. In some embodiments, R2 , R2A, and R2B are each independently selected from H, Cl, Br, methyl, ethyl, trifluoromethyl, methoxy, cyclopropyl, and hydroxymethyl. In some embodiments, R2 , R2A, and R2B are each independently selected from Cl, Br, methyl, ethyl, trifluoromethyl, methoxy, cyclopropyl, and hydroxymethyl. In some embodiments, R2 and R2A are each independently selected from H, Cl, Br, methyl, ethyl, trifluoromethyl, methoxy, cyclopropyl, and hydroxymethyl. In some embodiments, R2B is H. In some embodiments, R3 is H, C1-4 alkyl, -C(=O)-(C1-6 alkyl), or -S(=O)2-(C1- 6 alkyl). In some embodiments, R3 is H or C1-4 alkyl. In some embodiments, R3 is H. In some embodiments, R3 is a group of Formula (ii):
Figure imgf000012_0001
In some embodiments, n is 1, 2, 3, 4, or 5. In some embodiments, n is 1, 2, 3, or 4. In some embodiments, n is 1, 2, or 3. In some embodiments, n is 1 or 2. In some embodiments, n is 1. In some embodiments, n is 0, 1, 2, 3, or 4. In some embodiments, n is 0, 1, 2, or 3. In some embodiments, n is 0, 1, or 2. In some embodiments, n is 0 or 1. In some embodiments, n is 0. In some embodiments, each R4 is independently halo, nitro, cyano, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy. In some embodiments, each R4 is independently F, Cl, Br, I, CN, NO2, methyl, ethyl, CF3, CHF2, OCF3, or OCHF2. In some embodiments, each R4 is independently halo. In some embodiments, each R4 is independently F or Cl. In some embodiments, two adjacent R4 together with the atoms to which they are attached form a fused phenyl ring, C3-7 cycloalkyl ring, 5-7 membered heteroaryl ring, or 4-7 membered heterocycloalkyl ring, each optionally substituted with 1, 2, or 3 substituents independently selected from oxo, halo, nitro, cyano, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy. In some embodiments, two adjacent R4 together with the atoms to which they are attached form a fused phenyl ring or 4-7 membered heterocycloalkyl ring. In some embodiments, two adjacent R4 together with the atoms to which they are attached form a fused phenyl ring or 5-6 membered heterocycloalkyl ring. In some embodiments, two adjacent R4 together with the atoms to which they are attached form a fused phenyl ring. In some embodiments, two adjacent R4 together with the atoms to which they are attached form a fused 4-7 membered heterocycloalkyl ring. In some embodiments, two adjacent R4 together with the atoms to which they are attached form a fused phenyl ring or 5-6 membered heterocycloalkyl ring. In some embodiments, R5 and R6 are each independently selected from H, F, NH2, and OH. In some embodiments, one of R5 and R6 is H and the other is selected from H, F, NH2, and OH. In some embodiments, R5 and R6 are both H. In some embodiments, each R7 is independently selected from H and C1-4 alkyl. In some embodiments, each R7 is independently selected from H and methyl. In some embodiments, R7 is H. In some embodiments, R8 and R9 are each independently selected from H and methyl. In some embodiments, R8 and R9 are both H. In some embodiments, R3 and R5, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy. In some embodiments, R3 and R7, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy. In some embodiments, R3 and R8, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy. In some embodiments, R3 and R10, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy. In some embodiments, R4 and R9, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring fused with ring Z or a 5-7 membered heterocycloalkyl ring fused with ring Z, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy. In some embodiments, R5 and R9 together with the atoms to which they are attached form a C3-7 cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted with 1, 2 or 3 substituents independently selected from oxo, halo, NH2, OH, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy. In some embodiments, R5 and R10 together with the atoms to which they are attached form a 5-7 membered heterocycloalkyl ring optionally substituted with 1, 2 or 3 substituents independently selected from oxo, halo, NH2, OH, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy. In some embodiments, R8, R9, and R10 are each independently selected from H and C1-4 alkyl. In some embodiments, R10 is selected from H and C1-4 alkyl. In some embodiments, R10 is H. In some embodiments, the compound has Formula IIa:
Figure imgf000015_0001
IIa. In some embodiments, the compound has Formula IIb:
Figure imgf000015_0002
. In some embodiments, the compound has Formula IIIa:
Figure imgf000015_0003
IIIa. In some embodiments, the compound has Formula IIIb:
Figure imgf000015_0004
IIIb. It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination. At various places in the present specification, substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges. For example, the term “C1-6 alkyl” is specifically intended to individually disclose methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl. At various places in the present specification various aryl, heteroaryl, cycloalkyl, and heterocycloalkyl rings are described. Unless otherwise specified, these rings can be attached to the rest of the molecule at any ring member as permitted by valency. For example, the term “pyridinyl,” “pyridyl,” or “a pyridine ring” may refer to a pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl ring. At various places in the present specification a di-valent or linking group may be present. Each linking group is understood as linking in either direction. That is, if a linking group is described as -A-B-, then it is understood, unless otherwise specified, that the linking group is not directionally limited and can also be -B-A-. For example, when a linking group is written as -C(=O)-O-, it also means –O-C(=O)-. The term “n-membered,” where “n” is an integer, typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is “n”. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridyl is an example of a 6-membered heteroaryl ring, and 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group. For compounds of the invention in which a variable appears more than once, each variable can be a different moiety independently selected from the group defining the variable. For example, where a structure is described having two R groups that are simultaneously present on the same compound, the two R groups can represent different moieties independently selected from the group defined for R. As used herein, the phrase “optionally substituted” means unsubstituted or substituted. As used herein, the term “substituted” means that a hydrogen atom is replaced by a non-hydrogen group. It is to be understood that substitution at a given atom is limited by valency. In some embodiments, an atom substituted by oxo (=O) has two hydrogen atoms replaced by the oxo substituent. As used herein, the term “Ci-j,” where i and j are integers, employed in combination with a chemical group, designates a range of the number of carbon atoms in the chemical group with i-j defining the range. For example, C1-6 alkyl refers to an alkyl group having 1, 2, 3, 4, 5, or 6 carbon atoms. As used herein, the term “alkyl,” employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chain or branched. In some embodiments, the alkyl group contains 1 to 7, 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n- pentyl, 2-methyl-1-butyl, 3-pentyl, n-hexyl, 1,2,2-trimethylpropyl, n-heptyl, and the like. In some embodiments, the alkyl group is methyl, ethyl, or propyl. As used herein, “alkenyl,” employed alone or in combination with other terms, refers to an alkyl group having one or more carbon-carbon double bonds. In some embodiments, the alkenyl moiety contains 2 to 6 or 2 to 4 carbon atoms. Example alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n- butenyl, sec-butenyl, and the like. As used herein, “alkynyl,” employed alone or in combination with other terms, refers to an alkyl group having one or more carbon-carbon triple bonds. Example alkynyl groups include, but are not limited to, ethynyl, propyn-1-yl, propyn-2-yl, and the like. In some embodiments, the alkynyl moiety contains 2 to 6 or 2 to 4 carbon atoms. As used herein, “halo” or “halogen”, employed alone or in combination with other terms, includes fluoro, chloro, bromo, and iodo. In some embodiments, halo is F or Cl. As used herein, the term “haloalkyl,” employed alone or in combination with other terms, refers to an alkyl group having up to the full valency of halogen atom substituents, which may either be the same or different. In some embodiments, the halogen atoms are fluoro atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms. Example haloalkyl groups include CF3, C2F5, CHF2, CCl3, CHCl2, C2Cl5, and the like. As used herein, the term “alkoxy,” employed alone or in combination with other terms, refers to a group of formula -O-alkyl. Example alkoxy groups include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy, and the like. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms. As used herein, “haloalkoxy,” employed alone or in combination with other terms, refers to a group of formula -O-(haloalkyl). In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms. An example haloalkoxy group is -OCF3. As used herein, “amino,” employed alone or in combination with other terms, refers to NH2. As used herein, the term “cycloalkyl,” employed alone or in combination with other terms, refers to a non-aromatic cyclic hydrocarbon including cyclized alkyl and alkenyl groups. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3, or 4 fused, bridged, or spiro rings) ring systems. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane, cyclohexene, cyclohexane, and the like, or pyrido derivatives of cyclopentane or cyclohexane. Ring-forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo. Cycloalkyl groups also include cycloalkylidenes. The term “cycloalkyl” also includes bridgehead cycloalkyl groups (e.g., non-aromatic cyclic hydrocarbon moieties containing at least one bridgehead carbon, such as admantan-1-yl) and spirocycloalkyl groups (e.g., non- aromatic hydrocarbon moieties containing at least two rings fused at a single carbon atom, such as spiro[2.5]octane and the like). In some embodiments, the cycloalkyl group has 3 to 10 ring members, or 3 to 7 ring members. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is a C3-7 monocyclic cycloalkyl group. Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, tetrahydronaphthalenyl, octahydronaphthalenyl, indanyl, and the like. In some embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. As used herein, the term “heterocycloalkyl,” employed alone or in combination with other terms, refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene or alkynylene groups as part of the ring structure, which has at least one heteroatom ring member independently selected from nitrogen, sulfur, oxygen, and phosphorus. Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused, bridged, or spiro rings) ring systems. In some embodiments, the heterocycloalkyl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the non-aromatic heterocycloalkyl ring, for example, 1,2,3,4- tetrahydro-quinoline and the like. Heterocycloalkyl groups can also include bridgehead heterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least one bridgehead atom, such as azaadmantan-1-yl and the like) and spiroheterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least two rings fused at a single atom, such as [1,4-dioxa-8-aza-spiro[4.5]decan-N-yl] and the like). In some embodiments, the heterocycloalkyl group has 3 to 10 ring-forming atoms, 4 to 10 ring-forming atoms, or about 3 to 8 ring forming atoms. In some embodiments, the heterocycloalkyl group has 2 to 20 carbon atoms, 2 to 15 carbon atoms, 2 to 10 carbon atoms, or about 2 to 8 carbon atoms. In some embodiments, the heterocycloalkyl group has 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 heteroatoms, or 1 to 2 heteroatoms. The carbon atoms or heteroatoms in the ring(s) of the heterocycloalkyl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized. In some embodiments, the heterocycloalkyl portion is a C2-7 monocyclic heterocycloalkyl group. In some embodiments, the heterocycloalkyl group is a morpholine ring, pyrrolidine ring, piperazine ring, piperidine ring, tetrahydropyran ring, tetrahydropyridine, azetidine ring, or tetrahydrofuran ring. As used herein, the term “aryl,” employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., a fused ring system) aromatic hydrocarbon moiety, such as, but not limited to, phenyl, 1-naphthyl, 2-naphthyl, and the like. In some embodiments, aryl groups have from 6 to 10 carbon atoms or 6 carbon atoms. In some embodiments, the aryl group is a monocyclic or bicyclic group. In some embodiments, the aryl group is phenyl or naphthyl. In some embodiments, the aryl group is phenyl. As used herein, the term “heteroaryl,” employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., a fused ring system) aromatic hydrocarbon moiety, having one or more heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl group is a monocyclic or a bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen. Example heteroaryl groups include, but are not limited to, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, pyrrolyl, azolyl, quinolinyl, isoquinolinyl, benzisoxazolyl, imidazo[1,2-b]thiazolyl or the like. The carbon atoms or heteroatoms in the ring(s) of the heteroaryl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized, provided the aromatic nature of the ring is preserved. In some embodiments, the heteroaryl group has from 3 to 10 carbon atoms, from 3 to 8 carbon atoms, from 3 to 5 carbon atoms, from 1 to 5 carbon atoms, or from 5 to 10 carbon atoms. In some embodiments, the heteroaryl group contains 3 to 14, 4 to 12, 4 to 8, 9 to 10, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl group has 1 to 4, 1 to 3, or 1 to 2 heteroatoms. The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention may be isolated as a mixture of isomers or as separated isomeric forms. Compounds of the invention also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone – enol pairs, amide - imidic acid pairs, lactam – lactim pairs, enamine – imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole. Compounds of the invention also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. In some embodiments, the compounds of the invention include at least one deuterium atom. The term, “compound,” as used herein is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted, unless otherwise specified. The term “compound” is also not limited by the way in which it was made. Thus, a compound of the invention includes molecules that were made by a synthetic process or by a biological process (such as through enzyme conversion or metabolism), or combinations thereof. All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g., in the form of hydrates and solvates) or can be isolated. In some embodiments, the compounds of the invention, or salts thereof, are substantially isolated. By “substantially isolated” is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compounds of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of a compound of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art. The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. The present invention also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety. Methods of Use Compounds of the invention can inhibit the activity of SARM1. For example, the compounds of the invention can be used to inhibit activity or a function of SARM1 in a cell or in an individual or patient in need of inhibition of the enzyme by administering an inhibiting amount of a compound of the invention to the cell, individual, or patient. As used herein, the term “in a cell” includes both inside the cell membrane and on the surface of the cell membrane. Compounds of the invention, as SARM1 inhibitors, can increase levels of NAD+ in a cell. Accordingly, the present invention is further directed to a method of increasing the level of NAD+ in a sample or in a patient, comprising contacting the sample or administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the increased level of NAD+ is relative to the level of NAD+ prior to the contacting or administering. Compounds of the invention, as SARM1 inhibitors, can inhibit axonal degeneration. Accordingly, the present invention is further directed to a method of inhibiting axonal degeneration in a sample or in a patient, comprising contacting the sample or administering to the patient an inhibiting amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. The compounds of the invention are useful in the treatment and prevention of various diseases associated with abnormal expression or activity of SARM1. For example, the compounds of the invention are useful in the treatment and prevention of neurological disorders. The term "neurological disorder" generally refers to a disorder affecting the nervous system, including the central nervous system or the peripheral nervous system. The term “neurological disorder” also includes ocular indications having a nexus to the nervous system. In some embodiments, the neurological disorder treatable or preventable by administration of a compound of the invention includes neurodegenerative diseases. Neurodegenerative diseases are characterized by damage to the central nervous system and can be identified by progressive dysfunction, degeneration and death of specific populations of neurons which are often synaptically interconnected. Examples of neurodegenerative diseases include Parkinson’s disease (PD), Alzheimer’s disease (AD), Huntington’s disease (HD), prion disease, motor neuron diseases (MND), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), and epilepsy. Examples of neurological disorders treatable or preventable according to the methods of the invention include spinal muscular atrophy (SMA), Chemotherapy Induced Peripheral Neuropathy (representative chemotherapeutic agents include vinca-alkaloids, taxols and platins), multiple sclerosis (MS), traumatic brain injury (TBI), spinal cord injury, stroke, Parkinson’ disease, glaucoma, Huntington’s disease, Alzheimer’s disease, Charcot-Marie-Tooth disease (CMT), retinitis pigmentosa (RP), age-related macular degeneration (AMD), small fiber neuropathies, peripheral neuropathy (e.g., viral neuropathy), spinocerebellar ataxias, cystic fibrosis, familial amyloidotic polyneuropathy, spongiform encephalopathies, spinal and bulbar muscular atrophy, hereditary dentatorubral-pallidoluysian atrophy, adrenoleukodystrophy, adrenomyeloneuropathy, Alexander’s disease, amyotrophic lateral sclerosis (ALS), Bassen-Kornzweig syndrome, Bell’s palsy, progressive supra nuclear palsy (PSP), central pontine myelolysis, cluster headache, congenital hypomyelination, corticobasal degeneration, Creutzfeldt-Jakob disease, epilepsy, dementia (e.g., frontotemporal dementia and Lewy body dementia), demyelination disorders (e.g., ischemic demyelination), encephalomyelitis, Friedrich’s ataxia, Gaucher’s disease, hereditary sensory and autonomic neuropathy (HSAN), Hurler syndrome, Krabbe’s disease, metachromatic leukodystrophy, migraine and tension headaches, mild cognitive impairment, motor spinoneuron disease, neuromyelitis optica, Niemann-Pick disease, optic neuritis, Pelizaeus Merzbacher disease, peripheral neuropathy, periventricular leukomalacia, post-herpetic neuralgia, prion disease, progressive supranuclear palsy, progressive multifocal leukoencephalopathy, Tay- Sacks disease, thoracic disc herniation, traverse myelitis, trigeminal neuralgia, wallerian degeneration, cerebellar degeneration, chiari malformation, dystonia, encephalitis (e.g., pediatric viral encephalitis and La Crosse virus encephalitis), hyperekplexia, multifocal motor neuropathy, muscular dystrophy, myasthenia gravis, myopathy, neurofibromatosis, neuronal ceroid lipofuscinosis, neuropathies (e.g., peripheral neuropathy), pseudobulbar affect, restless legs syndrome, spina bifida, syringomyelia, thoracic outlet syndrome, and transverse myelitis. In other embodiments, the neurological disorder treatable or preventable by administration of a compound of the invention is a neuropathy. As used herein, the term “neuropathy” refers broadly to diseased conditions of the nervous system, including polyneuropathy; neuropathy, ataxia, and retinosa pigmentosa (NARP); familial amyloid neuropathies; diabetic neuropathy (peripheral neuropathy due to diabetes mellitus); peripheral neuropathy (e.g., chemotherapy-induced peripheral neuropathy (CIPN), including CIPN caused by vinca alkaloids, bortezomib, lxabepilone, thalidomide and its analogs, taxanes, and platinum-based agents); and cranial neuropathy (e.g., auditory neuropathy and optic neuropathy). The term also includes other neuropathies associated with genetic disorders (e.g., NMNAT2 genetic mutation disorders). In still other embodiments, the neurological disorder treatable or preventable by administration of a compound of the invention is an ocular neuropathy (e.g., optic neuropathy). The term “optic neuropathy” refers to damage to the optic nerve from a number of causes. Types of optic neuropathy include ischemic optic neuropathy (e.g., anterior and posterior ischemic optic neuropathy); optic neuritis (e.g., chronic relapsing inflammatory optic neuropathy (CRION), single isolated optic neuritis (SION), and relapsing isolated optic neuritis); compressive optic neuropathy; infiltrative optic neuropathy; traumatic optic neuropathy; mitochondrial optic neuropathies; and hereditary optic neuropathies (e.g., Leber’s hereditary optic neuropathy (LHON), hereditary neuropathy with liability to pressure palsy (HNPP), and dominant optic atrophy). In still other embodiments, the neurological disorder treatable or preventable by administration of a compound of the invention is multiple sclerosis (MS), chemotherapy-induced peripheral neuropathy (CIPN), amyotrophic lateral sclerosis (ALS), glaucoma, traumatic brain injury (TBI), or stroke. As used herein, the term “cell” is meant to refer to a cell that is in vitro, ex vivo or in vivo. In some embodiments, an ex vivo cell can be part of a tissue sample excised from an organism such as a mammal. In some embodiments, an in vitro cell can be a cell in a cell culture. In some embodiments, an in vivo cell is a cell living in an organism such as a mammal. As used herein, the term “contacting” refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, “contacting” SARM1 or “contacting” a cell with a compound of the invention includes the administration of a compound of the present invention to an individual or patient, such as a human, having SARM1, as well as, for example, introducing a compound of the invention into a sample containing a cellular or purified preparation containing SARM1. As used herein, the term “individual” or “patient,” used interchangeably, refers to mammals, and particularly humans. The individual or patient can be in need of treatment. As used herein, the phrase “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. As used herein, the phrase “inhibiting amount” refers to the amount of active compound or pharmaceutical agent that elicits a measurable SARM1 inhibition or axonal degeneration in a tissue, system, animal, individual or human. As used herein the term “treating” or “treatment” refers to 1) inhibiting the disease in an individual who is experiencing or displaying the pathology or symptomatology of the disease (i.e., arresting further development of the pathology and/or symptomatology), or 2) ameliorating the disease in an individual who is experiencing or displaying the pathology or symptomatology of the disease (i.e., reversing the pathology and/or symptomatology). As used herein the term “preventing” or “prevention” refers to preventing the disease in an individual who may be predisposed to the disease but does not yet experience or display the pathology or symptomatology of the disease. In some embodiments, the invention is directed to a method of preventing a disease in a patient, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. Combination Therapy One or more additional pharmaceutical agents or treatment methods can be used in combination with the compounds of the present invention. The agents can be combined with the present compounds in a single dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms. Examples of additional agents include acamprosate, agomelatine, almotriptan, amantadine, amisulpride, amitriptyline, apomorphine, aripiprazole, asenapine, atomoxetine, baclofen, botulinum toxin type A, bromocriptine, buccal midazolam, buprenorphine, buspirone, cabergoline, carbamazepine, chlordiazepoxide, chlorpromazine, citalopram, clobazam, clomethiazole, clomipramine, clonazepam, clozapine, denzapine, co-beneldopa, co-careldopa, dantrolene, dexamfetamine, diazepam, divalproex sodium, donepezil, doxepin, duloxetine, eletriptan, entacapone, epinephrine, escitalopram, eslicarbazepine, ethosuximide, fingolimod, fluoxetine, flupentixol, flupentixol, fluphenazine long-acting injection (modecate), fluvoxamine (Faverin), frovatriptan, gabapentin, galantamine, haloperidol, imipramine, lacosamide, lamotrigine, levetiracetam, levomepromazine, lisdexamfetamine, lithium, lofepramine, loprazolam, lorazepam, lormetazepam, lurasidone, melatonin, memantine, methylphenidate, mianserin, mirtazapine, moclobemide, modafinil, naratriptan, neostigmine, nitrazepam, nortriptyline, olanzapine, orlistat, orphenadrine, oxazepam, oxcarbazepine, paliperidone, paliperidone, paroxetine, perampanel, pergolide, pericyazine, phenobarbital, phenytoin, piracetam, pizotifen, pramipexole, pregabalin, primidone, prochlorperazine, procyclidine, pyridostigmine, quetiapine, rasagiline, reboxetine, risperidone, rivastigmine, rizatriptan, ropinirole, rotigotine, rufinamide, selegiline, sertraline, sodium oxybate, sodium valproate, sulpiride, sumatriptan, temazepam, tetrabenazine, tiagabine, tizanidine, tolcapone, topiramate, trazodone, trihexyphenidyl, trimipramine, valproate semisodium, venlafaxine, vigabatrin, vortioxetine, zolmitriptan, zolpidem, zonisamide, zopiclone, and zuclopenthixol. Pharmaceutical Formulations and Dosage Forms When employed as pharmaceuticals, the compounds of the invention can be administered in the form of pharmaceutical compositions. A pharmaceutical composition refers to a combination of a compound of the invention, or its pharmaceutically acceptable salt, and at least one pharmaceutically acceptable carrier. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be oral, topical (including ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), ocular, or parenteral. This invention also includes pharmaceutical compositions which contain, as the active ingredient, one or more of the compounds of the invention above in combination with one or more pharmaceutically acceptable carriers. In making the compositions of the invention, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10 % by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders. The compositions can be formulated in a unit dosage form. The term "unit dosage form" refers to a physically discrete unit suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. The active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these pre-formulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid pre-formulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate. The liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner. The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like. The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The therapeutic dosage of the compounds of the present invention can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 μg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems. The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of non-critical parameters which can be changed or modified to yield essentially the same results. The compounds of the Examples were found to be inhibitors of SARM1 according to one or more of the assays provided herein. EXAMPLES General Experimental: All reactions sensitive to air or moisture were carried out in flame-dried glassware under an atmosphere of nitrogen. All commercially available reagents were purchased from suppliers such as Sigma-Aldrich (MilliporeSigma), Combi-Blocks, Enamine, Sinopharm Chemical Reagent Co. (SCRC), or Alfa Aesar and were used without purification unless otherwise noted. Proton nuclear magnetic resonance (1H NMR) spectra were recorded on Bruker AVⅢ 400 or Bruker AVⅢ 500 spectrometers. Samples were dissolved in deuterated chloroform (CDCl3), dimethyl sulfoxide (DMSO-d6) or methanol (CD3OD). Chemical shifts are recorded in parts per million (ppm) and are referenced to the centerline of deuterochloroform (δ 7.26 ppm), of DMSO-d6 (δ 2.50 ppm), or of CD3OD (δ 3.31 ppm). Data were recorded as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, qt = quintet, m = multiplet, br = broad). Coupling constants (J values) are given in Hertz (Hz). Low resolution ESI mass spectra were recorded on a either an Agilent 1200 HPLC/6100 SQ system or an Agilent 1260 Infinity II HPLC/6125 SQ system. List of Abbreviations: MeCN acetonitrile Boc tert-butyloxycarbonyl Boc2O Boc anhydride or di-tert-butyl dicarbonate CDI 1,1’-carbonyl-diimidazole d day(s) D 2H (deuterium) DABCO 1,4-diazabicyclo[2.2.2]octane DCM dichloromethane DIAD diisopropyl azodicarboxylate DIPEA N,N-diisopropylethylamine DMAP 4-(dimethylamino)pyridine DMF dimethylformamide DMSO dimethylsulfoxide DPPA diphenyl phosphoryl azide ESI-MS electrospray ionization – mass spectrometry EtOAc ethyl acetate EtOH ethanol equiv equivalent(s) FA formic acid h hour(s) HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5- b]pyridinium 3-oxide hexafluorophosphate IPA isopropyl alcohol, 2-propanol LAH lithium aluminum hydride LCMS liquid chromatography mass spectrometry LiHMDS lithium bis(trimethylsilyl)amide MS mass spectrometry MeOH methanol MHz megahertz min minute(s) mg milligram(s) mL milliliter(s) mmol millimolar M molar mol mole(s) Ms methanesulfonyl N normal NBS N-bromosuccinimide NCS N-chlorosuccinimide Oxone® Potassium peroxymonosulfate Pd/C palladium on carbon Pd(dppf)Cl2 [1,1’-bis(diphenylphosphino)ferrocene]dichloropalladium(II) PE petroleum ether Ph phenyl 1H NMR proton nuclear magnetic resonance RP-HPLC reverse-phase high performance liquid chromatography rt room temperature SEM 2-(trimethylsilyl)ethoxymethyl SFC supercritical fluid chromatography T3P propylphosphonic anhydride TBAF tetrabutylammonium fluoride TBPH tert-butyl hydroperoxide solution (Luperox®, TBH70X) THF tetrahydrofuran TFA trifluoroacetic acid TLC thin layer chromatography Tol toluene wt % weight percent v/v % volume by volume percent w/v % weight by volume percent Reverse-Phase HPLC Purification: Compounds purified by RP-HPLC were run on one of the following four types of columns: Method A: RediSep® C18 prep column, 20 X 150 mm (100 Å / 5 micron) Method B: Phenomenex® C18 prep column, 21.2 X 250 mm (100 Å / Luna 10 micron) Method C: Xtimate® C18 prep column, 21.2 X 250 mm (10 micron) Method D: Boston Prep® C18 prep column 21.2 X 250 mm (10 micron) Intermediates: INTERMEDIATE #1 4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine
Figure imgf000033_0001
Step 1: 2-Methyl-3-oxo-3-(pyridin-4-yl)propanenitrile. A solution of propiononitrile (2.0 g, 36 mmol, 1.0 equiv) in anhydrous THF (150 mL, 0.24 M) under at atmosphere of nitrogen was cooled to −60 °C. To the cold solution was then added LiHMDS (1.0 M in THF, 75 mL, 75 mmol, 2.1 equiv) dropwise. The resulting mixture was warmed to 10 °C and stirred for 30 min. The reaction mixture was cooled again to −60 °C, and ethyl isonicotinate (10 g, 73 mmol, 2.0 equiv) was added. After the addition, the resulting mixture was warmed to rt and stirred for 3 h. The suspension was then filtered, and the solid was collected and triturated with DCM (200 mL) to obtain crude 2-methyl-3-oxo-3-(pyridin-4-yl)propanenitrile (9.0 g, 34 mmol, 60% purity) as an off-white solid. The crude material was used on the next step without further purification. LCMS: ESI-MS m/z: 161.1 [M+H]+. Step 2: 4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine. To a solution of crude 2-methyl-3-oxo-3-(pyridin-4-yl)propanenitrile (9.0 g, 34 mmol, 1.0 equiv) in ethanol (100 mL, 0.34 M) was added hydrazine hydrate (10 mL, 170 mmol, 5.0 equiv). The resulting mixture was heated to 90 °C and stirred for 12 h. The solution was then concentrated in vacuo, and the residue was purified directly by silica gel column chromatography (10% MeOH in DCM) to give 4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-amine (3.0 g, 17 mmol, 47% yield over 2 steps) as a light yellow solid.1H NMR (400 MHz, DMSO-d6) δ 11.9 (s, 1H), 8.57 (d, J = 4.1 Hz, 2H), 7.55 (d, J = 2.8 Hz, 2H), 4.67 (s, 2H), 2.04 (s, 3H). LCMS: ESI-MS m/z: 175.2 [M+H]+. INTERMEDIATE #2 4-Methyl-3-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5- amine
Figure imgf000034_0001
To a solution of 4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine (10 g, 57 mmol, 1.0 equiv) in anhydrous DMF (100 mL, 0.57 M) was added NaH (60 wt % in mineral oil, 2.8 g, 69 mmol, 1.2 equiv) under nitrogen at 0 °C. After the addition, the mixture was stirred at 0 °C for 30 min, then 2-(trimethylsilyl)ethoxymethyl chloride (11 g, 63 mmol, 1.1 equiv) was slowly added. The resulting solution was maintained at 0 °C for 30 min, then was slowly quenched with water (200 mL) and extracted with ethyl acetate (3 × 300 mL). The combined organic extracts were washed with brine (300 mL) and dried over Na2SO4, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (0–5% MeOH in DCM) to afford 4-methyl-3-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5- amine (11 g, 37 mmol, 64% yield) as a light-yellow solid. LCMS: ESI-MS m/z: 305.3 [M+H]+. INTERMEDIATE #3 3-(4-Chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)propenamide
Figure imgf000035_0001
To a solution of 3-(4-chlorophenyl)propanoic acid (10 g, 33 mmol, 1.0 equiv) in DMF (100 mL, 0.33 M), was added DIPEA (8.5 g, 66 mmol, 2.0 equiv) and the resulting solution was stirred at rt for 5 min. The solution was then cooled to 0 °C and T3P (50% w/w in EtOAc, 14 g, 43 mmol, 1.3 equiv) was added. The resulting reaction mixture was stirred for 5 min, followed by the addition of 4-methyl-3- (pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-amine (10 g, 33 mmol, 1.0 equiv). The mixture was stirred at rt for 20 hours. Upon completion, the reaction mixture was extracted with EtOAc (3 × 100 mL). The combined organic fractions were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by silica gel column chromatography (0–12% MeOH in DCM) to afford 3-(4-chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)propenamide (11 g, 23 mmol, 70% yield) as a light yellow solid. LCMS: ESI-MS m/z: 471.3 [M+H]+. INTERMEDIATE #4 4-Ethyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine
Figure imgf000036_0001
Step 1: 2-Isonicotinoylbutanenitrile. To a solution of butyronitrile (2.2 g, 32 mmol, 1.7 equiv) in anhydrous THF (20 mL, 1.6 M) was cooled to −40 °C and LiHMDS (1.0 M in THF, 40 mL, 40 mmol, 2.2 equiv) was added by dropwise addition. The resulting mixture was warmed to 0 °C and stirred for 1 h. The mixture was cooled again to −40 °C and methyl isonicotinate (2.5 g, 18 mmol, 1.0 equiv) was added. The reaction mixture was warmed to rt and stirred for 0.5 h. The organic material was then filtered and concentrated in vacuo to afford 2- isonicotinoylbutanenitrile (3.4 g, 18 mmol, >95% crude yield) as a white solid. The crude material was carried forward without further purification. LCMS: ESI-MS m/z: 175.1 [M+H]+. Step 2: 4-Ethyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine. A mixture of crude 2- isonicotinoylbutanenitrile (3.4 g, 18 mmol, 1.0 equiv) and hydrazine hydrate (85% w/w in water, 8.1 g, 140 mmol, 7.6 equiv) in EtOH (20 mL, 0.90 M) was heated to 80 °C and stirred for 20 h. The mixture was cooled to rt and concentrated in vacuo. The crude product was purified by silica gel column chromatography (0–5% MeOH in DCM) to afford 4-ethyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine (1.5 g, 8.2 mmol, 45% yield over 2 steps) as a light yellow solid. LCMS: ESI-MS m/z: 189.2 [M+H]+. INTERMEDIATE #5 3-(4-Chlorophenyl)-2-fluoropropanoic acid
Figure imgf000037_0001
Figure imgf000037_0002
Step 1: Dimethyl 2-(4-chlorobenzyl)-2-fluoromalonate. A solution of dimethyl 2-fluoromalonate (2.0 g, 9.7 mmol, 1.2 equiv) in anhydrous DMF (12 mL, 0.68 M) was cooled to 0 °C and was treated with sodium hydride (60 wt % dispersion in mineral oil, 320 mg, 8.1 mmol, 1.0 equiv). The resulting suspension was stirred at 0 °C for 1 h. Subsequently, 1-(bromomethyl)-4-chlorobenzene (1.2 g, 8.1 mmol, 1.0 equiv) was added to the mixture, and the solution was warmed to rt and stirred for 1 h. The mixture was then cooled to 0 °C and quenched by the slow addition of water (30 mL). After warming again to rt, the solution was extracted with EtOAc (3 × 30 mL). The organic material was washed with a saturated aqueous solution of NH4Cl, filtered over Na2SO4 and concentrated in vacuo to afford dimethyl 2-(4- chlorobenzyl)-2-fluoromalonate (3.0 g, 11 mmol, >95% crude yield) as an oil. The crude material was carried forward to the next step without further purification. LCMS: ESI-MS m/z: 275.1 [M+H]+. Step 2: Methyl 3-(4-chlorophenyl)-2-fluoropropanoate. A mixture of dimethyl 2-(4-chlorobenzyl)-2-fluoromalonate (3.0 g, 11 mmol, 1.0 equiv) and lithium chloride (630 mg, 15 mmol, 1.3 equiv) in a 10:1 solution of DMSO:water (22 mL, 0.50 M) was heated to 150 °C and stirred for 4 h. After cooling to rt, the solution was diluted with water (20 mL) and extracted with EtOAc (3 × 30 mL). The organic material was dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by silica gel column chromatography (0–25% EtOAc in PE) to afford methyl 3-(4-chlorophenyl)-2-fluoropropanoate (700 mg, 3.3 mmol, 30% yield) as a light yellow oil. LCMS: ESI-MS m/z: 217.1 [M+H]+. Step 3: 3-(4-Chlorophenyl)-2-fluoropropanoic acid. A mixture of methyl 3- (4-chlorophenyl)-2-fluoropropanoate (700 mg, 3.2 mmol, 1.0 equiv) and lithium hydroxide (160 mg, 6.5 mmol, 2.0 equiv) in a 4:1 solution of EtOH:water (25 mL, 0.13 M) was heated to 75 °C and stirred for 2 h. After cooling to rt, the solution was brought to pH ~5 by the addition of 2 M HCl and extracted with EtOAc (3 × 30 mL). The organic material was dried over Na2SO4, filtered, and concentrated in vacuo to afford 3-(4-chlorophenyl)-2-fluoropropanoic acid (500 mg, 2.5 mmol, 76% crude yield) as a white solid. The crude material was carried forward to the next step without further purification. LCMS: ESI-MS m/z: 203.1 [M+H]+. INTERMEDIATE #6 5-Methyl-1-(pyridin-4-yl)-1H-pyrazol-4-amine
Figure imgf000038_0001
Step 1: 4-(5-Methyl-4-nitro-1H-pyrazol-1-yl)pyridine: A solution of 5- methyl-4-nitro-1H-pyrazole (200 mg, 1.6 mmol, 1.0 equiv), pyridin-4-ylboronic acid (290 mg, 2.4 mmol, 1.5 equiv), copper(II) acetate (940 mg, 5.2 mmol, 3.3 equiv), and pyridine (250 mg, 3.2 mmol, 2.0 equiv) in DMF (5.0 mL, 0.31 M) was stirred at 95 °C under an oxygen balloon for 16 h. The mixture was diluted with ethyl acetate (15 mL) and sequentially washed with water (10 mL) and brine (10 mL). The organic phase was separated and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (0–10% MeOH in DCM) to give 4-(5-methyl-4-nitro-1H- pyrazol-1-yl)pyridine (170 mg, 53%) as a white solid. LCMS: ESI-MS m/z: 250.0 [M+H]+. Step 2: 5-Methyl-1-(pyridin-4-yl)-1H-pyrazol-4-amine: A mixture of 4-(5- methyl-4-nitro-1H-pyrazol-1-yl)pyridine (170 mg, 0.83 mmol), iron powder (70 mg, 1.3 mmol, 1.5 equiv), and ammonium chloride (130 mg, 2.5 mmol, 3.0 equiv) in ethanol–water (5:1, 6.0 mL, 0.14 M) was stirred at reflux for 3 h. The mixture was cooled to rt and then filtered. The filtrate was concentrated in vacuo and then purified by silica gel column chromatography (10% MeOH in DCM) to afford 5-methyl-1- (pyridin-4-yl)-1H-pyrazol-4-amine (120 mg, 83% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 8.58 (dd, J = 4.8, 1.6 Hz, 2H), 7.57 (dd, J = 4.8, 1.6 Hz, 2H), 7.32 (s, 1H), 4.07 (br s, 2H), 2.34 (s, 3H). LCMS: ESI-MS m/z: 175.0 [M+H]+. INTERMEDIATE #7 5-Chloro-1-(pyridin-4-yl)-1H-pyrazol-4-amine
Figure imgf000039_0001
Figure imgf000039_0002
Step 1: 4-(4-Nitro-1H-pyrazol-1-yl)pyridine: A mixture of 4-bromopyridine (1.0 g, 6.4 mmol, 1.0 equiv), 4-nitro-1H-pyrazole (720 mg, 6.4 mmol, 1.0 equiv), copper(I) iodide (120 mg, 0.64 mmol, 1.0 equiv), and potassium carbonate (1.8 g, 13 mmol, 2.0 equiv) in DMF (20 mL, 0.32 M) was stirred at 110 °C for 16 h. The reaction mixture was cooled to rt and filtered. The filtrate was treated with water (100 mL) and extracted with EtOAc (3 × 30 mL). The combined organic extracts were washed with a saturated aqueous solution of ammonium chloride (2 × 50 mL), then dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (5% MeOH in DCM) to give 4-(4-nitro-1H-pyrazol-1-yl)pyridine (600 mg, 50% yield) as a yellow solid. LCMS: ESI-MS m/z: 191.0 [M+H]+. Step 2: 4-(5-Chloro-4-nitro-1H-pyrazol-1-yl)pyridine: To a stirred solution of 4-(4-nitro-1H-pyrazol-1-yl)pyridine (500 mg, 2.6 mmol, 1.0 equiv) in anhydrous THF (10 mL, 0.26 M) was added LiHMDS (1 M in THF, 3.0 mL, 3.0 mmol, 1.1 equiv) at –70 °C. After the addition, the mixture stirred at rt for 30 min, then hexachloroethane (450 µL, 4.0 mmol, 1.5 equiv) was added dropwise at –70 °C. After the addition, the mixture was maintained at –70 °C for 1 h, then quenched with a saturated aqueous solution of ammonium chloride (10 mL). The mixture was extracted with EtOAc (3 × 10 mL). The combined organic extracts were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford crude 4-(5- chloro-4-nitro-1H-pyrazol-1-yl)pyridine (290 mg, 49% yield) that was carried forward in the next step without purification. LCMS: ESI-MS m/z: 225.0 [M+H]+. Step 3: 5-Chloro-1-(pyridin-4-yl)-1H-pyrazol-4-amine: A mixture of 4-(5- chloro-4-nitro-1H-pyrazol-1-yl)pyridine (290 mg, 1.3 mmol, 1.0 equiv), iron powder (360 mg, 6.5 mmol, 5.0 equiv), and ammonium chloride (700 mg, 13 mmol, 10 equiv) in EtOH (20 mL, 0.065 M) was heated at 80 °C for 5 h. The reaction mixture was cooled to rt and filtered. The filtrate was concentrated in vacuo and then purified by silica gel column chromatography (5% MeOH in DCM) to afford 5-chloro-1-(pyridin- 4-yl)-1H-pyrazol-4-amine (50 mg, 20% yield) as a light-yellow solid.1H NMR (400 MHz, DMSO-d6) δ 8.66 (dd, J = 4.7, 1.6 Hz, 2H), 7.69 (dd, J = 4.7, 1.6 Hz, 2H), 7.51 (s, 1H), 4.54 (s, 2H). LCMS: ESI-MS m/z: 195.1 [M+H]+. INTERMEDIATE #8 3-(4-Cyano-3,5-difluorophenyl)propanoic acid
Figure imgf000040_0001
Step 1: tert-Butyl (E)-3-(4-cyano-3,5-difluorophenyl)acrylate: A mixture of 4-bromo-2,6-difluorobenzonitrile (10 g, 46 mmol, 1.0 equiv), tert-butyl acrylate (8.8 g, 69 mmol, 1.5 equiv), K2CO3 (5.7 g, 41 mmol, 0.89 equiv), palladium(II) acetate (170 mg, 0.70 mmol, 15 mol %), and DABCO (170 mg, 1.5 mmol, 3.3 mol %) in anhydrous DMF (100 mL, 0.46 M) was stirred at 120 °C for 1 h. The reaction mixture was concentrated in vacuo and purified by silica gel column chromatography (5–35% EtOAc in petroleum ether) to give tert-butyl (E)-3-(4-cyano-3,5- difluorophenyl)acrylate (3.0 g, 11 mmol, 25% yield) as a light-yellow solid. LCMS: ESI-MS m/z: 266.1 [M+H]+. Step 2: tert-Butyl 3-(4-cyano-3,5-difluorophenyl)propanoate: To a mixture of tert-butyl (E)-3-(4-cyano-3,5-difluorophenyl)acrylate (3.2 g, 12 mmol) and cobalt(II) chloride hexahydrate (300 mg, 1.3 mmol, 10 mol %) in methanol (50 mL, 0.24 M) was added sodium borohydride (2.3 g, 60 mmol, 5.0 equiv) slowly at 0 °C. After the addition, the suspension stirred at 0 °C for 2 h. The mixture was diluted with EtOAc (150 mL) and washed with brine (2 × 50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give tert-butyl 3-(4-cyano-3,5-difluorophenyl)propanoate (1.9 g, 7.1 mmol, 59% yield) as a light- yellow liquid. This material was used with no further purification. LCMS: ESI-MS m/z: 268.1 [M+H]+. Step 3: 3-(4-Cyano-3,5-difluorophenyl)propanoic Acid: To a solution of tert-butyl 3-(4-cyano-3,5-difluorophenyl)propanoate (1.9 g, 7.1 mmol) in DCM (20 mL) was added TFA (4.2 g, 37 mmol, 5.2 equiv) dropwise at 0 °C. After the addition, the solution was stirred for 2 h at 0 °C. The mixture was concentrated in vacuo and the resulting residue was treated with ammonia in methanol (7 M) to adjust to pH 8, then concentrated in vacuo. The crude product was purified by silica gel column chromatography (5–25% MeOH in DCM) to give 3-(4-cyano-3,5- difluorophenyl)propanoic acid (1.5 g, 7.1 mmol, > 95% yield) as an off-white solid. LCMS: ESI-MS m/z: 212.1 [M+H]+. INTERMEDIATE #9 3-(4-Chloro-3,5-difluorophenyl)propanoic acid
Figure imgf000042_0001
Step 1: tert-Butyl (E)-3-(4-chloro-3,5-difluorophenyl)acrylate. A mixture of 5-bromo-2-chloro-1,3-difluorobenzene (2.0 g, 8.9 mmol, 1.0 equiv), tert-butyl acrylate (1.1 g, 8.9 mmol, 1.0 equiv), potassium carbonate (1.2 g, 8.9 mmol, 1.0 equiv), palladium(II) acetate (18 mg, 0.080 mmol), DABCO (50 mg, 0.44 mmol, 0.050 equiv) in anhydrous DMF (15 mL, 0.59 M) was stirred at 120 °C for 1 h. The reaction mixture was concentrated and purified directly by silica gel column chromatography (5–35% EtOAc in petroleum ether) to give tert-butyl (E)-3-(4- chloro-3,5-difluorophenyl)acrylate (800 mg, 2.9 mmol, 33 % yield) as a light yellow solid. LCMS: ESI-MS m/z: 219.0 [M–tBu]+. Step 2: tert-Butyl 3-(4-chloro-3,5-difluorophenyl)propanoate. To a mixture of tert-butyl (E)-3-(4-chloro-3,5-difluorophenyl)acrylate (800 mg, 2.9 mmol, 1.0 equiv) and NiCl (380 mg, 2.9 mmol, 1.0 equiv) in methanol (20 mL, 0.15 M) was added sodium borohydride (330 mg, 8.8 mmol, 3.0 equiv) slowly at 0 °C. After the addition, the suspension was stirred at 0 °C for 1 h. The mixture was diluted with ethyl acetate (100 mL), washed with brine (2 × 50 mL). The combined organic fractions were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo, and purified by silica gel column chromatography (10–30% EtOAc in petroleum ether) to give tert-butyl 3-(4-chloro-3,5-difluorophenyl)propanoate (600 mg, 2.2 mmol, 74% yield) as a light yellow liquid. LCMS: ESI-MS m/z: 203.1 [M– Boc]+. Step 3: 3-(4-Chloro-3,5-difluorophenyl)propanoic acid. To a solution of tert-butyl 3-(4-chloro-3,5-difluorophenyl)propanoate (600 mg, 2.2 mmol, 1.0 equiv) in DCM (20 mL, 0.11 M) was added TFA (2.5 g, 22 mmol, 10 equiv) dropwise at 0 °C. After the addition, the solution was stirred for 2 h at 0 °C. The mixture was concentrated in vacuo to remove solvent, and the resulting residue was treated with ammonia in methanol (7 M) to adjust to pH 6, then concentrated in vacuo and purified by silica gel column chromatography (5–25% MeOH in DCM) to afford 3-(4-chloro- 3,5-difluorophenyl)propanoic acid (470 mg, 2.1 mmol, 98% yield) as an off-white solid.1H NMR (400 MHz, CDCl3) δ 10.3 (br s, 1H), 6.35 (d, J = 8.4 Hz, 2H), 2.93 (t, J = 7.2 Hz, 2H), 2.68 (t, J = 7.2 Hz, 2 H). LCMS: ESI-MS m/z: 219.1 [M–H]+. INTERMEDIATE #10 3-(4-Cyano-3-fluorophenyl)propanoic acid
Figure imgf000043_0001
Formic acid (3.0 g, 66 mmol, 1.0 equiv) was treated with triethylamine (6.7 g, 66 mmol, 1.0 equiv) for 30 min at 0 °C. Subsequently, 2-fluoro-4-formylbenzonitrile (10 g, 67 mmol, 1.0 equiv) and 2,2-dimethyl-1,3-dioxane-4,6-dione (9.5 g, 66 mmol, 1.0 equiv) were added to the mixture. The reaction mixture was heated to 100 °C for 5 h, then cooled to rt. The mixture was then diluted with water (100 mL) and extracted with EtOAc (4 × 50 mL). The organic material was washed with brine, filtered over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by silica gel column chromatography (5–20% MeOH in DCM) to afford 3-(4-cyano- 3-fluorophenyl)propanoic acid (2.8 g, 15 mmol, 22% yield) as a white solid. LCMS: ESI-MS m/z: 194.1 [M+H]+. INTERMEDIATE #11 2-(5-Chloro-2,3-dihydro-1H-inden-1-yl)acetic acid
Figure imgf000044_0001
Step 1: 5-(5-Chloro-2,3-dihydro-1H-inden-1-ylidene)-2,2-dimethyl-1,3- dioxane-4,6-dione. An oven-dried flask was charged with titanium(IV) tetrachloride (230 mg, 1.2 mmol 2.0 equiv) and was dissolved in THF (3.0 mL, 0.20 M). The solution was cooled to 0 °C and 5-chloro-2,3-dihydro-1H-inden-1-one (100 mg, 0.60 mmol, 1.0 equiv) and 2,2-dimethyl-1,3-dioxane-4,6-dione (86 mg, 0.60 mmol, 1.0 equiv) were added. Pyridine (240 µL, 3.0 mmol, 5.0 equiv) was then added and the reaction mixture was warmed to rt over 2 h. The reaction mixture was suspended in EtOAc (50 mL) and water (50 mL) and was vigorously stirred for 30 min. The layers were separated and the aqueous layer was extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to afford the crude product. The crude material was purified by silica gel column chromatography (40% EtOAc in hexanes) to afford 5-(5-chloro-2,3-dihydro-1H-inden-1-ylidene)-2,2-dimethyl-1,3- dioxane-4,6-dione (10 mg, 0.030 mmol, 5.0% yield) as a white solid. LCMS: ESI-MS m/z: 291.1 [M–H]+. Step 2.5-(5-Chloro-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1,3-dioxane- 4,6-dione.5-(5-Chloro-2,3-dihydro-1H-inden-1-ylidene)-2,2-dimethyl-1,3-dioxane- 4,6-dione (10 mg, 0.030 mmol, 1.0 equiv) was dissolved in methanol (300 µL, 0.10 M). Sodium borohydride (6.5 mg, 0.17 mmol, 5.0 equiv) was then added and the reaction mixture was stirred at rt for 12 h. The reaction mixture was slowly quenched with 1 M HCl (5 mL). The aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic fractions were washed with brine (30 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo to afford 5-(5-chloro-2,3-dihydro-1H- inden-1-yl)-2,2-dimethyl-1,3-dioxane-4,6-dione (9.0 mg, 0.030 mmol, 89% yield) which was used without further purification. LCMS: ESI-MS m/z: 293.1 [M–H]+. Step 3.2-(5-Chloro-2,3-dihydro-1H-inden-1-yl)acetic acid. A solution of 5- (5-chloro-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1,3-dioxane-4,6-dione (7.0 mg, 0.020 mmol, 1.0 equiv) in 1,4-dioxane (250 µL, 0.080 M) was treated with 6 M HCl (60 µL) and the resulting mixture was heated to 100 °C for 12 h. The reaction mixture was then cooled to rt and extracted with EtOAc (3 x 10 mL). The combined organic fractions were dried over anhydrous sodium sulfate, concentrated in vacuo, and used without further purification. LCMS: ESI-MS m/z: 209.1 [M–H]+. INTERMEDIATE #12 2-(6-Chloro-1,2,3,4-tetrahydronaphthalen-1-yl)acetic acid
Figure imgf000045_0001
Step 1: Triethyl (6-chloro-1,2,3,4-tetrahydronaphthalen-1- yl)methanetricarboxylate. To a solution of 6-chloro-1,2,3,4-tetrahydronaphthalen-1- ol (160 mg, 0.87 mmol, 1.0 equiv) in toluene (8.6 mL, 0.10 M) was added triethyl methanetricarboxylate (370 µL, 1.7 mmol, 2.0 equiv), followed by tributylphosphane (430 µL, 1.7 mmol, 2.0 equiv). The solution was cooled to –50 °C, and DIAD (340 µL, 1.7 mmol, 2.0 equiv) was added slowly. The reaction mixture was warmed to rt and stirred for 3 h. After 3 h, the reaction mixture was concentrated in vacuo and purified directly by silica gel column chromatography (15% EtOAc in hexanes) to afford triethyl (6-chloro-1,2,3,4-tetrahydronaphthalen-1-yl)methanetricarboxylate (260 mg, 0.65 mmol, 76% yield) as a white solid. Step 2: 2-(6-Chloro-1,2,3,4-tetrahydronaphthalen-1-yl)acetic acid. To a solution of triethyl (6-chloro-1,2,3,4-tetrahydronaphthalen-1-yl)methanetricarboxylate (260 mg, 0.65 mmol, 1.0 equiv) in methanol (0.54 mL, 1.2 M), was added water (1.4 mL), and 5 M NaOH (0.70 mL). The reaction mixture was heated to 80 °C for 3 h. The reaction mixture was cooled to rt and concentrated in vacuo. Acetic acid (5 mL) was then added and the reaction was heated to 100 °C for 2 h. After 2 h, the reaction mixture was cooled to rt and concentrated in vacuo to afford a crude residue. The residue was dissolved in EtOAc (50 mL) and washed with water (50 mL). The layers were separated and the aqueous layer was extracted with EtOAc (3 × 30 mL). The combined organic fractions were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and purified by silica gel column chromatography (40% EtOAc in hexanes) to afford 2-(6-chloro-1,2,3,4-tetrahydronaphthalen-1-yl)acetic acid (62 mg, 0.28 mmol, 42% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.13 (d, J = 1.4 Hz, 1H), 7.10 (s, 0H), 3.35 (dq, J = 9.9, 5.0 Hz, 1H), 2.88–2.68 (m, 2H), 2.60 (dd, J = 15.7, 9.6 Hz, 1H), 2.04–1.92 (m, 1H), 1.91–1.69 (m, 1H). INTERMEDIATE #13 3-(Pyridin-4-yl)-1H-pyrazol-5-amine
Figure imgf000046_0001
Step 1: 3-Oxo-3-(pyridin-4-yl)propanenitrile. To a 2L three-neck round bottomed flask was added a solution of methyl isonicotinate (4.0 g, 29 mmol, 1.0 equiv) in anhydrous THF (40 mL, 0.73 M) under an atmosphere of nitrogen gas. The solution was cooled to –60 °C, and LiHMDS (1.0 M in THF, 43 mL, 1.0 M, 43 mmol, 1.5 equiv) was then added dropwise. After stirring at –60 °C for 1.5 h, anhydrous acetonitrile (2.2 mL, 43 mmol, 1.5 equiv) was slowly added, forming a thick slurry. The reaction was stirred for 1.5 h at –60 °C, and then warmed to rt. The reaction mixture was concentrated to a minimum amount of slurry and diluted with DCM (20 mL). After stirring for 5 min at –10 °C, the slurry was filtered and the solid was washed with 10 mL of cold DCM. The solid collected was dried in vacuo to afford 3- oxo-3-(pyridin-4-yl)propanenitrile (6.2 g, 29 mmol, >95% yield) as a light yellow solid which was directly used for the next step without further purification. LCMS: ESI-MS m/z: 147.0 [M+H]+. Step 2: 3-(Pyridin-4-yl)-1H-pyrazol-5-amine. A solution of 3-oxo-3- (pyridin-4-yl)propanenitrile (100 mg, 0.68 mmol, 1.0 equiv) and hydrazine hydrate (85% solution in H2O, 1.0 g, 17 mmol, 25 equiv) in EtOH (5 mL, 0.14 M) was stirred at 100 °C for 2 h. The solution was filtered, and the filtrate was concentrated in vacuo and directly purified by silica gel column chromatography (5% MeOH in DCM) to afford 3-(pyridin-4-yl)-1H-pyrazol-5-amine (50 mg, 46% yield) as a light yellow solid.1H NMR (400 MHz DMSO-d6) δ 11.7 (br s, 1H), 8.53 (dd, J =1.6 Hz, 4.8 Hz, 2H), 7.62 (dd, J = 1.6 Hz, 4.4 Hz, 2H), 5.89 (s, 1H), 5.04 (s, 2H). LCMS: ESI-MS m/z: 161.1 [M+H]+. INTERMEDIATE #14 3-(4-Cyano-3-fluorophenyl)-2-fluoropropanoic acid
Figure imgf000047_0001
Step 1: Dimethyl 2-(4-cyano-3-fluorobenzyl)-2-fluoromalonate. To a solution of dimethyl 2-fluoromalonate (370 mg, 2.5 mmol, 1.1 equiv) in anhydrous DMF (10 mL, 0.23 M) was added NaH (60 wt % in mineral oil, 120 mg, 3.0 mmol, 1.3 equiv) at 0 °C under an atmosphere of nitrogen. After the addition, the mixture was stirred for 1 h at 0 °C, followed by the addition of 4-(bromomethyl)-2- fluorobenzonitrile (500 mg, 2.3 mmol, 1.0 equiv). The mixture was stirred for 1 h at 0 °C, and then was diluted with water (30 mL) and extracted with EtOAc (3 × 20 mL). The combined extracts were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by silica gel column chromatography (5–60% EtOAc in hexanes) to afford dimethyl 2-(4-cyano-3- fluorobenzyl)-2-fluoromalonate (520 mg, 74% yield) as a light yellow solid. LCMS: ESI-MS m/z: 284.1 [M+H]+. Step 2: Methyl 3-(4-cyano-3-fluorophenyl)-2-fluoropropanoate. To a solution of dimethyl 2-(4-cyano-3-fluorobenzyl)-2-fluoromalonate (520 mg, 1.7 mmol, 1.0 equiv) in DMSO (5 mL, 0.34 M) was added LiCl (370 mg, 8.7 mmol, 5.1 equiv) and water (5 mL). The mixture was stirred at 150 °C for 3 h, and then cooled to rt. The mixture was then diluted with water (15 mL) and extracted with EtOAc (3 × 15 mL). The combined extracts were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude product was purified by silica gel column chromatography (5–80% EtOAc in hexanes) to afford methyl 3-(4-cyano- 3-fluorophenyl)-2-fluoropropanoate (140 mg, 35% yield) as a light yellow solid. LCMS: ESI-MS m/z: 226.1 [M+H]+. Step 3: 3-(4-Cyano-3-fluorophenyl)-2-fluoropropanoic acid. To a solution of methyl 3-(4-cyano-3-fluorophenyl)-2-fluoropropanoate (140 mg, 0.62 mmol, 1.0 equiv) in methanol (5 mL, 0.12 M) was added a solution of LiOH (15 mg, 0.62 mmol, 1.0 equiv) in water (5 mL). The mixture was stirred at 50 °C for 3 h, then cooled to rt and treated with an aqueous solution of HCl (0.5 M) until it reached pH 6. The mixture was then extracted with EtOAc (4 × 10 mL). The combined organic fractions were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to afford crude 3-(4-cyano-3-fluorophenyl)-2-fluoropropanoic acid (110 mg, 81% yield) as a light yellow solid. LCMS: ESI-MS m/z: 212.1 [M+H]+. INTERMEDIATE #15 1-Methyl-2-(pyridin-4-yl)-1H-imidazol-5-amine
Figure imgf000048_0001
Step 1: N-Methylisonicotinamide. To a solution of isonicotinic acid (500 mg, 4.1 mmol, 1.0 equiv) in anhydrous toluene (5 mL, 0.82 M) was added SOCl2 (2 mL, 27 mmol, 6.6 equiv) at rt. The mixture was stirred at rt for 2 h and then concentrated in vacuo. The residue was dissolved in anhydrous DCM (5 mL), and then methylamine hydrochloride (540 mg, 8.2 mmol, 2.0 equiv) was added, followed by the addition of triethylamine (840 mg, 8.1 mmol, 2.0 equiv). The resulting mixture was then stirred at rt for another 2 h. The mixture was treated with water (10 mL) and extracted with ethyl acetate (3 ×10 mL). The combined organic fractions were washed with a saturated solution of NH4Cl (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to afford N-methylisonicotinamide (300 mg, 54% yield) as a light yellow solid, which was used without further purification. LCMS: ESI-MS m/z: 137.1 [M+H]+. Step 2: 1-Methyl-2-(pyridin-4-yl)-1H-imidazol-5-amine. A mixture of crude N-methylisonicotinamide (300 mg, 2.2 mmol, 1.0 equiv) in SOCl2 (5 mL) was stirred at rt for 4 h. The reaction was monitored by TLC, and after complete consumption of the starting material, the reaction mixture was concentrated in vacuo. To the resulting residue was added 2-aminoacetonitrile (630 mg 11 mmol, 5.0 equiv) and toluene (5 mL) and the mixture was stirred at 100 °C for 2 h. It was then cooled to rt and concentrated in vacuo, and the resulting crude material was purified by silica gel column chromatography (5% MeOH in DCM) to afford 1-methyl-2-(pyridin-4-yl)- 1H-imidazol-5-amine (50 mg, 13% yield) as a light yellow solid. LCMS: ESI-MS m/z: 175.1 [M+H]+. INTERMEDIATE #16 3-(3-Methylpyridin-4-yl)-1H-pyrazol-5-amine
Figure imgf000049_0001
Step 1: 3-(3-Methylpyridin-4-yl)-3-oxopropanenitrile. To a three-necked round bottomed flask under an atmosphere of nitrogen was added a solution of methyl 3-methylisonicotinate (500 mg, 3.3 mmol, 1.0 equiv) in anhydrous THF (40 mL, 0.083 M), and the solution was cooled to –60 °C. To this solution was added n- butyllithium (2.5 M in hexanes, 2.0 mL, 5.0 mmol, 1.5 equiv) dropwise, maintaining the temperature below –55 °C. After stirring at –60 °C for 1.5 h, anhydrous acetonitrile (210 mg, 5.0 mmol, 1.5 equiv) was slowly added, maintaining the temperature below –55 °C, resulting in a thick slurry. The reaction was stirred for another 1.5 h at –60 °C and then warmed to rt. The mixture was concentrated in vacuo and to the resulting slurry was added 2 mL of DCM. After stirring for 5 min at –10 °C, the slurry was filtered and the solid was collected was dried in vacuo to give crude 3-(3-methylpyridin-4-yl)-3-oxopropanenitrile (400 mg,76% yield) as a light yellow solid which was used without further purification. LCMS: ESI-MS m/z: 161 [M+H]+. Step 2: 3-(3-Methylpyridin-4-yl)-1H-pyrazol-5-amine. To a stirred mixture of 3-(3-methylpyridin-4-yl)-3-oxopropanenitrile (400 mg, 2.5 mmol, 1.0 equiv) in ethanol (5.0 mL, 0.50 M) under an atmosphere of nitrogen was added hydrazine hydrate (0.40 mL, 8.0 mmol, 3.2 equiv), and the mixture was stirred at reflux for 3 h. The solvent was concentrated in vacuo and the residue was purified by silica gel column chromatography (0–10% MeOH in DCM) to afford 3-(3-methylpyridin-4-yl)- 1H-pyrazol-5-amine (400 mg, 92% yield) as a light yellow solid. LCMS: ESI-MS m/z: 175.2 [M+H]+. INTERMEDIATE #17 3-(2-Chlorothiazol-5-yl)propanoic acid
Figure imgf000050_0001
Formic acid (470 mg, 10 mmol, 3.0 equiv) was treated with triethylamine (410 mg, 4.1 mmol, 1.2 equiv) for 30 min at rt. Subsequently, 2-chlorothiazole-5- carbaldehyde (500 mg, 3.4 mmol, 1.0 equiv) and 2,2-dimethyl-1,3-dioxane-4,6-dione (490 mg, 3.4 mmol, 1.0 equiv) were added to the mixture. The reaction mixture was heated to 80 °C for 20 h, then cooled to rt. The mixture was then diluted with water (100 mL) and extracted with EtOAc (4 × 50 mL). The organic material was washed with brine, filtered over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by silica gel column chromatography (15–30% EtOAc in DCM) to afford 3-(2-chlorothiazol-5-yl)propanoic acid (310 mg, 15 mmol, 22% yield) as a white solid. LCMS: ESI-MS m/z: 194.1 [M+H]+. INTERMEDIATE #18 3-(5-Chlorothiazol-2-yl)propanoic acid
Figure imgf000051_0001
Formic acid (280 mg, 6.0 mmol, 3.0 equiv) was treated with triethylamine (247 mg, 2.4 mmol, 1.2 equiv) for 30 min at rt. Subsequently, 5-chlorothiazole-2- carbaldehyde (300 mg, 2.0 mmol, 1.0 equiv) and 2,2-dimethyl-1,3-dioxane-4,6-dione (293 mg, 2.0 mmol, 1.0 equiv) were added to the mixture. The reaction mixture was heated to 95 °C for 20 h, then cooled to rt. The mixture was then diluted with water (100 mL) and extracted with EtOAc (4 × 50 mL). The organic material was washed with brine, filtered over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by silica gel column chromatography (15–30% EtOAC in DCM) to afford 3-(5-chlorothiazol-2-yl)propanoic acid (320 mg, 83% yield) as a white solid. LCMS: ESI-MS m/z: 192.0 [M+H]+. INTERMEDIATE #19 1-(3-Methylpyridin-4-yl)-1H-pyrazol-4-amine
Figure imgf000051_0002
Step 1: 3-Methyl-4-(4-nitro-1H-pyrazol-1-yl)pyridine. A mixture of 4- hydrazineyl-3-methylpyridine hydrochloride (130 mg, 0.81 mmol, 1.0 equiv) and 2- nitromalonaldehyde (110 mg, 0.90 mmol, 1.1 equiv) in EtOH (2.5 mL, 0.32 M) and DMF (2.5 mL, 0.32 M, 0.16 M overall) was stirred at rt for 35 min, and then heated to 100 °C for 4 h. The reaction mixture was diluted with EtOAc (150 mL), then washed with a saturated solution of NaHCO3, water, and brine. The organic fraction was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to afford the crude product. The crude material was purified by silica gel column chromatography (5– 55% EtOAc in DCM) to afford 3-methyl-4-(4-nitro-1H-pyrazol-1-yl)pyridine (67 mg, 40% yield) as a white solid. LCMS: ESI-MS m/z: 205.1 [M+H]+. Step 2: 1-(3-Methylpyridin-4-yl)-1H-pyrazol-4-amine. A mixture of 3- methyl-4-(4-nitro-1H-pyrazol-1-yl)pyridine (67 mg, 0.33 mmol, 1.0 equiv) and SnCl2 (380 mg, 2.0 mmol, 6.1 equiv) in EtOH (8 mL, 0.041M) was stirred at 85 °C for 5 h. The mixture was then concentrated in vacuo and the residue was neutralized with a saturated solution of NaHCO3. The resulting solution was extracted with EtOAc (2 × 80 mL). The combined organic fractions were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated in vacuo and purified by silica gel column chromatography (5–25% EtOAc in hexanes) to afford 1-(3-methylpyridin-4-yl)-1H- pyrazol-4-amine (5.0 mg, 9.0% yield) as a white solid. LCMS: ESI-MS m/z: 175.1 [M+H]+. INTERMEDIATE #20 4-Methyl-3-(3-methylpyridin-4-yl)-1H-pyrazol-5-amine
Figure imgf000052_0001
Step 1: 2-Methyl-3-(3-methylpyridin-4-yl)-3-oxopropanenitrile A solution of propionitrile (1.2 g, 22 mmol, 2.2 equiv) in THF (20 mL, 0.50 M) was cooled to – 40 °C, and LiHMDS in THF (1.0 M solution in THF, 22 mL, 22 mmol, 2.2 equiv) was added dropwise. After the addition, the mixture was stirred at 0 °C for 1 h. Then the mixture was cooled to –40 °C again and methyl 3-methylisonicotinate (1.5 g, 9.9 mmol, 1.0 equiv) was added. After the addition, the mixture was stirred at rt for 30 min. The mixture was filtered and the white solid was collected and dried in vacuo to give crude 2-methyl-3-(3-methylpyridin-4-yl)-3-oxopropanenitrile (1.9 g, >95% yield) which was used directly in the next step without further purification. LCMS: ESI-MS: m/z: 175.1 [M+H]+. Step 2: 4-Methyl-3-(3-methylpyridin-4-yl)-1H-pyrazol-5-amine A mixture of crude 2-methyl-3-(3-methylpyridin-4-yl)-3-oxopropanenitrile (1.9 g, 11 mmol, 1.0 equiv) and hydrazine hydrate (85% w/w in water, 3.7 g, 63 mmol, 5.7 equiv) in ethanol (20 mL, 0.55 M) was stirred at 80 °C overnight. The mixture was concentrated, and purified by silica gel column chromatography (5 % MeOH in DCM) to give 4-methyl-3-(3-methylpyridin-4-yl)-1H-pyrazol-5-amine (0.55 g, 27 % over 2 steps) as a light yellow solid. LCMS: ESI-MS m/z: 189.1 [M+H]+. INTERMEDIATE #21 1-(Pyridin-4-yl)-1H-pyrazol-4-amine
Figure imgf000053_0001
Step 1: 4-(4-Nitro-1H-pyrazol-1-yl)pyridine: A mixture of 4-bromopyridine (1.0 g, 6.4 mmol, 1.0 equiv), 4-nitro-1H-pyrazole (0.72 g, 6.4 mmol, 1.0 equiv), CuI (120 mg, 0.64 mmol, 0.10 equiv), and potassium carbonate (1.8 g, 13 mmol, 2.0 equiv) in anhydrous DMF (20 mL, 0.30 M) was stirred at 110 °C under nitrogen gas for 16 h. The reaction was then cooled to rt and filtered. The filtrate was treated with water (100 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with saturated aqueous NH4Cl (2 × 50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Purification by silica gel column chromatography (5% MeOH in DCM) gave 4-(4-nitro-1H-pyrazol-1-yl)pyridine (600 mg, 49 % yield) as a yellow solid. LCMS: ESI-MS m/z: 191.0 [M+H]+. Step 2: 1-(Pyridin-4-yl)-1H-pyrazol-4-amine: A mixture of 4-(4-nitro-1H- pyrazol-1-yl)pyridine (600 mg, 3.1 mmol, 1.0 equiv), iron powder (960 mg, 17 mmol, 5.4 equiv), and ammonium chloride (930 mg, 17 mmol, 5.4 equiv) in ethanol (10 mL, 0.30 M) was stirred at 100 °C. After 2 h, the mixture was filtered and the filtrated was concentrated in vacuo to give 1-(pyridin-4-yl)-1H-pyrazol-4-amine (500 mg, 99 % yield) as a yellow solid. LCMS: ESI-MS m/z: 161.0 [M+H]+. INTERMEDIATE #22 (5-Amino-3-(pyridin-4-yl)-1H-pyrazol-4-yl)methanol
Figure imgf000054_0001
Step 1: Ethyl (Z)-3-amino-4,4,4-trichloro-2-isonicotinoylbut-2-enoate. To a solution of ethyl 3-oxo-3-(pyridin-4-yl)propanoate (20 g, 100 mmol, 1.0 equiv) in ethanol (500 mL, 0.20 M) was added 2,2,2-trichloroacetonitrile (15 g, 100 mmol, 1.0 equiv) and sodium acetate (8.5 g, 100 mmol, 1.0 equiv). The mixture was stirred at rt for 30 min. The mixture was then filtered, the filtrate was collected and dried in vacuo then used directly in the next step without further manipulation. LCMS: ESI- MS m/z: 337.0 [M +H]+. Step 2: Ethyl 5-amino-3-(pyridin-4-yl)-1H-pyrazole-4-carboxylate. To a solution of crude ethyl (Z)-3-amino-4,4,4-trichloro-2-isonicotinoylbut-2-enoate (100 mmol, 1.0 equiv) in ethanol (500 mL, 0.20 M) was added hydrazine hydrate (5.7 g, 110 mmol, 1.1 equiv) and triethylamine (11 g, 100 mmol, 1.0 equiv) at 0 °C. After the addition, the mixture was heated to 85 °C and stirred for 1 h. The mixture was cooled to rt, the suspension was filtered, the solid was collected and purified by silica gel column chromatography (105 DCM in MeOH) to afford ethyl 5-amino-3-(pyridin- 4-yl)-1H-pyrazole-4-carboxylate (14 g, 56 % over 2 steps) as a yellow solid. LCMS: ESI-MS m/z: 233.0 [M +H]+. Step 3: (5-Amino-3-(pyridin-4-yl)-1H-pyrazol-4-yl)methanol. To a solution of ethyl 5-amino-3-(pyridin-4-yl)-1H-pyrazole-4-carboxylate (1.0 g, 4.3 mmol, 1.0 equiv) in anhydrous THF (100 mL, 0.043 M) was added LiAlH4 (1.0 M solution in THF, 26 mL, 26 mmol, 6.0 equiv) dropwise at –40 °C under an atmosphere of nitrogen. After the addition, the reaction mixture was warmed to 0 °C and stirred for 4 h. At 0 °C, the reaction mixture was quenched carefully by adding 1.0 mL of water dropwise, followed by 3.0 M aqueous NaOH (1.0 mL), and another 1.0 mL of water. The mixture was filtered and the solid was washed a 1:5 solution of MeOH:DCM (3 × 60 mL). The filtrate was collected and concentrated in vacuo, then purified directly by silica gel column chromatography (10% MeOH in DCM + 5% ammonia) to obtain (5- amino-3-(pyridin-4-yl)-1H-pyrazol-4-yl)methanol (300 mg, 61 % yield) as a light yellow solid. LCMS: ESI-MS m/z: 191.1 [M +H]+. INTERMEDIATE #23 4-Chloro-3-(pyridin-4-yl)-1H-pyrazol-5-amine
Figure imgf000055_0001
A mixture of 3-(pyridin-4-yl)-1H-pyrazol-5-amine (Intermediate 13, 100 mg, 0.63 mmol, 1.0 equiv) and N-chlorosuccinimide (36 mg, 0.63 mmol, 1.0 equiv) in acetonitrile (2 mL, 0.32 M) was stirred at rt for 2 h. The reaction mixture was then concentrated in vacuo and purified by silica gel column chromatography (5% MeOH in DCM). The desired fractions were concentrated in vacuo to afford 4-chloro-3- (pyridin-4-yl)-1H-pyrazol-5-amine (50 mg, 0.31 mmol, 50% yield) as a light yellow solid. LCMS: ESI-MS m/z: 195.1 [M+H]+. INTERMEDIATE #24 3-(4-Chloro-3,5-difluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)propanamide
Figure imgf000056_0001
The product was prepared according to General Procedure #1 using Intermediate 2 and Intermediate 9 to afford the desired product 3-(4-chloro-3,5- difluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)- 1H-pyrazol-5-yl)propanamide (910 mg, 1.8 mmol, 55% yield) as a light yellow solid. LCMS: ESI-MS m/z: 507.2 [M+H]+. INTERMEDIATE #25 N-(4-Methyl-3-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5- yl)-3-(3,4,5-trifluorophenyl)propanamide N
Figure imgf000056_0002
The product was prepared according to General Procedure #1 using Intermediate 2 and 3-(3,4,5-trifluorophenyl)propanoic acid to afford the desired product N-(4-methyl-3-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazol-5-yl)-3-(3,4,5-trifluorophenyl)propanamide in 60% yield. LCMS: ESI-MS m/z: 491.1 [M+H]+. INTERMEDIATE #26 3-(4-Chlorophenyl)-2,2-difluoropropanoic acid
Figure imgf000057_0001
Step 1: Ethyl 3-(4-chlorophenyl)-2,2-difluoro-3-hydroxypropanoate. A mixture of 4-chlorobenzaldehyde (1.5 g, 11 mmol, 1.0 equiv), ethyl 2-bromo-2,2- difluoroacetate (2.4 g, 12 mmol, 1.1 equiv) and Zn dust (840 mg, 13 mmol, 1.2 equiv) in THF (30 mL, 0.37 M) was heated to 75 °C for 16 h. The reaction mixture was then cooled to rt, and an aqueous solution of HCl (2.0 M, 4.0 mL, 2.0 equiv) was added. The mixture was washed with water (20 mL) and extracted with EtOAc (3 × 30 mL). The combined organic fractions were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo, and the resulting residue was purified by silica gel column chromatography (10–60% EtOAc in hexanes). The desired fractions were concentrated in vacuo to afford ethyl 3-(4-chlorophenyl)-2,2-difluoro-3- hydroxypropanoate (1.8 g, 6.8 mmol, 64% yield) as a light-yellow oil.1H NMR (400 MHz, DMSO-d6) δ 7.46 (s, 4H), 6.75 (d, J =8.0 Hz, 1H), 5.16–5.08 (m, 1H), 4.32– 4.27 (m, 2H), 1.25 (t, J = 7.2 Hz, 2H). LCMS: ESI-MS m/z: 287.1 [M+Na]+. Step 2: Ethyl 3-bromo-3-(4-chlorophenyl)-2,2-difluoropropanoate. To a solution of ethyl 3-(4-chlorophenyl)-2,2-difluoro-3-hydroxypropanoate (1.8 g, 6.8 mmol, 1.0 equiv) in toluene (30 mL, 0.23 M) was added carbon tetrabromide (2.50 g, 7.5 mmol, 1.1 equiv) followed by triphenylphosphine (2.10 g, 8.1 mmol, 1.2 equiv). The reaction mixture was heated to 70 °C for 4 h. It was then cooled to rt and diluted with water (20 mL), and extracted with ethyl acetate (3 × 30 mL). The combined organic fractions were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (0– 50% EtOAc in petroleum ether). Fractions containing desired product were concentrated in vacuo to afford ethyl 3-bromo-3-(4-chlorophenyl)-2,2- difluoropropanoate (1.9 g, 5.8 mmol, 85% yield) as a light-yellow oil. No ionization was observed for the product using LCMS so the material was moved forward to the next reaction without further characterization. Step 3: Ethyl 3-(4-chlorophenyl)-2,2-difluoropropanoate. To a solution to ethyl 3-bromo-3-(4-chlorophenyl)-2,2-difluoropropanoate (600 mg, 1.8 mmol, 1.0 equiv) in methanol (20 mL, 0.090 M) was added Pd/C (10 wt. %, 200 mg). The atmosphere was exchanged with hydrogen gas, and a hydrogen gas balloon was attached. The reaction mixture was stirred at rt for 16 h. The mixture was then filtered, and the filtrate was concentrated and purified by RP-HPLC (Method C, 5–25 % MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3·H2O) to afford ethyl 3-(4- chlorophenyl)-2,2-difluoropropanoate (30 mg, 0.12 mmol, 6.5% yield) as a white solid. LCMS: ESI-MS m/z: 249.1 [M+H]+. Step 4: 3-(4-Chlorophenyl)-2,2-difluoropropanoic acid. Ethyl 3-(4- chlorophenyl)-2,2-difluoropropanoate (30 mg, 0.12 mmol, 1.0 equiv) was dissolved in a 2:1 solution of EtOH:H2O (6 mL, 0.020 M) and LiOH•H2O (5.1 mg, 0.12 mmol, 1.0 equiv) was added. The reaction mixture was stirred at 70 °C for 1 h. The mixture was cooled to rt, then treated with an aqueous solution of HCl (0.50 M) until pH 5~6. The solid that was precipitated was collected by filtration and dried in vacuo to afford 3-(4-chlorophenyl)-2,2-difluoropropanoic acid (22 mg, 0.10 mmol, 83% yield) as a white solid. LCMS: ESI-MS m/z: 203.0 [M-OH]+. This material was used with no further purification. INTERMEDIATE #27 (rac)-3-(4-Chloro-3,5-difluorophenyl)-2-fluoropropanoic acid
Figure imgf000059_0001
Figure imgf000059_0002
Step 1: 4-Chloro-3,5-difluorobenzaldehyde. To a stirred mixture of 5- bromo-2-chloro-1,3-difluorobenzene (4.5 g, 20 mmol, 1.0 equiv) and LiCl (850 mg, 20 mmol, 1.0 equiv) in anhydrous THF (50 mL, 0.40 M) was added isopropylmagnesium chloride (1.0 M solution in THF, 22 mL, 22 mmol, 1.1 equiv) at –40 °C under an atmosphere of nitrogen gas. After the addition, the mixture was stirred at –40 °C for 1 h, and then anhydrous DMF (1.83 g, 25 mmol, 1.3 equiv) was added dropwise. After the addition, the mixture was warmed to –20 °C for another 1 h. The mixture was quenched with water (20 mL), extracted with ethyl acetate (3 × 20 mL). The organic fractions were combined, washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to afford crude 4- chloro-3,5-difluorobenzaldehyde (3.4 g, 13 mmol, 68% yield) as a light yellow liquid.1H NMR (400 MHz, CDCl3) δ 9.85 (s, 1H), 7.45 (d, J = 6.4 Hz, 2H). LCMS: ESI-MS m/z: 191.1 [M+H]+. Step 2: (4-Chloro-3,5-difluorophenyl)methanol. To a stirred solution of 4- chloro-3,5-difluorobenzaldehyde (3.4 g, 13 mmol, 1.0 equiv) in methanol (40 mL, 0.33 M) was added sodium borohydride (1.1 g, 30 mmol, 2.3 equiv) portionwise at rt. After the addition, the mixture was stirred at rt for another 1 h. The mixture was concentrated in vacuo to remove methanol. The resulting residue was diluted with EtOAc (50 mL), washed with water (20 mL), brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to afford crude (4-chloro-3,5- difluorophenyl)methanol (3.3 g, 12 mmol, 89% yield) as a light yellow liquid. LCMS: ESI-MS m/z: 161.1 [M-17]+. Step 3: 5-(Bromomethyl)-2-chloro-1,3-difluorobenzene. To a stirred solution of (4-chloro-3,5-difluorophenyl)methanol (1.1 g, 4.0 mmol, 1.0 equiv) in DCM (10 mL, 0.40 M) was added phosphorus tribromide (1.4 g, 5.0 mmol, 1.3 equiv) at 0 °C. After the addition, the mixture was stirred at rt for another 2 h. The mixture was poured into ice water (15 mL), stirred for 3 min, and then extracted with DCM (3 × 15 mL). The organic fractions were combined, washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to afford the crude product. The crude material was purified by silica gel column chromatography (5– 10% EtOAc in petroleum ether) to afford 5-(bromomethyl)-2-chloro-1,3- difluorobenzene (800 mg, 3.3 mmol, 83% yield) as a light yellow liquid.1H NMR (400 MHz, CDCl3) δ 7.03 (d, J = 6.8 Hz, 2H), 4.39 (s, 2 H). Step 4: Dimethyl 2-(4-chloro-3,5-difluorobenzyl)-2-fluoromalonate. To a solution of dimethyl 2-fluoromalonate (530 mg, 3.5 mmol, 1.1 equiv) in anhydrous DMF (15 mL, 0.22 M) was added sodium hydride (60 wt % dispersion in mineral oil, 160 mg, 4.0 mmol, 1.1 equiv) at 0 °C under an atmosphere of nitrogen gas. After the addition, the mixture was stirred for 1 h at 0 °C. Then 5-(bromomethyl)-2-chloro-1,3- difluorobenzene (800 mg, 3.3 mmol, 1.0 equiv) was added at 0 °C. The mixture was stirred for 1 h at 0 °C, then was diluted with water (30 mL) and extracted with EtOAc (3 × 20 mL). The combined organic fractions were washed with brine, dried over anhydrous sodium sulfate, filtered, and purified by silica gel column chromatography (10–50% EtOAc in petroleum ether) to afford dimethyl 2-(4-chloro-3,5- difluorobenzyl)-2-fluoromalonate (950 mg, 3.2 mmol, 88% yield) as a light yellow solid. LCMS: ESI-MS m/z: 311.0 [M+H]+. Step 5: (rac)-Methyl 3-(4-chloro-3,5-difluorophenyl)-2-fluoropropanoate. To a solution of dimethyl 2-(4-chloro-3,5-difluorobenzyl)-2-fluoromalonate (950 mg, 3.1 mmol, 1.0 equiv) in DMSO (10 mL, 0.31 M) was added LiCl (650 mg, 15 mmol, 4.8 equiv) and water (10 mL). The mixture was stirred at 150 °C for 3 h, then cooled to rt. The mixture was diluted with water (30 mL) and extracted with EtOAc (3 × 30 mL). The combined organic fractions were washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, concentrated in vacuo, and purified by silica gel column chromatography (15–80% EtOAc in petroleum ether) to give (rac)-methyl 3- (4-chloro-3,5-difluorophenyl)-2-fluoropropanoate (250 mg, 0.99 mmol, 32% yield) as a light yellow solid. LCMS: ESI-MS m/z: 253.1 [M+H]+. Step 6: (rac)-3-(4-Chloro-3,5-difluorophenyl)-2-fluoropropanoic acid. To a solution of (rac)-methyl 3-(4-chloro-3,5-difluorophenyl)-2-fluoropropanoate (250 mg, 0.99 mmol, 1.0 equiv) in methanol (10 mL, 0.099 M) was added a solution of LiOH (72 mg, 3.0 mmol, 3.0 equiv) in water (10 mL). The mixture was stirred at rt for 4 h, and then treated with an aqueous solution of HCl (0.50 M) until pH~6, extracted with EtOAc (4 × 15 mL). The combined organic fractions were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give crude (rac)-3-(4-chloro-3,5-difluorophenyl)-2-fluoropropanoic acid (200 mg, 0.84 mmol, 84% yield) as a light yellow solid. This material was used with no further purification. LCMS: ESI-MS m/z: 219.1 [M-19]+. INTERMEDIATE #28 tert-Butyl 5-amino-4-methyl-3-(pyridin-4-yl)-1H-pyrazole-1-carboxylate
Figure imgf000061_0001
To a mixture of 4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine (Intermediate 1, 8.9 g, 51 mmol, 1.0 equiv) in DCM (100 mL, 0.51 M) and an aqueous solution of potassium hydroxide (2.0 M, 100 mL, 200 mmol, 3.9 equiv) was added Boc anhydride (22 g, 101 mmol, 2.0 equiv) in DCM (30 mL) slowly at 0 °C. After the addition, the mixture was stirred at rt for 8 h. The organic layer of the reaction mixture was then separated, and the aqueous fraction was extracted with DCM (2 × 100 mL). The combined organic fractions were then washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (5% DCM in MeOH) to afford tert-butyl 5-amino-4-methyl-3-(pyridin-4-yl)-1H-pyrazole-1-carboxylate (5.1 g, 18 mmol, 36% yield) as a light yellow solid.1HNMR (400 MHz, DMSO-d6): δ 8.64 (dd, J = 4.5, 1.6 Hz, 2H), 7.61 (dd, J = 4.5, 1.6 Hz, 2H), 6.21 (s, 2H), 1.99 (s, 3H), 1.59 (s, 9H). LCMS: ESI-MS m/z: 275.2 [M+H]+. INTERMEDIATE #29 N-(3-Bromo-1H-pyrazol-5-yl)-3-(4-chlorophenyl)propanamide B
Figure imgf000062_0001
To a solution of 3-bromo-1H-pyrazol-5-amine (100 mg, 0.62 mmol, 1.0 equiv) in DCM (3.0 mL, 0.21 M) was added 3-(4-chlorophenyl)propanoic acid (150 mg, 0.81 mmol, 1.3 equiv), T3P (50% w/w in EtOAc, 300 mg, 0.81 mmol, 1.3 equiv), DIPEA (200 mL, 1.7 mmol, 2.7 equiv). After the addition, the mixture was stirred at rt for 2 h. The reaction mixture was concentrated in vacuo and purified by silica gel column chromatography (15–100% EtOAc in hexanes) to afford N-(3-bromo-1H-pyrazol-5- yl)-3-(4-chlorophenyl)propanamide (140 mg, 0.43 mmol, 69% yield) as a white solid. LCMS: ESI-MS m/z: 328.1 [M+H]+. General procedures: Below are general synthetic protocols that can be used, and where indicated, were used, to prepare the compounds of the invention. GENERAL PROCEDURE #1
Figure imgf000063_0001
The appropriate acid (B) (1.0–1.5 equiv) is dissolved in either DCM, DMF, or DMA, (0.05–0.40 M) with either triethylamine or DIPEA (1.5–10 equiv) and stirred at 0 °C or rt for (5 min to 1 h). HATU (1.1–1.5 equiv) or T3P (50 w/v % in DMF or EtOAc, 1.5–2.0 equiv), is then added at 0 °C or rt and the reaction mixture is stirred for (5 min to 1 h). To the resulting reaction mixture, the appropriate amine (A, R2’ is H or an amino protecting group like Boc) (1.0 equiv) (neat or in a DMF solution (1.0– 1.8 M) is added and the reaction was warmed to rt (if at 0 °C) and was stirred for 5 min–16 h. Upon completion, the reaction mixture is concentrated and purified directly by silica gel column chromatography or RP-HPLC (either Method A: MeCN in H2O + 0.1% TFA, or Method C: MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3·H2O) to afford the desired amides (C) as either trifluoroacetic acid salts (Method A) or as the parent compound (silica gel column chromatography or Method C). GENERAL PROCEDURE #2
Figure imgf000064_0001
Step 1: A solution of amine (e.g., see Intermediate #3) (1.0 equiv) in anhydrous DMF (0.21 M) is treated with NaH (60 wt % dispersion in mineral oil, 1.2 equiv) for 0.5 h at 0 °C. Subsequently, acid chloride (A) (1.2 equiv) is added to the mixture. After stirring for 1 h at rt, a saturated aqueous solution of NH4Cl is added. The mixture is extracted with EtOAc (2 × 10 mL). The organic fractions are filtered over Na2SO4 and concentrated in vacuo to afford the desired compound (B) as a crude product. The material is carried forward to the next step without further purification. Step 2: A mixture of N-SEM protected pyrazole (B) (1.0 equiv) and TFA (2.0 mL) in DCM (0.07 M) are stirred at rt for 5 min to 1 h. The reaction mixture is concentrated in vacuo. The crude material is purified by RP-HPLC (Method A or Method C). Fractions containing the desired mass are combined and concentrated by lyophilization to afford pyrazole (C) as the desired product. GENERAL PROCEDURE #3
Figure imgf000065_0001
A mixture of N-SEM protected pyrazole (A) (1.0 equiv) and TFA (1–10 equiv) in DCM (0.05–0.60 M) is stirred at rt or 50 °C for 5 min to 1 h. The reaction mixture is concentrated in vacuo and the crude material is purified directly by RP- HPLC. Fractions containing the desired mass are combined and concentrated by lyophilization to afford pyrazole (B) as the desired product. GENERAL PROCEDURE #4
Figure imgf000065_0002
Figure imgf000065_0004
To a mixture of carboxylic acid A (1.0 equiv) in anhydrous DCM (x-x M) is added oxalyl chloride (1.5–3.0 equiv) and one drop of anhydrous DMF at 0 °C. After the addition, the mixture is warmed to rt and stirred for 1 h. The solution is then concentrated in vacuo to afford crude product B. This material is used without further purification. EXAMPLE 1 N-Acetyl-3-(4-chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide
Figure imgf000065_0003
The product was prepared according to General Procedure #2 using Intermediate 3 and acetyl chloride to give N-acetyl-3-(4-chlorophenyl)-N-(4-methyl- 3-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)propanamide (150 mg, 50% purity) as a crude intermediate. The crude material was then treated directly as outlined in Step 2 of the same general procedure to give N-acetyl-3-(4- chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (20 mg, 0.052 mmol, 13% yield over two steps) as a white solid.1H NMR (400 MHz, DMSO- d6) δ 13.7 (s, 1H), 8.73 (d, J = 5.3 Hz, 2H), 7.72 (s, 2H), 7.37–7.29 (m, 2H), 7.27– 7.20 (m, 2H), 2.84 (s, 4H), 2.23 (s, 3H), 1.99 (s, 3H). LCMS: ESI-MS m/z: 383.1 [M+H]+. EXAMPLE 2 3-(4-Chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-N- propionylpropanamide
Figure imgf000066_0001
The product was prepared according to General Procedure #2 using Intermediate 3 and propionyl chloride. The resulting intermediate was then treated directly with TFA as described in Step 2 of General Procedure #2 to give 3-(4- chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-N- propionylpropanamide (28 mg, 0.072 mmol, 18% yield over two steps) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.8 (s, 1H), 8.82 (s, 2H), 7.88 (s, 2H), 7.37– 7.22 (m, 4H), 2.89 (dd, J = 18.6, 6.4 Hz, 4H), 2.47 (s, 2H), 2.01 (s, 3H), 1.00 (t, J = 7.3 Hz, 3H). LCMS: ESI-MS m/z: 397.1 [M+H]+. EXAMPLE 3 3-(4-Chlorophenyl)-N-(3-(4-chlorophenyl)propanoyl)-N-(4-methyl-3-(pyridin-4- yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000066_0002
The product was prepared according to General Procedure #2 using Intermediate 3 and 3-(4-chlorophenyl)propanoyl chloride. The resulting acylated product was then subject to TFA according to Step 2 of the same general procedure to give 3-(4-chlorophenyl)-N-(3-(4-chlorophenyl)propanoyl)-N-(4-methyl-3-(pyridin-4- yl)-1H-pyrazol-5-yl)propanamide (38 mg, 0.10 mmol, 25% yield over two steps) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.6 (s, 1H), 8.68 (m, 2H), 7.62 (m, 2H), 7.35–7.21 (m, 8H), 2.83 (m, 8H), 1.87 (m, 3H). LCMS: ESI-MS m/z: 507.2 [M+H]+. EXAMPLE 4 3-(3-Chlorophenyl)-N-(3-(4-chlorophenyl)propanoyl)-N-(4-methyl-3-(pyridin-4- yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000067_0001
The product was prepared according to General Procedure #2 using Intermediate 3 and 3-(3-chlorophenyl)propanoyl chloride. The resulting intermediate was treated with TFA according to Step 2 of the same general procedure to give 3-(3- chlorophenyl)-N-(3-(4-chlorophenyl)propanoyl)-N-(4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-yl)propanamide (35 mg, 0.092 mmol, 23% yield over two steps) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.6 (s, 1H), 8.68 (d, J = 5.4 Hz, 2H), 7.62 (d, J = 5.4 Hz, 2H), 7.32–7.26 (m, 4H), 7.25–7.20 (m, 3H), 7.16 (d, J = 7.5 Hz, 1H), 2.84 (d, J = 12.0 Hz, 8H), 1.88 (s, 3H). LCMS: ESI-MS m/z: 507.1 [M+H]+. EXAMPLE 5 3-(2-Chlorophenyl)-N-(3-(4-chlorophenyl)propanoyl)-N-(4-methyl-3-(pyridin-4- yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000068_0001
The product was prepared according to General Procedure #2 using Intermediate 3 and 3-(2-chlorophenyl)propanoyl chloride. The resulting acylated intermediate was then treated with TFA according to Step 2 of the same general procedure, to give 3-(2-chlorophenyl)-N-(3-(4-chlorophenyl)propanoyl)-N-(4-methyl- 3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (35 mg, 0.092 mmol, 23% yield over two steps) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.6 (s, 1H), 8.68 (d, J = 5.8 Hz, 2H), 7.62 (d, J = 6.0 Hz, 2H), 7.39 (dd, J = 7.2, 1.9 Hz, 1H), 7.33–7.29 (m, 3H), 7.24 (ddd, J = 8.4, 5.1, 2.8 Hz, 4H), 2.84 (m, 8H), 1.90 (s, 3H). LCMS: ESI-MS m/z: 507.1 [M+H]+. EXAMPLE 6 3-(4-Chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-N-(3- phenylpropanoyl)propanamide
Figure imgf000068_0002
The product was prepared according to General Procedure #2 using Intermediate 3 and 3-phenylpropanoyl chloride. The resulting acylated intermediate was then treated with TFA according to Step 2 of the same general procedure to give 3-(4-chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-N-(3- phenylpropanoyl)propanamide (38 mg, 0.10 mmol, 25% yield over two steps) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.6 (s, 1H), 8.68 (d, J = 6.1 Hz, 2H), 7.62 (dd, J = 4.6, 1.6 Hz, 2H), 7.31 (d, J = 8.4 Hz, 2H), 7.27–7.21 (m, 4H), 7.19–7.15 (m, 3H), 2.84 (s, 8H), 1.87 (s, 3H). LCMS: ESI-MS m/z: 473.2 [M+H]+. EXAMPLE 7 N-(3-(4-Chlorophenyl)propanoyl)-4-methyl-N-(4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-yl)pentanamide N
Figure imgf000069_0001
The product was prepared according to General Procedure #2 using Intermediate 3 and 4-methylpentanoyl chloride. The resulting acylated intermediate was then treated with TFA according to Step 2 of the same general procedure to give N-(3-(4-chlorophenyl)propanoyl)-4-methyl-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol- 5-yl)pentanamide (31 mg, 0.080 mmol, 20% yield over two steps) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.6 (s, 1H), 8.69 (d, J = 5.9 Hz, 2H), 7.63 (d, J = 5.9 Hz, 2H), 7.32 (d, J = 8.3 Hz, 2H), 7.24 (d, J = 8.3 Hz, 2H), 2.86 (s, 4H), 2.47 (s, 2H), 1.95 (s, 3H), 1.53–1.45 (m, 1H), 1.40 (dd, J = 14.5, 7.3 Hz, 2H), 0.80 (d, J = 6.5 Hz, 6H). LCMS: ESI-MS m/z: 439.1 [M+H]+. EXAMPLE 8 3-(4-Chlorophenyl)-N-(3-cyclopentylpropanoyl)-N-(4-methyl-3-(pyridin-4-yl)- 1H-pyrazol-5-yl)propanamide N
Figure imgf000069_0002
, , The product was prepared according to General Procedure #2 using Intermediate 3 and 3-cyclopentylpropanoyl chloride. The resulting acylated intermediate was treated with TFA according to Step 2 of the same general procedure to give 3-(4-chlorophenyl)-N-(3-cyclopentylpropanoyl)-N-(4-methyl-3-(pyridin-4-yl)- 1H-pyrazol-5-yl)propanamide (46 mg, 0.12 mmol, 30% yield over two steps) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.6 (s, 1H), 8.69 (d, J = 5.3 Hz, 2H), 7.63 (d, J = 5.7 Hz, 2H), 7.32 (d, J = 8.4 Hz, 2H), 7.24 (d, J = 8.4 Hz, 2H), 2.86 (s, 4H), 2.47 (s, 2H), 1.95 (s, 3H), 1.71–1.59 (m, 3H), 1.56–1.40 (m, 6H), 1.03–0.93 (m, 2H). LCMS: ESI-MS m/z: 465.1 [M+H]+. EXAMPLE 9 3-(4-Chloro-3,5-difluorophenyl)-N-(3-(4-chloro-3,5-difluorophenyl)propanoyl)- N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000070_0001
The product was prepared according to General Procedure #2 using Intermediate 24 and 3-(4-chloro-3,5-difluorophenyl)propanoyl chloride (prepared according to General Procedure #4 from carboxylic acid Intermediate 9) to afford 3- (4-chloro-3,5-difluorophenyl)-N-(3-(4-chloro-3,5-difluorophenyl)propanoyl)-N-(4- methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (16 mg, 0.028 mmol, 16% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.6 (s, 1H), 8.77 (s, 2H), 7.65 (d, J = 4.3 Hz, 2H), 7.20 (d, J = 8.4 Hz, 4H), 2.87 (s, 8H), 1.93 (s, 3H). LCMS: ESI-MS m/z: 579.2 [M+H]+. EXAMPLE 10 N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5-trifluorophenyl)-N-(3- (3,4,5-trifluorophenyl)propanoyl)propanamide
Figure imgf000070_0002
The product was prepared according to General Procedure #2 using Intermediate 25 and 3-(3,4,5-trifluorophenyl)propanoyl chloride (prepared according to General Procedure #4 from carboxylic acid 3-(3,4,5-trifluorophenyl)propanoic acid) to afford N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5- trifluorophenyl)-N-(3-(3,4,5-trifluorophenyl)propanoyl)propanamide in 20% yield.1H NMR (400 MHz, DMSO-d6) δ 13.6 (s, 1H), 8.71 (d, J = 5.9 Hz, 2H), 7.67 (s, 2H), 7.19 (dd, J = 9.1, 6.9 Hz, 4H), 2.85 (s, 8H), 1.93 (s, 3H). LCMS: ESI-MS m/z: 547.2 [M+H]+. EXAMPLE 11 3-(4-Chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-N- (methylsulfonyl)propanamide
Figure imgf000071_0001
The product was prepared according to General Procedure #2 using Intermediate 3 and methanesulfonyl chloride. The resulting intermediate was then treated directly with TFA according to Step 2 of the same general procedure to give 3- (4-chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-N- (methylsulfonyl)propanamide (46 mg, 0.12 mmol, 30% yield over two steps) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.8 (s, 1H), 8.69 (d, J = 6.1 Hz, 2H), 7.64 (dd, J = 4.6, 1.6 Hz, 2H), 7.31–7.28 (m, 2H), 7.19 (d, J = 8.4 Hz, 2H), 3.51 (s, 3H), 2.81 (t, J = 7.5 Hz, 2H), 2.47 (d, J = 8.8 Hz, 2H), 2.12 (s, 3H). LCMS: ESI-MS m/z: 419.1 [M+H]+. EXAMPLE 12 3-(4-Chlorophenyl)-N-isobutyryl-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000072_0001
The product was prepared according to General Procedure #2 using Intermediate 3 and isobutyryl chloride. The resulting acylated intermediate was then treated directly with TFA according to Step 2 of the same general procedure to give 3- (4-chlorophenyl)-N-isobutyryl-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (38 mg, 0.10 mmol, 25% yield over two steps) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.6 (s, 1H), 8.69 (d, J = 5.8 Hz, 2H), 7.63 (d, J = 6.1 Hz, 2H), 7.35–7.30 (m, 2H), 7.28–7.22 (m, 2H), 2.94–2.89 (m, 1H), 2.88 (d, J = 3.7 Hz, 4H), 1.94 (s, 3H), 1.05 (d, J = 6.8 Hz, 6H). LCMS: ESI-MS m/z: 411.2 [M+H]+. EXAMPLE 13 3-(4-Chloro-3,5-difluorophenyl)-N-(4-ethyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000072_0002
The product was prepared according to General Procedure #1 using Intermediate 4 and Intermediate 9 to yield the desired product 3-(4-chloro-3,5- difluorophenyl)-N-(4-ethyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide (31 mg, 0.079 mmol, 30% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.0 (s, 1H), 9.74 (d, J = 113.7 Hz, 1H), 8.76–8.50 (m, 2H), 7.70–7.45 (m, 2H), 7.27 (d, J = 8.6 Hz, 2H), 2.96 (t, J = 7.2 Hz, 2H), 2.69 (s, 2H), 2.47–2.31 (m, 2H), 0.92 (s, 3H). LCMS: ESI-MS m/z: 391.0 [M+H]+. EXAMPLE 14 3-(4-Chlorophenyl)-N-(4-ethyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000073_0001
The product was prepared according to General Procedure #1 using Intermediate 4 and 3-(4-chlorophenyl)propanoic acid to give the desired product, 3- (4-chlorophenyl)-N-(4-ethyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (31 mg, 0.079 mmol, 30% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 8.66 (m, 2H), 7.53 (m, 2H), 7.38–7.28 (m, 3H), 7.26–7.17 (m, 2H), 3.05 (m, 2H), 2.76 (m, 2H), 2.49 (m, 2H), 1.06 (t, J = 7.2 Hz, 3H). LCMS: ESI-MS m/z: 355.1 [M+H]+. EXAMPLE 15 3-(4-Cyano-3,5-difluorophenyl)-N-(4-ethyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000073_0002
The product was prepared according to General Procedure #1 using Intermediate 4 and Intermediate 8 to give the desired product 3-(4-cyano-3,5- difluorophenyl)-N-(4-ethyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (29 mg, 0.074 mmol, 28% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 9.92–9.63 (m, 1H), 8.65 (s, 2H), 7.55 (s, 2H), 7.41 (d, J = 9.5 Hz, 2H), 3.04 (t, J = 7.2 Hz, 2H), 2.68 (dd, J = 14.1, 12.3 Hz, 2H), 2.35 (dd, J = 20.4, 19.4 Hz, 2H), 0.93 (s, 3H). LCMS: ESI-MS m/z: 382.1 [M+H]+. EXAMPLE 16 3-(4-Cyano-3-fluorophenyl)-N-(4-ethyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000074_0001
The product was prepared according to General Procedure #1 using Intermediate 4 and Intermediate 10 to afford the desire product, 3-(4-cyano-3- fluorophenyl)-N-(4-ethyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (33 mg, 0.084 mmol, 32% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.0–12.9 (m, 1H), 9.92–9.63 (m, 1H), 8.65 (s, 2H), 7.87 (t, J = 7.5 Hz, 1H), 7.55 (d, J = 1.2 Hz, 2H), 7.47 (d, J = 10.8 Hz, 1H), 7.35 (d, J = 7.5 Hz, 1H), 3.03 (t, J = 7.2 Hz, 2H), 2.72 (s, 2H), 2.41 (s, 2H), 0.93 (s, 3H). LCMS: ESI-MS m/z: 364.1 [M+H]+. EXAMPLE 17 3-(5-Chlorothiophen-2-yl)-N-(4-ethyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide
Figure imgf000074_0002
The product was prepared according to General Procedure 1 using Intermediate 4 and 3-(5-chlorothiophen-2-yl)propanoic acid to afford 3-(5- chlorothiophen-2-yl)-N-(4-ethyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide (23 mg, 58% yield) as a white solid, trifluoroacetic acid salt.1H NMR (400 MHz, DMSO- d6) δ 9.92 (s, 1H), 8.81–8.74 (m, 2H), 7.94 (s, 1H), 6.94 (d, J = 3.7 Hz, 1H), 6.79 (d, J = 3.8 Hz, 1H), 3.07 (t, J = 7.1 Hz, 2H), 2.70 (t, J = 7.1 Hz, 2H), 2.56 (q, J = 7.3 Hz, 2H), 1.00 (t, J = 7.5 Hz, 3H). LCMS: ESI-MS m/z: 361.1 [M+H]+. EXAMPLE 18 (rac)-3-(4-chlorophenyl)-2-fluoro-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000075_0001
Step 1: (rac)-3-(4-Chlorophenyl)-2-fluoro-N-(4-methyl-3-(pyridin-4-yl)-1- ((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)propenamide. The product was prepared according to General Procedure #1 using Intermediate 2 and Intermediate 5 to give the desired product (rac)-3-(4-chlorophenyl)-2-fluoro-N-(4-methyl-3-(pyridin- 4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)propanamide (400 mg, 0.82 mmol, >95% crude yield, 65% purity) as an oil. The crude material was carried forward to the next step without further purification. LCMS: ESI-MS m/z: 489.2 [M+H]+. Step 2: (rac)-3-(4-Chlorophenyl)-2-fluoro-N-(4-methyl-3-(pyridin-4-yl)- 1H-pyrazol-5-yl)propanamide. A mixture of (rac)3-(4-chlorophenyl)-2-fluoro-N-(4- methyl-3-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5- yl)propanamide (400 mg, 0.82 mmol, 1.0 equiv) and TFA (3.0 mL) in DCM (6.0 mL, 0.14 M) was stirred at rt for 2 h. The reaction mixture was concentrated in vacuo and the crude material was purified directly by RP-HPLC (Method C, 15–40% MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3·H2O). Fractions containing the desired mass were combined and concentrated by lyophilization to afford (rac)-3-(4-chlorophenyl)- 2-fluoro-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (110 mg, 0.32 mmol, 65% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.2–13.1 (m, 1H), 10.2–10.0 (m, 1H), 8.67–8.62 (m, 2H), 7.65–7.59 (m, 2H), 7.42–7.34 (m, 4H), 5.43–5.29 (m, 1H), 3.31–3.12 (m, 2H), 1.94 (s, 3H). LCMS: ESI-MS m/z: 359.1 [M+H]+. EXAMPLE 19 3-(4-Chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000076_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-chlorophenyl)propanoic acid to afford 3-(4-chlorophenyl)-N- (4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide (3.3 g, 48% yield) as an off- white solid.1H NMR (400 MHz, DMSO-d6) δ 13.0 (s, 1H), 9.81 (s, 1H), 8.63 (d, J = 5.6 Hz, 2H), 7.58 (d, J = 5.6 Hz, 2H), 7.36–7.29 (m, 4H), 2.91 (t, J = 7.6 Hz, 2H), 2.64 (t, J = 7.6 Hz, 2H), 1.98 (s, 3H). LCMS: ESI-MS m/z: 341.1 [M+H]+. EXAMPLE 20 3-(Benzo[d][1,3]dioxol-5-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000076_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(benzo[d][1,3]dioxol-5-yl)propanoic acid to afford 3- (benzo[d][1,3]dioxol-5-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide (41% yield) as a white solid.1H NMR (500 MHz, DMSO-d6) δ 14.0 (s, 1H), 9.77 (s, 1H), 8.63 (d, J = 5.5 Hz, 2H), 7.59 (d, J = 6.0 Hz, 2H), 6.83–6.73 (m, 3H), 5.96 (s, 2H), 2.84 (t, J = 7.0 Hz, 2H), 2.60 (t, J = 7.5 Hz, 2H), 1.99 (s, 3H). LCMS: ESI-MS m/z: 351.1 [M+H]+. EXAMPLE 21 3-(3,5-Dichlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000077_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(3,5-dichlorophenyl)propanoic acid to afford 3-(3,5- dichlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide (27% yield) as a white solid.1H NMR (500 MHz, DMSO-d6) δ 13.1–13.0 (m, 1H), 10.0– 9.71 (m, 1H), 8.65–8.58 (m, 2H), 7.64–7.57 (m, 2H), 7.44–7.36 (m, 3H), 2.94 (t, J = 7.2 Hz, 2H), 2.72–2.64 (m, 2H), 2.04–1.94 (m, 3H). LCMS: ESI-MS m/z: 375.0 [M+H]+. EXAMPLE 22 N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-phenylpropanamide
Figure imgf000077_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-phenylpropanoic acid to afford N-(4-methyl-3-(pyridin-4-yl)- 1H-pyrazol-5-yl)-3-phenylpropanamide (42% yield). 1H NMR (500 MHz, DMSO-d6) δ 13.1–13.0 (m, 1H), 9.97–9.70 (m, 1H), 8.65–8.59 (m, 2H), 7.64–7.57 (m, 2H), 7.31–7.18 (m, 5H), 2.91 (d, J = 6.7 Hz, 2H), 2.74–2.57 (m, 2H), 2.05–1.95 (m, 3H). LCMS: ESI-MS m/z: 307.1 [M+H]+. EXAMPLE 23 3-(2-Chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000077_0003
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(2-chlorophenyl)propanoic acid to afford 3-(2-chlorophenyl)-N- (4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide (20% yield).1H NMR (500 MHz, DMSO-d6) δ 13.0 (s, 1H), 9.80 (s, 1H), 8.63 (d, J = 5.2 Hz, 2H), 7.60 (d, J = 5.5 Hz, 2H), 7.45–7.39 (m, 2H), 7.32–7.22 (m, 2H), 3.03 (t, J = 7.7 Hz, 2H), 2.67 (t, J = 7.6 Hz, 2H), 2.01 (s, 3H). LCMS: ESI-MS m/z: 341.0 [M+H]+. EXAMPLE 24 N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(p-tolyl)propanamide
Figure imgf000078_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(p-tolyl)propanoic acid to afford N-(4-methyl-3-(pyridin-4-yl)- 1H-pyrazol-5-yl)-3-(p-tolyl)propenamide (37% yield).1H NMR (500 MHz, DMSO- d6) δ 13.1–12.9 (m, 1H), 9.96–9.68 (m, 1H), 8.66–8.58 (m, 2H), 7.64–7.56 (m, 2H), 7.16–7.09 (m, 4H), 2.88–2.85 (m, 2H), 2.67–2.57 (m, 2H), 2.26 (s, 3H), 2.05–1.95 (m, 3H). LCMS: ESI-MS m/z: 321.2 [M+H]+. EXAMPLE 25 N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(m-tolyl)propanamide
Figure imgf000078_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(m-tolyl)propanoic acid to afford the desired compound, N-(4- methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(m-tolyl)propenamide in 25% yield.1H NMR (500 MHz, DMSO-d6) δ 13.2–12.9 (m, 1H), 9.94–9.69 (m, 1H), 8.65 (s, 2H), 7.59 (s, 1H), 7.18 (t, J = 7.5 Hz, 1H), 7.12–7.03 (m, 1H), 7.01 (d, J = 7.4 Hz, 1H), 2.88 (t, J = 7.6 Hz, 2H), 2.62 (s, 2H), 2.04–1.97 (m, 3H). LCMS: ESI-MS m/z: 321.1 [M+H]+. EXAMPLE 26 N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(o-tolyl)propanamide
Figure imgf000079_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(o-tolyl)propanoic acid to afford N-(4-methyl-3-(pyridin-4-yl)- 1H-pyrazol-5-yl)-3-(o-tolyl)propenamide (40% yield).1H NMR (500 MHz, DMSO- d6) δ 13.1–13.0 (m, 1H), 10.0–9.63 (m, 1H), 8.66–8.59 (m, 2H), 7.65–7.57 (m, 2H), 7.20–7.09 (m, 4H), 2.90 (t, J = 6.6 Hz, 2H), 2.64–2.57 (m, 2H), 2.32 (s, 3H), 2.07 (s, 3H). LCMS: ESI-MS m/z: 321.1 [M+H]+. EXAMPLE 27 3-(4-Methoxyphenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000079_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-methoxyphenyl)propanoic acid to afford 3-(4- methoxyphenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide (22% yield).1H NMR (500 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 9.95–9.68 (m, 1H), 8.66–8.59 (m.2H), 7.64–4.56 (m, 2H), 7.18 (d, J = 8.4 Hz, 2H), 6.85 (d, J = 8.4 Hz, 2H), 3.72 (s, 3H), 2.85–2.83 (m, 2H), 2.66–2.56 (m, 2H), 2.06–1.95 (m, 3H). LCMS: ESI-MS m/z: 337.1 [M+H]+. EXAMPLE 28 N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(naphthalen-2-yl)propanamide
Figure imgf000080_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(naphthalen-2-yl)propanoic acid to afford N-(4-methyl-3- (pyridin-4-yl)-1H-pyrazol-5-yl)-3-(naphthalen-2-yl)propenamide in 18% yield.1H NMR (500 MHz, DMSO-d6) δ 13.1–13.0 (m, 1H), 10.0–9.73 (m, 1H), 8.65–8.58 (m, 2H), 7.94–7.72 (m, 4H), 7.70–7.37 (m, 5H), 3.10 (s, 2H), 2.80–2.73 (m, 2H), 2.03– 1.98 (m, 3H). LCMS: ESI-MS m/z: 357.1 [M+H]+. EXAMPLE 29 N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(naphthalen-1-yl)propanamide N
Figure imgf000080_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(naphthalen-1-yl)propanoic acid to afford N-(4-methyl-3- (pyridin-4-yl)-1H-pyrazol-5-yl)-3-(naphthalen-1-yl)propenamide (29% yield).1H NMR (500 MHz, DMSO-d6) δ 13.1–13.0 (m, 1H), 10.0–9.75 (m, 1H), 8.67–8.58 (m, 2H), 8.21–8.06 (m, 1H), 7.94 (d, J = 8.1 Hz, 1H), 7.84–7.74 (m, 1H), 7.67–7.50 (m, 4H), 7.44 (d, J = 3.4 Hz, 2H), 3.41 (dd, J = 14.9, 7.5 Hz, 2H), 2.83–2.73 (m, 2H), 2.06–1.98 (m, 3H). LCMS: ESI-MS m/z: 357.1 [M+H]+. EXAMPLE 30 3-(3-Chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000080_0003
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(3-chlorophenyl)propanoic acid to afford 3-(3-chlorophenyl)-N- (4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide (17 % yield).1H NMR (500 MHz, DMSO-d6) δ 13.0 (s, 1H), 9.76 (s, 1H), 8.63 (s, 2H), 7.59 (s, 2H), 7.33 (dd, J = 14.2, 6.3 Hz, 2H), 7.25 (t, J = 8.7 Hz, 2H), 2.93 (t, J = 7.5 Hz, 2H), 2.65 (dd, J = 12.7, 5.0 Hz, 2H), 1.97 (s, 3H). LCMS: ESI-MS m/z: 341.1 [M+H]+. EXAMPLE 31 3-(3,4-Dichlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000081_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(3,4-dichlorophenyl)propanoic acid to afford 3-(3,4- dichlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 23% yield.1H NMR (400 MHz, DMSO-d6) δ 13.1–13.0 (m, 1H), 9.97–9.71 (m, 1H), 8.65– 8.59 (m, 2H), 7.64–7.55 (m, 4H), 7.28 (dd, J = 8.3, 1.9 Hz, 1H), 2.93 (t, J = 7.0 Hz, 2H), 2.66 (dd, J = 18.5, 11.5 Hz, 2H), 2.04–1.94 (m, 3H). LCMS: ESI-MS m/z: 375.0 [M+H]+. EXAMPLE 32 N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4- (trifluoromethyl)phenyl)propanamide
Figure imgf000081_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-(trifluoromethyl)phenyl)propanoic acid to afford N-(4- methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-(trifluoromethyl)phenyl)propenamide in 33% yield. 1H NMR (500 MHz, DMSO-d6) δ 13.1–13.0 (m, 1H), 9.99–9.73 (m, 1H), 8.75–8.48 (m, 2H), 7.69–7.34 (m, 6H), 3.09–2.85 (m, 2H), 2.74–2.67 (m, 2H), 2.03–1.93 (m, 3H). LCMS: ESI-MS m/z: 375.1 [M+H]+. EXAMPLE 33 3-(4-Fluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000082_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-fluorophenyl)propanoic acid to afford 3-(4-fluorophenyl)-N- (4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 26% yield.1H NMR (500 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 9.96–9.69 (m, 1H), 8.66–8.58 (m, 2H), 7.65– 7.56 (m, 2H), 7.30 (dd, J = 8.1, 5.8 Hz, 2H), 7.11 (t, J = 8.7 Hz, 2H), 2.94–2.89 (m, 2H), 2.69–2.60 (m, 2H), 2.05–1.94 (m, 3H). LCMS: ESI-MS m/z: 325.1 [M+H]+. EXAMPLE 34 3-(4-Ethylphenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000082_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-ethylphenyl)propanoic acid to afford 3-(4-ethylphenyl)-N-(4- methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide (20% yield).1H NMR (400 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 10.0–9.68 (m, 1H), 8.75–8.42 (m, 2H), 7.73– 7.44 (m, 2H), 7.30–7.00 (m, 4H), 2.89 (dt, J = 14.0, 4.0 Hz, 2H), 2.70–2.53 (m, 4H), 2.05–1.95 (m, 3H), 1.16 (t, J = 7.6 Hz, 3H). LCMS: ESI-MS m/z: 335.1 [M+H]+. EXAMPLE 35 3-(4-Bromophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000083_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-bromophenyl)propanoic acid to afford 3-(4-bromophenyl)-N- (4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 34% yield.1H NMR (500 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 9.97–9.70 (m, 1H), 8.66–8.58 (m, 2H), 7.65– 7.56 (m, 2H), 7.48 (d, J = 8.2 Hz, 2H), 7.24 (d, J = 8.3 Hz, 2H), 2.90 (q, J = 7.1 Hz, 2H), 2.70– 2.60 (m, 2H), 2.05–1.94 (m, 3H). LCMS: ESI-MS m/z: 385.0 [M+H]+. EXAMPLE 36 3-(4-Cyanophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide N
Figure imgf000083_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-cyanophenyl)propanoic acid to afford 3-(4-cyanophenyl)-N- (4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 14% yield.1H NMR (500 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 10.0–9.73 (m, 1H), 8.66–8.59 (m, 2H), 7.77 (d, J = 8.1 Hz, 2H), 7.64–7.48 (m, 4H), 3.01–2.99 (m, 2H), 2.75–2.64 (m, 2H), 2.05– 1.93 (m, 3H). LCMS: ESI-MS m/z: 332.1 [M+H]+. EXAMPLE 37 N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-nitrophenyl)propanamide
Figure imgf000083_0003
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-nitrophenyl)propanoic acid to afford N-(4-methyl-3-(pyridin- 4-yl)-1H-pyrazol-5-yl)-3-(4-nitrophenyl)propenamide (13% yield).1H NMR (500 MHz, DMSO-d6) δ 13.0 (s, 1H), 9.84 (s, 1H), 8.63 (d, J = 5.6 Hz, 2H), 7.58 (t, J = 7.8 Hz, 4H), 8.18 (d, J = 8.6 Hz, 2H), 3.10–2.92 (m, 2H), 2.72 (t, J = 7.5 Hz, 2H), 1.97 (s, 3H). LCMS: ESI-MS m/z: 352.2 [M+H]+. EXAMPLE 38 3-(6-Chloropyridin-3-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000084_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(6-chloropyridin-3-yl)propanoic acid to afford 3-(6- chloropyridin-3-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 26% yield.1H NMR (400 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 10.0–9.73 (m, 1H), 8.67–8.58 (m, 2H), 8.33 (d, J = 0.6 Hz, 1H), 7.78 (dd, J = 8.2, 2.3 Hz, 1H), 7.65–7.55 (m, 2H), 7.45 (s, 1H), 2.94 (d, J = 7.1 Hz, 2H), 2.74–2.63 (m, 2H), 2.04–1.92 (m, 3H). LCMS: ESI-MS m/z: 342.1 [M+H]+. EXAMPLE 39 3-(5-Chloropyridin-2-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000084_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(5-chloropyridin-2-yl)propanoic acid to afford 3-(5- chloropyridin-2-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 24% yield.1H NMR (400 MHz, DMSO-d6) δ 13.0 (s, 1H), 9.83 (s, 1H), 8.63 (dd, J = 3.7, 1.0 Hz, 2H), 8.54 (d, J = 2.2 Hz, 1H), 7.84 (dd, J = 8.4, 2.5 Hz, 1H), 7.70–7.54 (m, 2H), 7.37 (d, J = 8.3 Hz, 1H), 3.07 (dd, J = 9.6, 5.3 Hz, 2H), 2.78 (dd, J = 9.0, 5.1 Hz, 2H), 2.00 (s, 3H). LCMS: ESI-MS m/z: 342.0 [M+H]+. EXAMPLE 40 3-(4-Chloro-2,5-difluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000085_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-chloro-2,5-difluorophenyl)propanoic acid to afford 3-(4- chloro-2,5-difluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide in 38% yield.1H NMR (400 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 10.0–9.75 (m, 1H), 8.67–8.58 (m, 2H), 7.60 (ddd, J = 16.8, 9.3, 4.2 Hz, 3H), 7.51– 7.36 (m, 1H), 2.93 (t, J = 6.6 Hz, 2H), 2.68 (dt, J = 14.5, 7.7 Hz, 2H), 2.05–1.94 (m, 3H). LCMS: ESI-MS m/z: 377.0 [M+H]+. EXAMPLE 41 3-(4-Chloro-2-fluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000085_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-chloro-2-fluorophenyl)propanoic acid to afford 3-(4-chloro-2- fluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 45% yield.1H NMR (400 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 10.0–9.74 (m, 1H), 8.66– 8.60 (m, 2H), 7.64–7.58 (m, 2H), 7.38 (t, J = 8.3 Hz, 2H), 7.24 (dd, J = 8.2, 1.7 Hz, 1H), 2.93 (t, J = 7.1 Hz, 2H), 2.64 (s, 2H), 2.04–1.95 (m, 3H). LCMS: ESI-MS m/z: 359.0 [M+H]+. EXAMPLE 42 3-(4-Chloro-2-methylphenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000086_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-chloro-2-methylphenyl)propanoic acid to afford 3-(4-chloro- 2-methylphenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 26% yield.1H NMR (400 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 10.0–9.73 (m, 1H), 8.66– 8.59 (m, 2H), 7.64–7.58 (m, 2H), 7.44–6.96 (m, 3H), 2.89 (t, J = 7.5 Hz, 2H), 2.58 (s, 2H), 2.32 (s, 3H), 2.17–1.90 (m, 3H). LCMS: ESI-MS m/z: 355.1 [M+H]+. EXAMPLE 43 3-(4-Chloro-3-methylphenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000086_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-chloro-3-methylphenyl)propanoic acid to afford 3-(4-chloro- 3-methylphenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 35% yield.1H NMR (400 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 9.96–9.69 (m, 1H), 8.73– 8.52 (m, 2H), 7.64–7.57 (m, 2H), 7.32 (d, J = 8.1 Hz, 1H), 7.26 (s, 1H), 7.12 (d, J = 9.9 Hz, 1H), 2.88 (t, J = 7.2 Hz, 2H), 2.75–2.57 (m, 2H), 2.30 (s, 3H), 2.05–1.95 (m, 3H). LCMS: ESI-MS m/z: 355.1 [M+H]+. EXAMPLE 44 3-(3,4-Difluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000087_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(3,4-difluorophenyl)propanoic acid to afford 3-(3,4- difluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 29% yield.1H NMR (400 MHz, DMSO-d6) δ 13.2–13.1 (m, 1H), 9.98–9.72 (m, 1H), 8.65 (s, 2H), 7.59 (s, 2H), 7.50–7.20 (m, 2H), 7.19–6.94 (m, 1H), 2.92 (t, J = 7.4 Hz, 2H), 2.65 (s, 2H), 2.04–1.96 (m, 3H). LCMS: ESI-MS m/z: 343.0 [M+H]+. EXAMPLE 45 3-(2,4-Difluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000087_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(2,4-difluorophenyl)propanoic acid 3-(2,4-difluorophenyl)-N-(4- methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 34% yield.1H NMR (400 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 10.0–9.73 (m, 1H), 8.66–8.59 (m, 2H), 7.63– 7.57 (m, 2H), 7.47–6.90 (m, 3H), 2.92 (s, 2H), 2.74–2.56 (m, 2H), 2.05–1.94 (m, 3H). LCMS: ESI-MS m/z: 343.1 [M+H]+. EXAMPLE 46 3-(4-Iodophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000088_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-iodophenyl)propanoic acid to afford 3-(4-iodophenyl)-N-(4- methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 72% yield.1H NMR (400 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 10.0–9.70 (m, 1H), 8.66–8.59 (m, 2H), 7.66– 7.57 (m, 4H), 7.10 (d, J = 8.2 Hz, 2H), 2.88 (t, J = 7.2 Hz, 2H), 2.67–2.61 (m, 2H), 2.04–1.95 (m, 3H). LCMS: ESI-MS m/z: 433.0 [M+H]+. EXAMPLE 47 N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5- trichlorophenyl)propanamide
Figure imgf000088_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(3,4,5-trichlorophenyl)propanoic acid to afford N-(4-methyl-3- (pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5-trichlorophenyl)propenamide in 38% yield. 1H NMR (400 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 9.92–9.72 (m, 1H), 8.65–8.59 (m, 2H), 7.76–7.44 (m, 4H), 2.95 (s, 2H), 2.68–2.66 (m, 2H), 2.04–1.94 (m, 3H). LCMS: ESI-MS m/z: 409.0 [M+H]+. EXAMPLE 48 3-(4-Chloro-3,5-difluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000089_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and Intermediate 9 to afford 3-(4-chloro-3,5-difluorophenyl)-N-(4- methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 45% yield.1H NMR (400 MHz, DMSO-d6) δ 13.1–13.0 (m, 1H), 9.99–9.72 (m, 1H), 8.65–8.57 (m, 2H), 7.63– 7.57 (m, 2H), 7.27 (d, J = 8.8 Hz, 2H), 2.96 (t, J = 7.2 Hz, 2H), 2.73–2.61 (m, 2H), 2.04–1.94 (m, 3H). LCMS: ESI-MS m/z: 377.0 [M+H]+. EXAMPLE 49 3-(4-Chloro-2,3-difluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000089_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-chloro-2,3-difluorophenyl)propanoic acid to afford 3-(4- chloro-2,3-difluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide in 25% yield.1H NMR (400 MHz, DMSO-d6) δ 13.1–13.0 (m, 1H), 10.0–9.74 (m, 1H), 8.66–8.59 (m, 2H), 7.64–7.57 (m, 2H), 7.39 (t, J = 7.0 Hz, 1H), 7.22 (t, J = 7.2 Hz, 1H), 2.98 (s, 2H), 2.67 (s, 2H), 2.04–1.94 (m, 3H). LCMS: ESI- MS m/z: 377.1 [M+H]+. EXAMPLE 50 N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5- trifluorophenyl)propanamide
Figure imgf000090_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(3,4,5-trifluorophenyl)propanoic acid to afford N-(4-methyl-3- (pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5-trifluorophenyl)propenamide in 16% yield. 1H NMR (400 MHz, DMSO-d6) δ 13.1 (s, 1H), 9.77 (s, 1H), 8.74–8.49 (m, 2H), 7.60 (d, J = 1.6 Hz, 2H), 7.26 (dd, J = 9.0, 6.9 Hz, 2H), 2.92 (t, J = 7.4 Hz, 2H), 2.67 (dd, J = 9.5, 4.3 Hz, 2H), 2.01 (d, J = 28.1 Hz, 3H). LCMS: ESI-MS m/z: 361.1 [M+H]+. EXAMPLE 51 N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(2,3,4- trifluorophenyl)propanamide
Figure imgf000090_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(2,3,4-trifluorophenyl)propanoic acid to afford N-(4-methyl-3- (pyridin-4-yl)-1H-pyrazol-5-yl)-3-(2,3,4-trifluorophenyl)propenamide in 13% yield. 1H NMR (400 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 10.13–9.66 (m, 1H), 8.64 (s, 2H), 7.66–7.58 (m, 2H), 7.25 (dt, J = 16.8, 8.7 Hz, 2H), 2.96 (t, J = 7.3 Hz, 2H), 2.67 (s, 2H), 2.04–1.94 (m, 3H). LCMS: ESI-MS m/z: 361.1 [M+H]+. EXAMPLE 52 N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(2,4,5- trifluorophenyl)propanamide
Figure imgf000091_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(2,4,5-trifluorophenyl)propanoic acid to afford N-(4-methyl-3- (pyridin-4-yl)-1H-pyrazol-5-yl)-3-(2,4,5-trifluorophenyl)propanamide in 26% yield. 1H NMR (400 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 10.0–9.73 (m, 1H), 8.66–8.61 (m, 2H), 7.71–7.35 (m, 4H), 2.91 (t, J = 7.2 Hz, 2H), 2.66 (s, 2H), 2.05–1.95 (m, 3H). LCMS: ESI-MS m/z: 361.1 [M+H]+. EXAMPLE 53 3-(4-Cyano-3-fluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000091_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and Intermediate 10 to afford 3-(4-cyano-3-fluorophenyl)-N-(4- methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (1.1 g, 3.1 mmol, 38% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.1 (s, 1H), 9.74 (s, 1H), 8.65 (s, 2H), 7.86 (t, J = 7.5 Hz, 1H), 7.58 (s, 2H), 7.48 (d, J = 10.6 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H), 3.03 (t, J = 7.4 Hz, 2H), 2.70 (s, 2H), 1.94 (s, 3H). LCMS: ESI-MS m/z: 350.2 [M+H]+. EXAMPLE 54 N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4- (trifluoromethoxy)phenyl)propanamide
Figure imgf000092_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-(trifluoromethoxy)phenyl)propanoic acid to afford N-(4- methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4- (trifluoromethoxy)phenyl)propenamide in 35% yield.1H NMR (400 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 9.96–9.71 (m, 1H), 8.65 (s, 2H), 7.63–7.57 (m, 2H), 7.40 (d, J = 8.6 Hz, 2H), 7.29 (d, J = 8.2 Hz, 2H), 2.96 (t, J = 7.3 Hz, 2H), 2.66 (s, 2H), 2.02–1.92 (s, 3H). LCMS: ESI-MS m/z: 391.1 [M+H]+. EXAMPLE 55 3-(4-(Difluoromethoxy)phenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000092_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-(difluoromethoxy)phenyl)propanoic acid to afford 3-(4- (difluoromethoxy)phenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide in 25% yield.1H NMR (400 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 10.0–9.71 (m, 1H), 8.65 (s, 2H), 7.58 (s, 2H), 7.42–6.96 (m, 5H), 2.92 (t, J = 7.4 Hz, 2H), 2.64 (s, 2H), 2.04–1.95 (m, 3H). LCMS: ESI-MS m/z: 373.1 [M+H]+. EXAMPLE 56 3-(4-(Fluoromethyl)phenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide N
Figure imgf000093_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-(fluoromethyl)phenyl)propanoic acid to afford 3-(4- (fluoromethyl)phenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 26% yield.1H NMR (400 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 9.96–9.70 (m, 1H), 8.64 (s, 2H), 7.58 (s, 2H), 7.34 (q, J = 8.1 Hz, 4H), 5.37 (d, J = 48.0 Hz, 2H), 2.95 (t, J = 7.2 Hz, 2H), 2.66 (s, 2H), 2.04–1.96 (m, 3H). LCMS: ESI-MS m/z: 339.1 [M+H]+. EXAMPLE 57 3-(4-(Difluoromethyl)phenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide N
Figure imgf000093_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-(difluoromethyl)phenyl)propanoic acid to afford 3-(4- (difluoromethyl)phenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 30% yield. 1H NMR (400 MHz, DMSO-d6) δ 13.1 (s, 1H), 9.71 (s, 1H), 8.65 (s, 2H), 7.58 (s, 2H), 7.50 (d, J = 7.9 Hz, 2H), 7.42 (d, J = 8.0 Hz, 2H), 6.99 (t, J = 56.0 Hz, 1H), 2.98 (t, J = 7.3 Hz, 2H), 2.67 (s, 2H), 2.03–1.94 (m, 3H). LCMS: ESI-MS m/z: 357.1 [M+H]+. EXAMPLE 58 N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(perfluorophenyl)propanamide
Figure imgf000094_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(perfluorophenyl)propanoic acid to afford N-(4-methyl-3- (pyridin-4-yl)-1H-pyrazol-5-yl)-3-(perfluorophenyl)propenamide in 29% yield.1H NMR (400 MHz, DMSO-d6) δ 13.1 (s, 1H), 9.94 (d, J = 80.2 Hz, 1H), 8.64 (s, 2H), 7.59 (s, 2H), 3.03 (t, J = 7.2 Hz, 2H), 2.68 (s, 2H), 1.99 (s, 3H). LCMS: ESI-MS m/z: 397.0 [M+H]+. EXAMPLE 59 3-(6-Fluoropyridin-3-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000094_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(6-fluoropyridin-3-yl)propanoic acid to afford 3-(6- fluoropyridin-3-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 31% yield.1H NMR (400 MHz, DMSO-d6) δ 13.0 (s, 1H), 9.94–9.73 (m, 1H), 8.63 (d, J = 1.3 Hz, 2H), 8.14 (s, 1H), 7.90 (td, J = 8.2, 2.3 Hz, 1H), 7.60 (t, J = 8.1 Hz, 2H), 7.12 (dd, J = 8.4, 2.7 Hz, 1H), 2.95 (t, J = 7.3 Hz, 2H), 2.68 (s, 2H), 2.13–1.83 (m, 3H). LCMS: ESI-MS m/z: 326.1 [M+H]+. EXAMPLE 60 3-(2-Fluoropyrimidin-5-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide 3
Figure imgf000095_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(2-fluoropyrimidin-5-yl)propanoic acid to afford 3-(2- fluoropyrimidin-5-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 10% yield.1H NMR (500 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 10.0–9.74 (m, 1H), 8.73 (s, 2H), 8.65–8.59 (m, 2H), 7.63–7.57 (m, 2H), 2.97 (t, J = 7.2 Hz, 2H), 2.72 (s, 2H), 2.10–1.84 (m, 3H). LCMS: ESI-MS m/z: 327.2 [M+H]+. EXAMPLE 61 3-(2-Chloropyrimidin-5-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000095_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(2-chloropyrimidin-5-yl)propanoic acid to afford 3-(2- chloropyrimidin-5-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 15% yield.1H NMR (400 MHz, DMSO-d6) δ 13.1 (s, 1H), 9.76 (s, 1H), 8.72 (s, 2H), 8.64 (s, 2H), 7.58 (s, 2H), 2.95 (t, J = 7.2 Hz, 2H), 2.73 (s, 2H), 1.95 (s, 3H). LCMS: ESI-MS m/z: 343.0 [M+H]+. EXAMPLE 62 2-(4-Chlorophenoxy)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)acetamide
Figure imgf000095_0003
The product was prepared according to General Procedure #1 using Intermediate 1 and 2-(4-chlorophenoxy)acetic acid to afford 2-(4-chlorophenoxy)-N- (4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)acetamide in 36% yield. 1H NMR (400 MHz, DMSO-d6) δ 13.2 (s, 1H), 9.97 (s, 1H), 8.66 (s, 2H), 7.60 (s, 2H), 7.38 (d, J = 8.9 Hz, 2H), 7.05 (d, J = 8.9 Hz, 2H), 4.75 (s, 2H), 2.04 (s, 3H). LCMS: ESI-MS m/z: 343.0 [M+H]+. EXAMPLE 63 2-((4-Chlorophenyl)thio)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)acetamide
Figure imgf000096_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 2-((4-chlorophenyl)thio)acetic acid to afford 2-((4- chlorophenyl)thio)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)acetamide in 37% yield.1H NMR (400 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 10.3–10.0 (m, 1H), 8.65– 8.59 (m, 2H), 7.64–7.57 (m, 2H), 7.46 (d, J = 8.7 Hz, 2H), 7.40 (d, J = 8.6 Hz, 2H), 3.89 (s, 2H), 2.06–1.94 (m, 3H). LCMS: ESI-MS m/z: 359.0 [M+H]+. EXAMPLE 64 3-(4-Chloro-3-fluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000096_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-chloro-3-fluorophenyl)propanoic acid to afford 3-(4-chloro-3- fluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 42% yield.1H NMR (400 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 9.96–9.72 (m, 1H), 8.64 5 (s, 2H), 7.58 (s, 2H), 7.50 (t, J = 8.1 Hz, 1H), 7.34 (dd, J = 10.7, 1.5 Hz, 1H), 7.15 (dd, J = 8.2, 1.3 Hz, 1H), 2.94 (t, J = 7.4 Hz, 2H), 2.67 (s, 2H), 2.04–1.95 (m, 3H). LCMS: ESI-MS m/z: 359.1 [M+H]+. EXAMPLE 65 3-(4-Cyano-3,5-difluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000097_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and Intermediate 8 to afford 3-(4-cyano-3,5-difluorophenyl)-N-(4- methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 25% yield.1H NMR (400 MHz, DMSO-d6) δ 13.1–12.9 (m, 1H), 10.0–9.75 (m, 1H), 8.65–8.59 (m, 2H), 7.64– 7.57 (m, 2H), 7.41 (d, J = 9.5 Hz, 2H), 3.04 (t, J = 7.3 Hz, 2H), 2.71 (s, 2H), 2.11– 1.88 (m, 3H). LCMS: ESI-MS m/z: 368.1 [M+H]+. EXAMPLE 66 N-[4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl]-2-(1,2,3,4-tetrahydronaphthalen- 1-yl)acetamide
Figure imgf000097_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 2-(1,2,3,4-tetrahydronaphthalen-1-yl)acetic acid to afford N-[4- methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl]-2-(1,2,3,4-tetrahydronaphthalen-1- yl)acetamide (25 mg, 0.070 mmol, 50% yield) as colorless solid. LCMS: ESI-MS m/z: 347.1 [M+H]+. 6 EXAMPLE 67 2-(5-Chloro-2,3-dihydro-1H-inden-1-yl)-N-[4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-yl]acetamide
Figure imgf000098_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and Intermediate 11 to afford 2-(5-chloro-2,3-dihydro-1H-inden-1-yl)- N-[4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl]acetamide (8.0 mg, 0.020 mmol, 64% yield) as white solid, trifluoroacetic acid salt. LCMS: ESI-MS m/z: 367.1 [M+H]+. EXAMPLE 68 2-(6-Chloro-1,2,3,4-tetrahydronaphthalen-1-yl)-N-[4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-yl]acetamide
Figure imgf000098_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and Intermediate 12 to afford 2-(6-chloro-1,2,3,4- tetrahydronaphthalen-1-yl)-N-[4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl]acetamide (54 mg, 0.11 mmol, 50% yield) as white solid, trifluoroacetic acid salt. LCMS: ESI- MS m/z: 381.1 [M+H]+. EXAMPLE 69 (E)-3-(4-chlorophenyl)-2,3-difluoro-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)acrylamide 7
Figure imgf000099_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and (2E)-3-(4-chlorophenyl)-2,3-difluoroprop-2-enoic acid to afford (E)-3-(4-chlorophenyl)-2,3-difluoro-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)acrylamide (1.7 mg, 0.0040 mmol, 8.0% yield) as a white solid, trifluoroacetic acid salt. LCMS: ESI-MS m/z: 375.1 [M+H]+. EXAMPLE 70 (rac)-3-(4-Cyano-3-fluorophenyl)-2-fluoro-N-(4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-yl)propanamide
Figure imgf000099_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and Intermediate 14 to afford (rac)-3-(4-cyano-3-fluorophenyl)-2- fluoro-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide as a white solid in 17% yield.1H NMR (400 MHz, DMSO-d6) δ 13.2 (s, 1H), 10.1 (s, 1H), 8.66 (s, 2H), 7.93 (t, J = 7.5 Hz, 1H), 7.60 (s, 2H), 7.53 (d, J = 10.5 Hz, 1H), 7.40 (d, J = 8.2 Hz, 1H), 5.49 (d, J = 45.8 Hz, 1H), 3.47–3.38 (m, 2H), 1.95 (s, 3H). LCMS: ESI-MS m/z: 368.2 [M+H]+. EXAMPLE 71 (rac)-3-(4-Chloro-3,5-difluorophenyl)-2-fluoro-N-(4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-yl)propanamide 8
Figure imgf000100_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and Intermediate 27 to afford (rac)-3-(4-chloro-3,5-difluorophenyl)-2- fluoro-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide in 21% yield as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.2–13.1 (m, 1H), 10.2–10.0 (m, 1H), 8.66 (s, 2H), 7.59 (s, 2H), 7.32 (d, J = 8.0 Hz, 2H), 5.45 (d, J = 48.0 Hz, 1H), 3.41– 3.23 (m, 2H), 1.95 (s, 3H). LCMS: ESI-MS m/z: 395.0 [M+H]+. EXAMPLE 72 3-(4-Chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propiolamide
Figure imgf000100_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-chlorophenyl)propiolic acid to afford 3-(4-chlorophenyl)-N- (4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propiolamide, trifluoroacetic acid salt (53 mg, >95% yield) as a white solid. LCMS: ESI-MS m/z: 337.1 [M+H]+. EXAMPLE 73 3-(4-Chlorothiophen-2-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide
Figure imgf000100_0003
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-chlorothiophen-2-yl)propanoic acid to afford 3-(4- chlorothiophen-2-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide (32 mg, 40% yield) as a white solid, trifluoroacetic acid salt.1H NMR (400 MHz, DMSO- d6) δ 10.0 (s, 1H), 8.82–8.75 (m, 2H), 7.97 (s, 1H), 7.38 (d, J = 1.6 Hz, 1H), 6.92 (d, J = 1.5 Hz, 1H), 3.10 (d, J = 14.3 Hz, 2H), 2.73 (t, J = 7.2 Hz, 2H), 2.09 (s, 3H). LCMS: ESI-MS m/z: 347.1 [M+H]+. EXAMPLE 74 3-(5-Chlorothiophen-2-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide
Figure imgf000101_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(5-chlorothiophen-2-yl)propanoic acid to afford 3-(5- chlorothiophen-2-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide (31 mg, 39% yield) as a white solid, trifluoroacetic acid salt.1H NMR (400 MHz, DMSO- d6) δ 10.0 (s, 1H), 8.81–8.75 (m, 2H), 7.97 (s, 2H), 6.94 (d, J = 3.7 Hz, 1H), 6.79 (d, J = 3.7 Hz, 1H), 3.07 (t, J = 7.1 Hz, 2H), 2.70 (t, J = 7.2 Hz, 2H), 2.09 (s, 3H). LCMS: ESI-MS m/z: 347.1 [M+H]+. EXAMPLE 75 3-(2-Chlorothiazol-5-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000101_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and Intermediate 17 to afford 3-(2-chlorothiazol-5-yl)-N-(4-methyl-3- (pyridin-4-yl)-1H-pyrazol-5-yl)propenamide (62 mg, >95% yield), as a white solid, trifluoroacetic acid salt.1H NMR (400 MHz, DMSO-d6) δ 10.0 (s, 1H), 8.83–8.71 (m, 00 2H), 7.96 (s, 2H), 7.50 (d, J = 1.1 Hz, 1H), 3.13 (t, J = 6.9 Hz, 2H), 2.74 (t, J = 6.9 Hz, 2H), 2.09 (s, 3H). LCMS: ESI-MS m/z: 348.1 [M+H]+. EXAMPLE 76 3-(5-Chlorothiazol-2-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide
Figure imgf000102_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and Intermediate 18 to afford 3-(4-chlorothiophen-2-yl)-N-(4-methyl- 3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide (29 mg, 36% yield) as a white solid, trifluoroacetic acid salt.1H NMR (400 MHz, DMSO-d6) δ 10.1 (s, 1H), 8.85–8.75 (m, 2H), 7.96 (s, 2H), 7.72 (s, 1H), 3.27 (d, J = 14.1 Hz, 2H), 2.86 (t, J = 7.0 Hz, H), 2.10 (s, 3H). LCMS: ESI-MS m/z: 348.1 [M+H]+. EXAMPLE 77 3-(4-Chloro-1H-pyrazol-1-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide
Figure imgf000102_0002
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(4-chloro-1H-pyrazol-1-yl)propanoic acid to afford 3-(4-chloro- 1H-pyrazol-1-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide (11 mg, 14% yield) as a white solid, trifluoroacetic acid salt.1H NMR (400 MHz, DMSO-d6) δ 10.1 (s, 1H), 8.80 (d, J = 5.8 Hz, 2H), 8.01 (s, 2H), 7.95 (s, 1H), 7.56 (s, 1H), 4.39 (t, J = 6.7 Hz, 2H), 2.93 (d, J = 13.2 Hz, 2H), 2.07 (s, 3H). LCMS: ESI-MS m/z: 331.1 [M+H]+. 01 EXAMPLE 78 3-(3-Chloroisoxazol-5-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000103_0001
The product was prepared according to General Procedure #1 using Intermediate 1 and 3-(3-chloroisoxazol-5-yl)propanoic acid to afford 3-(3- chloroisoxazol-5-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (6.5 mg, 8.0% yield) as a white solid, trifluoroacetic acid salt.1H NMR (400 MHz, DMSO-d6) δ 10.1 (s, 1H), 8.78 (d, J = 6.0 Hz, 2H), 7.97 (s, 2H), 6.64 (s, 1H), 3.11 (t, J = 7.2 Hz, 2H), 2.81 (t, J = 7.2 Hz, 2H), 2.10 (s, 3H). LCMS: ESI-MS m/z: 332.1 [M+H]+. EXAMPLE 79 2-((4-Chlorophenyl)amino)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)acetamide
Figure imgf000103_0002
Step 1: tert-Butyl (4-chlorophenyl)carbamate: To a solution of 4- chloroaniline (3.0 g, 24 mmol, 1.0 equiv) in DCM (30 mL, 0.80 M) was added triethylamine (6.0 g, 59 mmol, 2.5 equiv), DMAP (290 mg, 2.4 mmol, 0.10 equiv) 02 and Boc anhydride (5.7 g, 26 mmol, 1.1 equiv). After the addition, the mixture was stirred at rt for 8 h. The mixture was washed with water (15 mL), brine (15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude residue was purified by silica gel column chromatography (20–90% EtOAc in hexanes) to afford tert-butyl (4-chlorophenyl)carbamate (4.3 g, 19 mmol, 81% yield) as a light yellow liquid. LCMS: ESI-MS m/z: 172.1 [M–55]+. Step 2: Ethyl N-(tert-butoxycarbonyl)-N-(4-chlorophenyl)glycinate: To a solution of tert-butyl (4-chlorophenyl)carbamate (500 mg, 2.2 mmol, 1.0 equiv) in DMF (5.0 mL, 0.44 M) was added sodium hydride (60 wt % dispersion in mineral oil, 100 mg, 2.6 mmol, 60% in mineral oil, 1.2 equiv) at 0 °C. After stirring for 5 min at 0 °C, potassium iodide (360 mg, 2.2 mmol, 1.0 equiv) and ethyl 2-bromoacetate (470 mg, 2.4 mmol, 1.1 equiv) were added to the suspension. After the addition, the reaction mixture heated to 50 °C for 1 h. Then the mixture was cooled to rt, treated with water (20 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic fractions were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified directly by silica gel column chromatography (10–50% EtOAc in hexanes) to afford ethyl N-(tert- butoxycarbonyl)-N-(4-chlorophenyl)glycinate (400 mg, 1.3 mmol, 58% yield) as a light yellow liquid. LCMS: ESI-MS m/z: 214.1 [M–99]+. Step 3: N-(tert-Butoxycarbonyl)-N-(4-chlorophenyl)glycine: A mixture of N-(tert-butoxycarbonyl)-N-(4-chlorophenyl)glycinate (400 mg, 1.3 mmol, 1.0 equiv), lithium hydroxide monohydrate (270 mg, 6.4 mmol, 4.9 equiv) in a solution of ethanol (10 mL, 0.13 M) and water (5.0 mL, 0.26 M) was stirred at rt for 6 h. The reaction was concentrated in vacuo to remove ethanol, then the residual aqueous phase was diluted with water (10 mL) and washed with ethyl acetate (2 × 10 mL). The aqueous fraction was separated, and treated with a 1.0 M aqueous solution of HCl to adjust to pH 5~ 6. This solution was then extracted with ethyl acetate (3 × 20 mL). All combined organic fractions were then washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to afford N-(tert- butoxycarbonyl)-N-(4-chlorophenyl)glycine (310 mg, 1.1 mmol, 85% yield) as a light yellow solid. This material was moved onto subsequent reactions with no further purification. LCMS: ESI-MS m/z: 186.1 [M–99]+. Step 4: 2-((4-Chlorophenyl)amino)-N-(4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-yl)acetamide. To a mixture of N-(tert-butoxycarbonyl)-N-(4- chlorophenyl)glycine (310 mg, 1.1 mmol, 1.0 equiv), 4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-amine (Intermediate 1, 210 mg, 1.2 mmol, 1.1 equiv) in anhydrous DMF (5.0 mL, 0.22 M) was added T3P (50% w/w in EtOAc, 890 mg, 1.4 mmol, 1.3 equiv) and DIPEA (280 mg, 2.2 mmol, 2.0 equiv). After the addition, the mixture was stirred at rt for 16 h. The mixture was then diluted with ethyl acetate (20 mL), washed with water (10 mL), and brine (10 mL). The organic fraction was separated and treated with a 4.0 M solution of HCl in 1,4-dioxane (10 mL). The mixture was stirred at rt for 2 h, and then concentrated in vacuo. The residue was dissolved in water (20 mL) and washed with ethyl acetate (10 mL). The aqueous fraction was separated, treated with a saturated solution of aqueous NH4HCO3 to adjust to pH 8, then extracted with a 10:1 solution of DCM:MeOH (3 × 15 mL). All organic fractions were combined and concentrated in vacuo, and the crude residue was purified by RP-HPLC (Method C, 5–25 % MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3·H2O) to afford 2-((4- chlorophenyl)amino)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)acetamide (66 mg, 0.19 mmol, 18% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.1– 13.0 (m, 1H), 10.0–9.79 (m, 1H), 8.65 (s, 2H), 7.59 (s, 2H), 7.13 (d, J = 8.7 Hz, 2H), 6.63 (d, J = 8.7 Hz, 2H), 6.24 (s, 1H), 3.89 (s, 2H), 2.02 (s, 3H). LCMS: ESI-MS m/z: 342.0 [M+H]+. EXAMPLE 80 3-(4-Chlorophenyl)-2,2-difluoro-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide 04
Figure imgf000106_0001
Step 1: 3-(4-Chlorophenyl)-2,2-difluoro-N-(4-methyl-3-(pyridin-4-yl)-1- ((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)propanamide. The product was prepared according to General Procedure #1 using Intermediate 2 and Intermediate 26 to afford 3-(4-chlorophenyl)-2,2-difluoro-N-(4-methyl-3-(pyridin-4- yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)propanamide (30 mg, 0.059 mmol, 59%) as a light yellow oil which was carried forward without further purification. LCMS: ESI-MS m/z: 507.1 [M+H]+. Step 2: 3-(4-Chlorophenyl)-2,2-difluoro-N-(4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-yl)propenamide. The product was prepared according to General Procedure #3 using 3-(4-chlorophenyl)-2,2-difluoro-N-(4-methyl-3-(pyridin-4-yl)-1- ((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)propanamide to afford 3-(4- chlorophenyl)-2,2-difluoro-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide (12 mg, 0.032 mmol, 54%) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.3 (s, 1H), 10.5 (s, 1H), 8.67 (s, 2H), 7.59–7.35 (m, 6H), 3.56 (t, J = 17.6 Hz, 2H), 1.90 (s, 3H). LCMS: ESI-MS m/z: 377.0 [M+H]+. EXAMPLE 81 2-((4-Chlorophenyl)thio)-N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4- yl)acetamide
Figure imgf000106_0002
105 The product was prepared according to General Procedure #1 using Intermediate 6 and 2-((4-chlorophenyl)thio)acetic acid to afford 2-((4- chlorophenyl)thio)-N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)acetamide in 19% yield.1H NMR (400 MHz, DMSO-d6) δ 9.81 (s, 1H), 8.68 (d, J = 5.6 Hz, 2H), 7.91 (s, 1H), 7.64 (dd, J = 4.8, 1.6 Hz, 2H), 7.46–7.39 (m, 4H), 3.89 (s, 2H), 2.35 (s, 3H). LCMS: ESI-MS m/z: 359.0 [M+H]+. EXAMPLE 82 3-(6-Chloropyridin-3-yl)-N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4- yl)propenamide
Figure imgf000107_0001
The product was prepared according to General Procedure #1 using Intermediate 6 and 3-(6-chloropyridin-3-yl)propanoic acid to afford 3-(6- chloropyridin-3-yl)-N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)propanamide in 20% yield.1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 8.67 (d, J = 6.0 Hz, 2H), 8.31 (d, J = 2.4 Hz, 1H), 7.91 (s, 1H), 7.76 (dd, J = 2.4, Hz, 2.4 Hz, 1H), 7.63 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 8.4 Hz, 1H), 2.93 (t, J = 6.8 Hz, 2H), 2.67 (t, J = 7.2 Hz, 2H), 2.32 (s, 3H). LCMS: ESI-MS m/z: 342.0 [M+H]+. EXAMPLE 83 3-(4-Chloro-3,5-difluorophenyl)-N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4- yl)propanamide
Figure imgf000107_0002
The product was prepared according to General Procedure #1 using Intermediate 6 and Intermediate 9 to afford 3-(4-chloro-3,5-difluorophenyl)-N-(5- 06 methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)propanamide in 25% yield.1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 8.67 (dd, J = 1.6 Hz, 2H), 7.90 (s, 1H), 7.64 (dd, J = 1.6 Hz, 2H), 7.26 (d, J = 8.4 Hz, 2H), 2.95 (t, J = 7.6 Hz, 2H), 2.68 (t, J = 7.6 Hz, 2H), 2.32 (s, 3H). LCMS: ESI-MS m/z: 377.0 [M+H]+. EXAMPLE 84 N-(5-Methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)-3-(3,4,5- trifluorophenyl)propanamide
Figure imgf000108_0001
The product was prepared according to General Procedure #1 using Intermediate 6 and 3-(3,4,5-trifluorophenyl)propanoic acid to afford N-(5-methyl-1- (pyridin-4-yl)-1H-pyrazol-4-yl)-3-(3,4,5-trifluorophenyl)propanamide in 25% yield. 1H NMR (400 MHz, DMSO-d6) δ 9.50 (s, 1H), 8.72 (d, J = 6.0 Hz, 2H), 7.90 (s, 1H), 7.64 (dd, J = 4.4, 1.6 Hz, 2H), 7.27–7.23 (m, 2H), 2.91 (t, J = 7.6 Hz, 2H), 2.66 (t, J = 7.6 Hz, 2H), 2.34 (s, 3H). LCMS: ESI-MS m/z: 361.0 [M+H]+. EXAMPLE 85 2-(4-Chlorophenoxy)-N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)acetamide
Figure imgf000108_0002
The product was prepared according to General Procedure #1 using Intermediate 6 and 2-(4-chlorophenoxy)acetic acid to afford 2-(4-chlorophenoxy)-N- (5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)acetamide in 82% yield. 1H NMR (400 MHz, DMSO-d6) δ 9.76 (s, 1H), 8.69 (d, J = 1.6 Hz, 2H), 7.89 (s, 1H), 7.66 (d, J = 1.6 Hz, 2H), 7.37 (d, J = 9.2 Hz, 2H), 7.04 (d, J = 8.8 Hz, 2H), 4.74 (s, 2H), 2.37 (s, 3H). LCMS: ESI-MS m/z: 343.0 [M+H]+. 07 EXAMPLE 86 3-(4-Chlorophenyl)-N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)propenamide
Figure imgf000109_0001
The product was prepared according to General Procedure #1 using intermediate 6 and 3-(4-chlorophenyl)propanoic acid to afford 3-(4-chlorophenyl)-N- (5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)propenamide, trifluoroacetic acid salt (6.0 mg, 26% yield) as a beige solid. LCMS: ESI-MS m/z: 341.1 [M+H]+. EXAMPLE 88 3-(4-Chloro-3,5-difluorophenyl)-N-[1-(pyridin-4-yl)-1H-pyrazol-4- yl]propanamide
Figure imgf000109_0003
The product was prepared according to General Procedure #1 using Intermediate 21 and Intermediate 9 to afford 3-(4-chloro-3,5-difluorophenyl)-N-[1- (pyridin-4-yl)-1H-pyrazol-4-yl]propanamide (150 mg, 0.41 mmol, 88% yield) as a white solid.1H NMR: (400 MHz, DMSO-d6) δ 10.2 (s, 1H), 8.70 (s, 1H), 8.64–8.53 (m, 2H), 7.87–7.75 (m, 3H), 7.31–7.19 (m, 2H), 2.95 (t, J = 7.5 Hz, 2H), 2.68 (t, J = 7.5 Hz, 2H). LCMS: ESI-MS m/z: 363.1 [M+H]+. EXAMPLE 89 3-(4-Chlorophenyl)-N-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)propanamide
Figure imgf000109_0002
108 The product was prepared according to General Procedure #1 using Intermediate 21 and 3-(4-chlorophenyl)propanoic acid to afford 3-(4-chlorophenyl)- N-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)propanamide (130 mg, 85% yield) as a white solid, trifluoroacetic acid salt. LCMS: ESI-MS m/z: 327.7 [M+H]+. EXAMPLE 90 N-(5-Chloro-1-(pyridin-4-yl)-1H-pyrazol-4-yl)-3-(4-chlorophenyl)propenamide
Figure imgf000110_0001
The product was prepared according to General Procedure #1 using Intermediate 7 and 3-(4-chlorophenyl)propanoic acid to afford N-(5-chloro-1- (pyridin-4-yl)-1H-pyrazol-4-yl)-3-(4-chlorophenyl)propenamide in 21% yield. 1H NMR (400 MHz, DMSO-d6) δ 9.80 (s, 1H), 8.74 (dd, J = 4.7, 1.6 Hz, 2H), 8.17 (s, 1H), 7.73 (dd, J = 4.6, 1.6 Hz, 2H), 7.35 (d, J = 8.5 Hz, 2H), 7.29 (d, J = 8.5 Hz, 2H), 2.90 (t, J = 7.5 Hz, 2H), 2.68 (t, J = 7.6 Hz, 2H). LCMS: ESI-MS m/z: 361.0 [M+H]+. EXAMPLE 91 N-(5-Chloro-1-(pyridin-4-yl)-1H-pyrazol-4-yl)-3-(4-chloro-3,5- difluorophenyl)propanamide
Figure imgf000110_0002
The product was prepared according to General Procedure #1 using Intermediate 7 and Intermediate 9 to afford N-(5-chloro-1-(pyridin-4-yl)-1H-pyrazol- 4-yl)-3-(4-chloro-3,5-difluorophenyl)propanamide in 22% yield.1H NMR (400 MHz, DMSO-d6) δ 9.82 (s, 1H), 8.74 (dd, J = 4.6, 1.6 Hz, 2H), 8.16 (s, 1H), 7.73 (dd, J = 4.6, 1.6 Hz, 2H), 7.26 (d, J = 8.4 Hz, 2H), 2.95 (t, J = 7.5 Hz, 2H), 2.72 (t, J = 7.5 Hz, 2H). LCMS: ESI-MS m/z: 397.0 [M+H]+. 09 EXAMPLE 92 N-(5-Chloro-1-(pyridin-4-yl)-1H-pyrazol-4-yl)-3-(3,4,5- trifluorophenyl)propanamide
Figure imgf000111_0001
The product was prepared according to General Procedure #1 using Intermediate 7 and 3-(3,4,5-trifluorophenyl)propanoic acid to afford N-(5-chloro-1- (pyridin-4-yl)-1H-pyrazol-4-yl)-3-(3,4,5-trifluorophenyl)propanamide in 25% yield. 1H NMR (400 MHz, DMSO-d6) δ 9.81 (s, 1H), 8.74 (dd, J = 4.7, 1.6 Hz, 2H), 8.16 (s, 1H), 7.74 (dd, J = 4.7, 1.6 Hz, 2H), 7.25 (dd, J = 9.1, 6.9 Hz, 2H), 2.91 (t, J = 7.6 Hz, 2H), 2.70 (t, J = 7.5 Hz, 2H). LCMS: ESI-MS m/z: 381.0 [M+H]+. EXAMPLE 93 N-(5-Chloro-1-(pyridin-4-yl)-1H-pyrazol-4-yl)-3-(4-cyano-3,5- difluorophenyl)propanamide
Figure imgf000111_0002
The product was prepared according to General Procedure #1 using Intermediate 7 and Intermediate 8 to afford N-(5-chloro-1-(pyridin-4-yl)-1H-pyrazol- 4-yl)-3-(4-cyano-3,5-difluorophenyl)propanamide in 25% yield.1H NMR (400 MHz, DMSO-d6) δ 9.85 (s, 1H), 8.74 (dd, J = 4.6, 1.6 Hz, 2H), 8.16 (s, 1H), 7.73 (dd, J = 4.6, 1.6 Hz, 2H), 7.40 (d, J = 9.4 Hz, 2H), 3.03 (t, J = 7.5 Hz, 2H), 2.76 (t, J = 7.5 Hz, 2H). LCMS: ESI-MS m/z: 388.0 [M+H]+. 10 EXAMPLE 94 N-(5-Chloro-1-(pyridin-4-yl)-1H-pyrazol-4-yl)-3-(4-cyano-3- fluorophenyl)propanamide
Figure imgf000112_0001
The product was prepared according to General Procedure #1 using Intermediate 7 and Intermediate 10 to afford N-(5-chloro-1-(pyridin-4-yl)-1H- pyrazol-4-yl)-3-(4-cyano-3-fluorophenyl)propanamide as a white solid in 22% yield. 1H NMR (400 MHz, DMSO-d6) δ 9.83 (s, 1H), 8.74 (dd, J = 4.7, 1.6 Hz, 2H), 8.16 (s, 1H), 7.88–7.83 (m, 1H), 7.73 (dd, J = 4.6, 1.6 Hz, 2H), 7.47 (d, J = 10.7 Hz, 1H), 7.33 (dd, J = 8.0, 1.3 Hz, 1H), 3.02 (t, J = 7.5 Hz, 2H), 2.75 (t, J = 7.5 Hz, 2H). LCMS: ESI-MS m/z: 370.1 [M+H]+. EXAMPLE 95 3-(4-Chlorophenyl)-N-(1-(pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4- yl)propanamide
Figure imgf000112_0002
The product was prepared according to General Procedure #1 using 1- (pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine and 3-(4- chlorophenyl)propanoic acid to afford 3-(4-chlorophenyl)-N-(1-(pyridin-4-yl)-5- (trifluoromethyl)-1H-pyrazol-4-yl)propanamide (7.0 mg, 11% yield) as a pale yellow solid, trifluoroacetic acid salt. LCMS: ESI-MS m/z: 395.1 [M+H]+. EXAMPLE 96 N-(4-Chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-chlorophenyl)propanamide 11
Figure imgf000113_0001
The product was prepared according to General Procedure #1 using Intermediate 23 and 3-(4-chlorophenyl)propanoic acid to afford N-(4-chloro-3- (pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-chlorophenyl)propenamide (10 mg, 0.028 mmol, 11%) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.7 (br s, 1H), 10.1 (br s, 1H), 8.69 (s, 2H), 7.80 (s, 2H), 7.36–7.29 (m, 4H), 2.92 (t, J = 7.4 Hz, 2H), 2.71–2.63 (m 2H). LCMS: ESI-MS m/z: 361.1 [M+H]+. EXAMPLE 97 3-(4-Chloro-3,5-difluorophenyl)-N-(4-chloro-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000113_0002
The product was prepared according to General Procedure #1 using Intermediate 23 and Intermediate 9 to afford 3-(4-chloro-3,5-difluorophenyl)-N-(4- chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide in 12% yield.1H NMR (400 MHz, DMSO-d6) δ 13.6 (br s, 1H), 10.05 (br s, 1H), 8.69 (d, J = 5.6 Hz, 2H), 7.80 (dd, J = 1.6 Hz, J = 4.8 Hz, 2H), 7.27 (d, J = 8.8 Hz, 2H), 2.96 (t, J = 7.4 Hz, 2H), 2.72 (t, J = 7.0 Hz, 2H). LCMS: ESI-MS m/z: 397.1 [M+H]+. EXAMPLE 98 3-(4-Chlorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000113_0003
112 The product was prepared according to General Procedure #1 using Intermediate 13 and 3-(4-chlorophenyl)propanoic acid to afford 3-(4-chlorophenyl)- N-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide (6.0 mg, 12% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.2 (s, 1H), 10.6 (s, 1H), 8.65–8.57 (m, 1H), 8.22–8.17 (m, 1H), 7.71 (s, 2H), 7.34 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H), 7.11–7.07 (m, 1H), 2.90 (t, J = 11.8 Hz, 2H), 2.63 (t, J = 11.6 Hz, 2H). LCMS: ESI- MS m/z: 327.1 [M+H]+. EXAMPLE 99 3-(Benzo[d][1,3]dioxol-5-yl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide N
Figure imgf000114_0001
The product was prepared according to General Procedure #1 using Intermediate 13 and 3-(benzo[d][1,3]dioxol-5-yl)propanoic acid to afford 3- (benzo[d][1,3]dioxol-5-yl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide as a white solid in 24% yield.1H NMR (400 MHz, DMSO-d6) δ 13.2 (s, 1H), 10.5 (s, 1H), 8.60 (s, 2H), 7.70 (d, J = 6.4 Hz, 2H), 7.11 (s, 1H), 6.80–6.83 (m, 2H), 6.70 (dd, J = 1.6 Hz, 1.6 Hz, 1H), 5.95 (s, 2H), 2.82 (t, J = 7.2 Hz, 2H), 2.59 (t, J = 7.6 Hz, 2H). LCMS: ESI-MS m/z: 337.0 [M+H]+. EXAMPLE 100 3-(3-Chlorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000114_0002
The product was prepared according to General Procedure #1 using Intermediate 13 and 3-(3-chlorophenyl)propanoic acid to afford 3-(3-chlorophenyl)- N-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide as a white solid in 26% yield.1H 13 NMR (400 MHz, DMSO-d6) δ 13.2 (s, 1H), 10.5 (s, 1H), 8.61–8.60 (m, 2H), 7.70 (d, J = 5.6 Hz, 2H), 7.40–7.21 (m, 4H), 7.10 (s, 1H), 2.93–2.89 (m, 2H), 2.67–2.63 (m, 2H). LCMS: ESI-MS m/z: 327.0 [M+H]+. EXAMPLE 101 3-(4-Chloro-3,5-difluorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000115_0001
The product was prepared according to General Procedure #1 using Intermediate 13 and Intermediate 9 to afford 3-(4-chloro-3,5-difluorophenyl)-N-(3- (pyridin-4-yl)-1H-pyrazol-5-yl)propanamide as a white solid in 23% yield.1H NMR (400 MHz, DMSO-d6) δ 13.2 (s, 1H), 10.6 (s, 1H), 8.61 (d, J = 4 Hz, 2H), 7.69 (d, J = 5.2 Hz, 2H), 7.25 (d, J = 8.8 Hz, 2H), 7.10 (s, 1H), 2.94 (t, J = 7.2 Hz, 2H), 2.67 (t, J = 7.2 Hz, 2H). LCMS: ESI-MS m/z: 363.0 [M+H]+. EXAMPLE 102 N-(3-(Pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5-trifluorophenyl)propanamide
Figure imgf000115_0002
The product was prepared according to General Procedure #1 using Intermediate 13 and 3-(3,4,5-trifluorophenyl)propanoic acid to afford N-(3-(pyridin-4- yl)-1H-pyrazol-5-yl)-3-(3,4,5-trifluorophenyl)propenamide as a white solid in 23% yield.1H NMR (400 MHz, DMSO-d6) δ 13.2 (s, 1H), 10.6 (s, 1H), 8.61 (s, 2H), 7.70 (d, J = 4.4 Hz, 2H), 7.25 (t, J = 4.4 Hz, 2H), 7.11 (s, 1H), 2.90 (t, J = 7.4 Hz, 2H), 2.67 (t, J = 4.2 Hz, 2H). LCMS: ESI-MS m/z: 347.1 [M+H]+. 14 EXAMPLE 103 3-(4-Cyano-3-fluorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide
Figure imgf000116_0001
The product was prepared according to General Procedure #1 using Intermediate 13 and Intermediate 10 to afford 3-(4-cyano-3-fluorophenyl)-N-(3- (pyridin-4-yl)-1H-pyrazol-5-yl)propenamide as a white solid in 25% yield.1H NMR (400 MHz, DMSO-d6) δ 10.6 (s, 1H), 8.61 (dd, J = 6.4 Hz, 2H), 7.86 (t, J = 14.8 Hz, 1H), 7.70 (dd, J = 6.4 Hz, 2H), 7.47 (d, J = 10.0 Hz, 1H), 7.33 (dd, J = 8.4 Hz, 1H), 7.00 (s, 1H), 3.02 (t, J = 15.2 Hz, 2H), 2.70 (t, J = 15.2 Hz, 2H). LCMS: ESI-MS m/z: 336.0 [M+H]+. EXAMPLE 104 3-(4-Cyano-3,5-difluorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000116_0002
The product was prepared according to General Procedure #1 using Intermediate 13 and Intermediate 8 to afford 3-(4-cyano-3,5-difluorophenyl)-N-(3- (pyridin-4-yl)-1H-pyrazol-5-yl)propanamide as a white solid in 20% yield.1H NMR (400 MHz, DMSO-d6) δ 13.2 (s, 1H), 10.6 (s, 1H), 8.62 (d, J = 5.2 Hz, 2H), 7.73 (s, 2H), 7.40 (d, J = 9.2 Hz, 2H), 7.10 (s, 1H), 3.03 (t, J = 14.8 Hz, 2H), 2.72 (t, J = 14.8 Hz, 2H). LCMS: ESI-MS m/z: 354.1 [M+H]+. 15 EXAMPLE 105 3-(4-Chlorophenyl)-N-(1-methyl-2-(pyridin-4-yl)-1H-imidazol-5-yl)propanamide
Figure imgf000117_0001
The product was prepared according to General Procedure #1 using Intermediate 15 and 3-(4-chlorophenyl)propanoic acid to afford 3-(4-chlorophenyl)- N-(1-methyl-2-(pyridin-4-yl)-1H-imidazol-5-yl)propanamide (3.0 mg, 7.0% yield) as a white solid.1H NMR (400 MHz, CDCl3) δ 8.70 (d, J = 4.8 Hz, 2H), 7.56 (d, J = 5.2 Hz, 2H), 7.29 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H), 7.09–7.08 (m, 1H), 6.99 (s, 1H), 3.44 (s, 3H), 3.06 (t, J = 7.0 Hz, 2H), 2.74 (t, J = 7.0 Hz, 2H). LCMS: ESI- MS m/z: 341.1 [M+H]+. EXAMPLE 106 3-(4-Chlorophenyl)-N-(3-(3-methylpyridin-4-yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000117_0002
The product was prepared according to General Procedure #1 using Intermediate 16 and 3-(4-chlorophenyl)propanoic acid to afford 3-(4-chlorophenyl)- N-(3-(3-methylpyridin-4-yl)-1H-pyrazol-5-yl)propanamide (30 mg, 15% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 10.6 (s, 1H), 8.52 (s, 1H), 8.46 (d, J = 5.2 Hz, 1H), 7.50 (d, J = 4.8 Hz, 1H), 7.34 (d, J = 8.4 Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H), 6.80 (s, 1H), 2.89 (t, J = 8 Hz, 2H), 2.63 (t, J = 7.6 Hz, 2H), 2.42 (s, 3H). LCMS: ESI-MS m/z: 341.0 [M+H]+. 16 EXAMPLE 107 3-(4-Chlorophenyl)-N-(3-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)propenamide
Figure imgf000118_0001
The product was prepared according to General Procedure #1 using 3-methyl- 1-(pyridin-4-yl)-1H-pyrazol-4-amine and 3-(4-chlorophenyl)propanoic acid to afford 3-(4-chlorophenyl)-N-(3-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)propenamide, trifluoroacetic acid salt (77 mg, 74% yield) as a white solid.1H NMR (400 MHz, MeOD) δ 8.85 (s, 1H), 8.72–8.67 (m, 2H), 8.23–8.17 (m, 2H), 7.31–7.21 (m, 4H), 3.01 (t, J = 7.5 Hz, 2H), 2.77 (t, J = 7.5 Hz, 2H), 2.32 (s, 3H). LCMS: ESI-MS m/z: 341.1 [M+H]+. EXAMPLE 108 3-(4-Chlorophenyl)-N-(4-(pyridin-4-yl)-1H-imidazol-2-yl)propenamide N
Figure imgf000118_0002
, , , The product was prepared according to General Procedure #1 using 4- (pyridin-4-yl)-1H-imidazol-2-amine and 3-(4-chlorophenyl)propanoic acid to afford 3-(4-chlorophenyl)-N-(4-(pyridin-4-yl)-1H-imidazol-2-yl)propenamide, trifluoroacetic acid salt (20 mg, 36% yield) as a white solid. LCMS: ESI-MS m/z: 327.1 [M+H]+. EXAMPLE 109 3-(4-Chlorophenyl)-N-(1-(3-methylpyridin-4-yl)-1H-pyrazol-4-yl)propanamide N
Figure imgf000118_0003
117 The product was prepared according to General Procedure #1 using Intermediate 19 and 3-(4-chlorophenyl)propanoic acid to afford 3-(4-chlorophenyl)- N-(1-(3-methylpyridin-4-yl)-1H-pyrazol-4-yl)propanamide (1.9 mg, 15% yield) as a white solid, trifluoroacetic acid salt.1H NMR (400 MHz, 400 MHz, CD3OD) δ 8.73 (s, 1H), 8.62 (s, 1H), 8.01 (d, J = 5.6 Hz, 1H), 1.88 (s, 1H), 7.33–7.11 (m, 6H), 3.00 (t, J = 7.5 Hz, 2H), 2.78–2.70 (m, 2 H), 2.69 (s, 3H). LCMS: ESI-MS m/z: 341.1 [M+H]+. EXAMPLE 110 3-(4-Chlorophenyl)-N-(4-methyl-3-(3-methylpyridin-4-yl)-1H-pyrazol-5- yl)propenamide
Figure imgf000119_0001
The product was prepared according to General Procedure #1 using Intermediate 20 and 3-(4-chlorophenyl)propanoic acid to afford 3-(4-chlorophenyl)- N-(4-methyl-3-(3-methylpyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 33% yield. 1HNMR (500 MHz, DMSO-d6) δ 12.8–12.6 (m, 1H), 9.95–9.71 (m, 1H), 8.54–8.46 (m, 2H), 7.35 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 7.24 (d, J = 5.0 Hz, 1H), 2.91 (t, J = 7.3 Hz, 2H), 2.64 (s, 2H), 2.24 (s, 3H), 1.71 (s, 3H). LCMS: ESI-MS m/z: 355.2 [M+H]+. EXAMPLE 111 3-(4-Chloro-3,5-difluorophenyl)-N-(4-methyl-3-(3-methylpyridin-4-yl)-1H- pyrazol-5-yl)propanamide
Figure imgf000119_0002
The product was prepared according to General Procedure #1 using Intermediate 20 and Intermediate 9 to afford 3-(4-chloro-3,5-difluorophenyl)-N-(4- 118 methyl-3-(3-methylpyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 34 % yield. 1H NMR (500 MHz, DMSO-d6) δ 12.8–12.6 (m, 1H), 9.72 (s, 1H), 8.51 (d, J = 39.3 Hz, 2H), 7.26 (dd, J = 14.2, 6.8 Hz, 3H), 2.95 (t, J = 7.3 Hz, 2H), 2.66 (d, J = 13.6 Hz, 2H), 2.23 (s, 3H), 1.70 (s, 3H). LCMS: ESI-MS m/z: 391.1 [M+H]+. EXAMPLE 112 3-(4-Cyano-3-fluorophenyl)-N-(4-methyl-3-(3-methylpyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000120_0001
The product was prepared according to General Procedure #1 using Intermediate 20 and Intermediate 10 to afford 3-(4-cyano-3-fluorophenyl)-N-(4- methyl-3-(3-methylpyridin-4-yl)-1H-pyrazol-5-yl)propanamide in 36 % yield. 1H NMR (500 MHz, DMSO-d6) δ 12.8–12.6 (m, 1H), 9.76 (s, 1H), 8.65–8.36 (m, 2H), 7.86 (t, J = 7.5 Hz, 1H), 7.48 (d, J = 10.7 Hz, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.25 (d, J = 4.9 Hz, 1H), 3.03 (t, J = 7.3 Hz, 2H), 2.70 (s, 2H), 2.24 (s, 3H), 1.76–1.70 (m, 3H). LCMS: ESI-MS m/z: 364.3 [M+H]+ EXAMPLE 113 3-(4-Cyano-3,5-difluorophenyl)-N-(4-methyl-3-(3-methylpyridin-4-yl)-1H- pyrazol-5-yl)propenamide
Figure imgf000120_0002
The product was prepared according to General Procedure #1 using Intermediate 20 and Intermediate 8 to afford 3-(4-cyano-3,5-difluorophenyl)-N-(4- methyl-3-(3-methylpyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 36 % yield. 1H NMR (500 MHz, DMSO-d6) δ 12.6 (s, 1H), 9.77 (s, 1H), 8.51 (d, J = 40.8 Hz, 2H), 19 7.41 (d, J = 9.5 Hz, 2H), 7.25 (d, J = 4.9 Hz, 1H), 3.04 (t, J = 7.3 Hz, 2H), 2.71 (s, 2H), 2.23 (s, 3H), 1.71 (s, 3H). LCMS: ESI-MS m/z: 382.2 [M+H]+. EXAMPLE 114 3-(4-Bromophenyl)-N-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)propanamide
Figure imgf000121_0001
The product was prepared according to General Procedure #1 using Intermediate 21 and 3-(4-bromophenyl)propanoic acid to afford 3-(4-bromophenyl)- N-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)propanamide in 20 % yield. 1H NMR (400 MHz, DMSO-d6) δ 10.3 (s, 1H), 8.69 (s, 1H), 8.60 (d, J = 6.0 Hz, 2H), 7.83–7.82 (m, 3H), 7.47 (d, J = 8.4 Hz, 2H), 7.22 (d, J = 8.4 Hz, 2H), 2.90 (t, J = 7.6 Hz, 2H), 2.62 (t, J = 7.4 Hz, 2H). LCMS: ESI-MS m/z: 327.0 [M+H]+. EXAMPLE 115 3-(4-Fluorophenyl)-N-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)propenamide
Figure imgf000121_0002
The product was prepared according to General Procedure #1 using Intermediate 21 and 3-(4-fluorophenyl)propanoic acid to afford 3-(4-fluorophenyl)-N- (1-(pyridin-4-yl)-1H-pyrazol-4-yl)propenamide in 50% yield. 1H NMR (400 MHz, DMSO-d6) δ 10.3 (s, 1H), 8.70 (s, 1H), 8.60 (dd, J = 6.4 Hz, 2H), 7.83–7.81 (m, 3H), 7.30–7.26 (m, 2H), 7.13–7.07 (m, 2H), 2.91 (t, J = 16.0 Hz, 2H), 2.62 (t, J = 15.2 Hz, 2H). LCMS: ESI-MS m/z: 311.0 [M+H]+. 20 EXAMPLE 116 3-(4-Chlorophenyl)-N-(4-(hydroxymethyl)-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000122_0001
The product was prepared according to General Procedure #1 using Intermediate 22 and 3-(4-chlorophenyl)propanoic acid to afford 3-(4-chlorophenyl)- N-(4-(hydroxymethyl)-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 31% yield. 1H NMR (400 MHz, CD3OD) δ 8.63 (d, J = 22.0 Hz, 2H), 7.88–7.78 (m, 2H), 7.32– 7.21 (m, 4H), 4.45–4.38 (m, 2H), 3.04 (t, J = 15.2 Hz, 2H), 2.78 (t, J = 14.4 Hz, 2H). LCMS: ESI‐MS m/z: 357.1 [M+H]+. EXAMPLE 117 3-(4-Chloro-3,5-difluorophenyl)-N-(4-(hydroxymethyl)-3-(pyridin-4-yl)-1H- pyrazol-5-yl)propanamide
Figure imgf000122_0002
The product was prepared according to General Procedure #1 using Intermediate 22 and Intermediate 9 to afford 3-(4-chloro-3,5-difluorophenyl)-N-(4- (hydroxymethyl)-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide in 33 % yield. 1H NMR (400 MHz, DMSO-d6) δ 13.3–13.0 (br s, 1H), 10.2–10.0 (br s, 1H), 8.67 (s, 2H), 7.80–7.72 (m, 2H), 7.28 (d, J = 8.4 Hz, 2H), 4.90–4.69 (m, 1H), 4.42–3.65 (m, 2H), 2.96 (t, J = 7.4 Hz, 2H), 2.78–2.67 (m, 2H). LCMS: ESI‐MS m/z: 393.0 [M+H]+. 21 EXAMPLE 118 3-(4-Chloro-3-fluorophenyl)-N-(4-(hydroxymethyl)-3-(pyridin-4-yl)-1H-pyrazol- 5-yl)propenamide
Figure imgf000123_0001
The product was prepared according to General Procedure #1 using Intermediate 22 and 3-(4-chloro-3-fluorophenyl)propanoic acid to afford 3-(4-chloro- 3-fluorophenyl)-N-(4-(hydroxymethyl)-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide in 32 % yield. 1H NMR (400 MHz, DMSO-d6) δ 13.3 (s, 1H), 10.1 (s, 1H), 8.65 (s, 2H), 7.75 (s, 2H), 7.51 (t, J = 16.0 Hz, 1H), 7.36 (d, J = 10.4 Hz, 1H), 7.16 (d, J = 8.4 Hz, 1H), 4.30 (s, 2H), 2.95 (t, J = 14.8 Hz, 2H), 2.71 (t, J = 14.8 Hz, 2H). LCMS: ESI‐MS m/z: 375.0 [M+H]+. EXAMPLE 119 N-(4-(Hydroxymethyl)-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5- trifluorophenyl)propenamide
Figure imgf000123_0002
The product was prepared according to General Procedure #1 using Intermediate 22 and 3-(3,4,5-trifluorophenyl)propanoic acid to afford N-(4- (hydroxymethyl)-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5- trifluorophenyl)propenamide in 32% yield. 1H NMR (400 MHz, DMSO-d6) δ 13.3– 13.0 (br s, 1H), 10.2–10.0 (br s, 1H), 8.67 (s, 2H), 7.83–7.72 (m, 2H), 7.28 (dd, J = 8.8 Hz, 6.8 Hz, 2H), 4.88–4.71 (m, 1H), 4.38–4.24 (m, 2H), 2.93 (t, J = 7.4 Hz, 2H), 2.71–2.67 (m, 2H). LCMS: ESI‐MS m/z: 377.0 [M+H]+. 22 EXAMPLES 120 and 121 2-((4-chlorophenyl)sulfinyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)acetamide (Ex.120) and 2-((4-chlorophenyl)sulfonyl)-N-(4-methyl-3-(pyridin- 4-yl)-1H-pyrazol-5-yl)acetamide (Ex.121)
Figure imgf000124_0001
To a solution of 2-((4-chlorophenyl)thio)-N-(4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-yl)acetamide (Example 63, 65 mg, 0.18 mmol, 1.0 equiv) in DMF (3.0 mL, 0.060 M) was added Oxone® (110 mg, 0.18 mmol, 1.0 equiv) in water (1 mL). The mixture was stirred at rt for 2 h. The mixture was then treated with a saturated aqueous solution of Na2SO3 (5 mL) and extracted with EtOAc (3 × 5.0 mL). The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The resulting residue was purified by RP- HPLC (Method C, 5–25 % MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3 ·H2O) to afford 2-((4-chlorophenyl)sulfinyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)acetamide (Ex.120) (18 mg, 0.048 mmol, 26% yield) and 2-((4- chlorophenyl)sulfonyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)acetamide (Ex. 121) (41 mg, 0.11 mmol 58% yield) as white solids. Ex.120: 1H NMR (400 MHz, DMSO-d6) δ 13.2 (s, 1H), 10.1 (s, 1H), 8.66 (s, 2H), 7.78 (d, J = 8.6 Hz, 2H), 7.70 (d, J = 8.6 Hz, 2H), 7.59 (s, 2H), 4.05 (dd, J = 61.3, 13.3 Hz, 2H), 2.01 (s, 3H). LCMS: ESI-MS m/z: 375.0 [M+H]+; first eluting peak (retention time = 1.64 min). Ex.121: 1H NMR (400 MHz, DMSO-d6) δ 13.2 (s, 1H), 10.2 (s, 1H), 8.65 (s, 2H), 7.93 (d, J = 8.6 Hz, 2H), 7.80–7.71 (m, 2H), 7.58 (s, 2H), 4.66 (d, J = 66.9 Hz, 2H), 1.98 (s, 3H). LCMS: ESI-MS m/z: 391.0 [M+H]+; second eluting peak (retention time = 1.71 min). 23 EXAMPLE 122 3-(4-Chlorophenyl)-N-(4-methoxy-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000125_0001
Step 1: 2-Methoxy-3-oxo-3-(pyridin-4-yl)propanenitrile. To a solution of 2- methoxyacetonitrile (210 mg, 3.7 mmol, 2.5 equiv) in anhydrous THF (10 mL, 0.14 M) was added LiHMDS (1.0 M in THF, 3.7 mL, 3.7 mmol, 2.5 equiv) dropwise at – 78 °C under a N2 atmosphere. The mixture was then warmed to rt and stirred for 30 min. Subsequently, methyl isonicotinate (200 mg, 1.5 mmol, 1.0 equiv) was added. After 1 h at rt, saturated aqueous solution of NH4Cl (20 mL) was added. The mixture was extracted with EtOAc (3 × 20 mL). The organic material was filtered over anhydrous sodium sulfate and concentrated in vacuo to afford 2-methoxy-3-oxo-3- (pyridin-4-yl)propanenitrile (130 mg, 0.73 mmol, 50% yield) as a light yellow liquid. The material was carried forward to the next step without further purification. LCMS: ESI-MS m/z: 177.1 [M+H]+. Step 2: 4-Methoxy-3-(pyridin-4-yl)-1H-pyrazol-5-amine. A mixture of crude 2-methoxy-3-oxo-3-(pyridin-4-yl)propanenitrile (200 mg, 1.1 mmol, 1.0 equiv) and hydrazine hydrate (210 mg, 3.7 mmol, 3.2 equiv) in EtOH (10 mL, 0.11 M) was stirred at 80 °C for 3 h. The mixture was concentrated in vacuo. The crude product was purified directly by RP-HPLC (Method C, 10–90 % MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3·H2O) Fractions containing the desired mass were combined and concentrated by lyophilization to afford 4-methoxy-3-(pyridin-4-yl)-1H-pyrazol- 24 5-amine (140 mg, 0.73 mmol, 65% yield) as a white solid. LCMS: ESI-MS m/z: 191.1 [M+H]+. Step 3: 4-Methoxy-3-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)- 1H-pyrazol-5-amine. A solution of 4-methoxy-3-(pyridin-4-yl)-1H-pyrazol-5-amine (90 mg, 0.47 mmol, 1.0 equiv) in anhydrous DMF (2.0 mL, 0.24 M) under an N2 atmosphere was cooled 0 °C and treated with sodium hydride (60 wt % dispersion in mineral oil, 29 mg, 0.71 mmol, 1.5 equiv). The resulting suspension was stirred for 30 min at 0 °C. Subsequently, (2-chloromethoxyethyl)trimethylsilane (117 mg, 0.71 mmol, 1.5 equiv) was added to the mixture, and the reaction was warmed to rt. After 1 h at rt, the mixture was diluted with EtOAc (20 mL) and washed with a saturated aqueous solution of NH4Cl (2 × 10 mL). The organic material was filtered over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by silica gel column chromatography (0–25% MeOH in DCM) to afford 4-methoxy- 3-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-amine (100 mg, 0.31 mmol, 66% yield) as a light yellow oil. LCMS: ESI-MS m/z: 321.2 [M+H]+. Step 4: 3-(4-Chlorophenyl)-N-(4-methoxy-3-(pyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)propenamide. The product was prepared according to General Procedure #1 using 4-methoxy-3-(pyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-amine and 3-(4-chlorophenyl)propanoic acid to afford 3-(4-chlorophenyl)-N-(4-methoxy-3-(pyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)propanamide (70 mg, 0.14 mmol, 46% yield) as a light yellow solid. LCMS: ESI-MS m/z: 487.2 [M+H]+. Step 5: 3-(4-chlorophenyl)-N-(4-methoxy-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide. The product was prepared according to General Procedure #3 to afford 3-(4-chlorophenyl)-N-(4-methoxy-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide (12 mg, 0.034 mmol, 23% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.1 (s, 1H), 10.2 (s, 1H), 8.63–8.52 (m, 2H), 7.79–7.66 (m, 2H), 7.35 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 3.63 (s, 3H), 2.91 (t, J = 7.6 Hz, 2H), 2.73-2.58 (m, 2H). LCMS: ESI-MS m/z: 357.0 [M+H]+. 25 EXAMPLE 123 3-(4-Chlorophenyl)-N-(4-cyclopropyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000127_0001
Step 1: 2-Cyclopropyl-3-oxo-3-(pyridin-4-yl)propanenitrile. To a solution of 2-cyclopropylacetonitrile (240 mg, 2.9 mmol, 1.9 equiv) in anhydrous THF (10 mL, 0.15 M) was added LiHMDS (1.0 M solution in THF, 3.7 mL, 3.7 mmol, 2.5 equiv) dropwise at –78 °C under an atmosphere of nitrogen gas. After the addition, the mixture was stirred at that temperature for 30 min. Then, methyl isonicotinate (200 mg, 1.5 mmol, 1.0 equiv) was added, and the mixture was stirred at rt for 1 h. The mixture was then treated with a saturated solution of NH4Cl (30 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic fractions were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to get afford crude 2-cyclopropyl-3-oxo-3-(pyridin-4-yl)propanenitrile (230 mg, 0.62 mmol, 42% yield, 50% purity) as a light yellow liquid. LCMS: ESI-MS m/z: 187.0 [M+H]+. Step 2: 4-Cyclopropyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine. A mixture of crude 2-cyclopropyl-3-oxo-3-(pyridin-4-yl)propanenitrile (230 mg, 0.62 mmol, 50% purity, 1.0 equiv) and tert-butyl carbazate (120 mg, 0.92 mmol, 1.5 equiv) in ethanol (10 mL, 0.062 M) was stirred at reflux for 3 h. LCMS indicated product formation though the Boc group had cleaved during the reaction. The mixture was concentrated 26 in vacuo, and the residue was purified directly by RP-HPLC (Method C, 10–90% MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3 ·H2O) to afford 4-cyclopropyl-3- (pyridin-4-yl)-1H-pyrazol-5-amine (100 mg, 0.50 mmol, 81% yield) as a white solid. LCMS: ESI-MS m/z: 201.1 [M+H]+. Step 3: 3-(4-chlorophenyl)-N-(4-cyclopropyl-3-(pyridin-4-yl)-1H-pyrazol- 5-yl)propanamide. The product was prepared according to General Procedure #1 using 4-cyclopropyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine and 3-(4- chlorophenyl)propanoic acid to afford 3-(4-chlorophenyl)-N-(4-cyclopropyl-3- (pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (20 mg, 0.054 mmol, 22% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.1 (s, 1H), 9.66 (s, 1H), 8.67 (d, J = 5.2 Hz, 2H), 7.73 (d, J = 5.2 Hz, 2H), 7.33 (dd, J = 8.4 Hz, 19.2 Hz, 4H), 2.95–2.90 (m, 2H), 2.72–2.61 (m, 2H), 1.66–1.64 (m, 1H), 0.79–0.66 (m, 2H), 0.23–0.14 (m, 2H). LCMS: ESI-MS m/z: 367.0 [M+H]+. EXAMPLE 124 3-(4-Chlorophenyl)-N-[4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl]propanethioamide
Figure imgf000128_0001
A suspension of 3-(4-chlorophenyl)-N-[4-methyl-3-(pyridin-4-yl)-1H-pyrazol- 5-yl]propanamide (Example 19, 10 mg, 0.020 mmol, 1.0 equiv) in toluene (300 µL, 0.067 M) was treated with Lawesson’s reagent (78 µL, 0.060 mmol, 3.0 equiv) and the reaction mixture was heated to 95 °C for 14 h. The reaction mixture was then cooled to rt and concentrated in vacuo. The residue was diluted with water (1.0 mL) and purified directly by RP-HPLC (Method A, 10–100% MeCN in H2O + 0.1% TFA). Fractions containing the desired product were combined and concentrated by lyophilization to afford 3-(4-chlorophenyl)-N-[4-methyl-3-(pyridin-4-yl)-1H-pyrazol- 5-yl]propanethioamide (4.4 mg, 0.010 mmol, 44% yield) as a white solid, trifluoroacetic acid salt. LCMS: ESI-MS m/z: 357.1 [M+H]+. 27 EXAMPLE 125 3-(4-Chlorophenyl)-N-[3-(pyridin-4-yl)-4-(trifluoromethyl)-1H-pyrazol-5- yl]propanamide
Figure imgf000129_0001
To a solution of 3-(4-chlorophenyl)-N-[3-(pyridin-4-yl)-1H-pyrazol-5- yl]propanamide (Example 98, 16 mg, 0.040 mmol, 1.0 equiv) in DMSO (300 µL, 0.13 M) was added zinc(II) bis(trifluoromethyl)-λ⁶-sulfanoylolate (48 mg, 0.18 mmol, 5.0 equiv), followed by TBHP (70 wt. % in water, 32 µL, 0.36, 10 equiv). The reaction mixture was heated to 50 °C and stirred for 2 h, after which it was cooled to rt and diluted with MeCN:water (1:1, 1 mL). The material was directly purified by RP-HPLC (Method A, 10–100% MeCN in H2O + 0.1% TFA). Fractions containing the desired product were combined and concentrated by lyophilization to afford 3-(4- chlorophenyl)-N-[3-(pyridin-4-yl)-4-(trifluoromethyl)-1H-pyrazol-5-yl]propanamide (2.0 mg, 0.030 mmol, 11% yield) as white solid, trifluoroacetic acid salt. LCMS: ESI- MS m/z: 463.1 [M+H]+. EXAMPLE 126 N-[5-Chloro-1-(pyridin-4-yl)-1H-pyrazol-4-yl]-3-(3-chlorophenyl)propanamide
Figure imgf000129_0002
A solution of 3-(3-chlorophenyl)-N-[1-(pyridin-4-yl)-1H-pyrazol-4- yl]propanamide (9.7 mg, 0.030 mmol, 1.0 equiv) in DMF (300 µL) was treated with N-chlorosuccinimide (5.1 mg, 0.040 mmol, 1.3 equiv) and the reaction mixture was heated to 40 °C and stirred for 24 h. The reaction mixture was then cooled to rt and purified directly by silica gel column chromatography (100% EtOAc) to afford N-[5- chloro-1-(pyridin-4-yl)-1H-pyrazol-4-yl]-3-(3-chlorophenyl)propanamide (4.8 mg, 0.010 mmol, 45% yield) as a white solid.1H NMR (400 MHz, CDCl3) δ 8.74 (d, J = 28 5.5 Hz, 2H), 8.37 (s, 1H), 7.79 (d, J = 5.3 Hz, 2H), 7.28–7.14 (m, 4H), 6.89 (s, 1H), 3.08 (t, J = 7.5 Hz, 2H), 2.76 (t, J = 7.5 Hz, 2H). LCMS: ESI-MS m/z: 361.1 [M+H]+. EXAMPLE 127 N-[5-Bromo-1-(pyridin-4-yl)-1H-pyrazol-4-yl]-3-(4-chloro-3,5- difluorophenyl)propanamide
Figure imgf000130_0001
A solution of 3-(4-chloro-3,5-difluorophenyl)-N-[1-(pyridin-4-yl)-1H-pyrazol- 4-yl]propanamide (Example 88, 23 mg, 0.060 mmol, 1.0 equiv) in DMF (630 µL, 0.10 M) was treated with N-bromosuccinimide (18 mg, 0.10 mmol, 1.6 equiv). After stirring at rt for 48 h, the reaction mixture was diluted with EtOAc (20 mL) and a saturated aqueous solution of NH4Cl (20 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (3 × 10 mL). The combined organic fractions were washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by silica gel column chromatography (100% EtOAc) to afford N-[5-bromo-1-(pyridin-4-yl)-1H- pyrazol-4-yl]-3-(4-chloro-3,5-difluorophenyl)propanamide (13 mg, 0.030 mmol, 47% yield) as a white solid.1H NMR (400 MHz, CDCl3) δ 8.76 (d, J = 5.5 Hz, 2H), 8.40 (d, J = 1.8 Hz, 1H), 7.81 (s, 2H), 6.96–6.89 (m, 2H), 3.08 (t, J = 7.3 Hz, 2H), 2.76 (t, J = 7.3 Hz, 2H). LCMS: ESI-MS m/z: 443.0 [M+H]+. 29 EXAMPLE 128 N-(4-Chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-cyano-3,5-difluorophenyl) propenamide
Figure imgf000131_0001
Step 1: 3-(Pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol- 5-amine. To a solution of 3-(pyridin-4-yl)-1H-pyrazol-5-amine (Intermediate 13, 500 mg, 3.1 mmol, 1.0 equiv) in anhydrous DMF (10 mL, 0.31 M) was added sodium hydride (60 wt % dispersion in mineral oil, 190 mg, 4.7 mmol, 1.5 equiv) at 0 °C under an atmosphere of nitrogen gas. After the addition, the mixture was stirred at 0 °C for 40 min. Then SEM-Cl (780 mg, 4.7 mmol, 1.4 equiv) was added dropwise at 0 °C. After the addition, the mixture was stirred at 0 °C for 2 h. The mixture was then treated with EtOAc (50 mL), washed with a saturated solution of NH4Cl (2 × 30 mL). The organic fraction was separated and concentrated in vacuo, and the resulting residue was purified by silica gel column chromatography (5% DCM in MeOH) to afford 3-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-amine (500 mg, 1.7 mmol, 55% yield) as a light yellow solid. LCMS: ESI-MS m/z: 291.0 [M+H]+. Step 2: 3-(4-Cyano-3,5-difluorophenyl)-N-(3-(pyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy) methyl)-1H-pyrazol-5-yl)propenamide. To a stirred solution of 3-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-amine 30 (22 mg, 0.080 mmol, 1.0 equiv) in DCM (5 mL, 0.016 M) was added Intermediate 8 (21 mg, 0.10 mmol, 1.3 equiv), T3P (50 w/v % in EtOAc, 96 mg, 0.15 mmol, 1.9 equiv) at 0 °C. The mixture was stirred at rt for 30 min, then DIPEA (20 mg, 0.15 mmol, 1.9 equiv) was added. The mixture was stirred at rt for 1.5 h. The mixture was diluted with ethyl acetate (30 mL) and then was washed with water (2 × 10 mL), followed by brine (10 mL). The organic fraction was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to afford the crude product. The crude material was purified by silica gel column chromatography (50% EtOAc in petroleum ether) to afford 3-(4-cyano-3,5-difluorophenyl)-N-(3-(pyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy) methyl)-1H-pyrazol-5-yl)propenamide (14 mg, 36% yield) as a white solid. LCMS: ESI-MS m/z: 484.0 [M+H]+. Step 3: 3-(4-Cyano-3,5-difluorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide. To a stirred solution of 3-(4-cyano-3,5-difluorophenyl)-N-(3- (pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy) methyl)-1H-pyrazol-5-yl)propenamide (14 mg, 0.030 mmol, 1.0 equiv) in DCM (1 mL, 0.030 M) was added TFA (0.20 mL, 2.7 mmol, 90 equiv) at rt. The mixture was stirred at rt for 1 h, concentrated in vacuo, and then the resulting residue was treated with ammonia in methanol (7M) to adjust to pH 8, and concentrated again in vacuo to afford the crude product. The crude material was purified by silica gel column chromatography (5% MeOH in DCM) to afford 3- (4-cyano-3,5-difluorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide (5.0 mg, 47% yield) as a white solid. LCMS: ESI-MS m/z: 354.0 [M+H]+. Step 4: N-(4-Chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-cyano-3,5- difluorophenyl) propenamide. To a stirred solution of 3-(4-cyano-3,5- difluorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide (18 mg, 0.050 mmol, 1.0 equiv) in acetonitrile (3 mL, 0.017 M) was added NCS (7.1 mg, 0.050 mmol, 1.0 equiv) at 0 °C. The mixture was stirred at rt for 1 h, concentrated in vacuo, then purified directly by silica gel column chromatography (5% MeOH in DCM) to afford N-(4-chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-cyano-3,5-difluorophenyl) propenamide (10 mg, 52% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.7 (s, 1H), 10.4 (s, 1H), 8.70 (s, 2H), 7.80 (s, 2H), 7.42 (d, J = 9.6 Hz, 2H), 3.04 (t, J = 14.4 Hz, 2H), 2.79 (t, J = 19.6 Hz, 2H). LCMS: ESI-MS m/z: 388.0 [M+H]+. 31 EXAMPLE 129 N-(4-Chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-cyano-3- fluorophenyl)propenamide
Figure imgf000133_0001
To a stirred solution of 3-(4-cyano-3-fluorophenyl)-N-(3-(pyridin-4-yl)-1H- pyrazol-5-yl)propanamide (12 mg, 0.036 mmol, 1.0 equiv) in anhydrous DMF (1 mL, 0.036 M) was added NCS (7.1 mg, 0.050 mmol, 1.4 equiv) at 0 °C. After the addition, the mixture was stirred at rt for 1 h, concentrated in vacuo, and purified directly by RP-HPLC (Method C, 10–90 % MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3 ·H2O) to afford N-(4-chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-cyano-3- fluorophenyl)propenamide (5.0 mg, 0.014 mmol, 38% yield) as a white solid.1H NMR (400MHz, DMSO-d6) δ 13.7 (s, 1H), 9.97 (s, 1H), 8.69 (s, 2H), 7.87 (t, J = 15.2 Hz, 1H), 7.80 (d, J = 4.8 Hz, 2H), 7.49 (d, J = 10.4 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H), 3.03 (t, J = 14.8 Hz, 2H), 2.73 (t, J = 15.2 Hz, 2H). LCMS: ESI-MS m/z: 370.2 [M+H]+. EXAMPLE 130 4-Chlorobenzyl (4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)carbamate.
Figure imgf000133_0002
Pyridine (13 mg, 0.16 mmol, 1.5 equiv) was added to a solution of Intermediate 1 (22 mg, 0.12 mmol, 1.1 equiv) and 4-chlorobenzyl carbonochloridate (22 mg, 0.11 mmol, 1.0 equiv) in anhydrous THF (5 ml, 0.022 M) and was stirred for 2 h at rt. The mixture was then concentrated in vacuo and directly purified by RP- HPLC (Method A, 10–90% MeCN in H2O + 0.1% TFA) to afford 4-chlorobenzyl (4- methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)carbamate (5.0 mg, 10% yield) as a white solid, trifluoroacetic acid salt.1H NMR (400 MHz, DMSO-d6) δ 9.58 (s, 1H), 8.86– 32 8.65 (m, 2H), 7.92 (s, 2H), 7.46 (d, J = 5.9 Hz, 4H), 5.14 (s, 2H), 2.11 (s, 3H). LCMS: ESI-MS m/z: 343.1 [M+H]+. EXAMPLE 131 1-(4-Chlorobenzyl)-1-methyl-3-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)urea
Figure imgf000134_0001
A solution of 4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine (50 mg, 0.29 mmol, 1.0 equiv) and CDI (70 mg, 0.43 mmol, 1.5 equiv) in DMF (1.5 mL, 0.19 M) was treated with triethylamine (0.16 mL, 1.2 mmol, 4 equiv), and the resulting solution was heated to 90 °C and stirred for 2 h. The reaction mixture was then cooled to rt and treated with 1-(4-chlorophenyl)-N-methylmethanamine (45 mg, 0.29 mmol, 1.0 equiv). Heating was then resumed at 90 °C and the reaction was stirred for a subsequent 6 h. The reaction mixture was cooled to rt and purified directly by RP- HPLC (Method A, 5–100% MeCN in H2O + 0.1% TFA) to give 1-(4-Chlorobenzyl)- 1-methyl-3-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)urea (34 mg, 25% yield) as an off-white solid, trifluoroacetic acid salt.1H NMR (400 MHz, DMSO-d6) δ 8.80–8.82 (m, 2H), 8.55 (s, 1H), 8.09 (br s, 2H), 7.42–7.46 (m, 2H), 7.29–7.32 (m, 2H), 4.54 (s, 2H), 2.93 (s, 3H), 2.14 (s, 3H). LCMS: ESI-MS m/z: 356.2 [M+H]+. EXAMPLES 132 and 133 3-(4-Chlorophenyl)-N-(1-methyl-5-(pyridin-4-yl)-1H-imidazol-2-yl)propenamide and 3-(4-chlorophenyl)-N-methyl-N-(1-methyl-5-(pyridin-4-yl)-1H-imidazol-2- yl)propanamide 33
Figure imgf000135_0001
A solution of 3-(4-chlorophenyl)-N-(5-(pyridin-4-yl)-1H-imidazol-2- yl)propenamide (Example 108, 40 mg, 0.091 mmol, 1 equiv) in anhydrous THF (1.0 mL, 0.091 M) was cooled to 0 °C and treated with NaH (60 wt % dispersion in mineral oil, 7.3 mg, 0.18 mmol, 2.0 equiv). The resulting suspension was stirred at 0 °C for 15 min, then treated with methyl iodide (0.0073 mL, 0.12 mmol, 1.2 equiv). The reaction mixture was then warmed to rt and stirred for 0.5 h until the starting material was consumed (as monitored by LCSM). The mixture was the purified directly by RP-HPLC (Method A, 5–100% MeCN in H2O + 0.1% TFA) to give (Ex. 132) 3-(4-chlorophenyl)-N-(1-methyl-5-(pyridin-4-yl)-1H-imidazol-2-yl)propenamide (3.5 mg, 0.0077 mmol, 8.5% yield) and (Ex.133) 3-(4-chlorophenyl)-N-methyl-N-(1- methyl-5-(pyridin-4-yl)-1H-imidazol-2-yl)propenamide (7.0 mg, 0.015 mmol, 16% yield), both as white solid, trifluoroacetic acid salts. Ex.132: 3-(4-Chlorophenyl)-N-(1-methyl-5-(pyridin-4-yl)-1H-imidazol-2- yl)propenamide: 1H NMR (400 MHz, CD3OD) δ 8.63 (dd, J = 7.1, 2.1 Hz, 2H), 8.33– 8.18 (m, 2H), 8.00 (d, J = 2.0 Hz, 1H), 7.35–7.19 (m, 4H), 4.27 (s, 3H), 3.03 (t, J = 7.5 Hz, 2H), 2.77 (t, J = 7.6, 2H). LCMS: ESI-MS m/z: 341.1 [M+H]+; second eluting peak (retention time = 0.82 min). Ex.133: 3-(4-Chlorophenyl)-N-methyl-N-(1-methyl-5-(pyridin-4-yl)-1H-imidazol-2- yl)propenamide: 1H NMR (400 MHz, CD3OD) δ 8.71–8.63 (m, 2H), 8.30–8.18 (m, 2H), 8.16 (s, 1H), 7.41–7.24 (m, 4H), 4.29 (s, 3H), 3.51 (s, 3H), 3.04 (t, J = 7.4 Hz, 2H), 2.82 (t, J = 7.4 Hz, 2H). LCMS: ESI-MS m/z: 355.2 [M+H]+; first eluting peak (retention time = 0.80 min). EXAMPLE 134 3-(4-Chlorophenyl)-N-methyl-N-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)propanamide 34
Figure imgf000136_0001
A solution of 3-(4-chlorophenyl)-N-(1-(pyridin-4-yl)-1H-pyrazol-4- yl)propanamide (Example 89, 40 mg, 0.12 mmol, 1 equiv) in anhydrous THF (1.0 mL, 0.12 M) was cooled to 0 °C and treated with NaH (60 wt % dispersion in mineral oil, 11 mg, 0.27 mmol, 2.2 equiv). The resulting suspension was stirred at 0 °C for 15 min, then treated with methyl iodide (0.011 mL, 0.18 mmol, 1.5 equiv). The reaction mixture was then warmed to rt and stirred for 3 h until the starting material was consumed (as monitored by LCSM). The mixture was the purified directly by RP- HPLC (Method A, 10–100% MeCN in H2O + 0.1% TFA) to give 3-(4-chlorophenyl)- N-methyl-N-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)propenamide (30 mg, 0.066 mmol, 54% yield) as a white solid, trifluoroacetic acid salt. LCMS: ESI-MS m/z: 341.1 [M+H]+. EXAMPLE 135 2-(4-Chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)cyclopropane- 1-carboxamide
Figure imgf000136_0002
A vial was charged with 2-(4-chlorophenyl)cyclopropane-1-carboxylic acid (95 mg, 0.48 mmol, 1.2 equiv). After dissolving in DMF (1.0 mL, 0.40 M), the solution was cooled to 0 °C and DIPEA (100 mg, 0.80 mmol, 2.0 equiv) and T3P (50% w/v % solution in DMF, 380 mg, 0.60 mmol, 1.5 equiv) were added. After 5 min at rt, 4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine (70 mg, 0.40 mmol, 1.0 equiv) was subsequently added. The solution was stirred at 40 °C for 4 h. The crude material was purified directly by RP-HPLC (Method A, 10–35% MeCN in H2O + 0.1% TFA). Fractions containing the desired mass were combined and concentrated by lyophilization to afford 2-(4-chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H- 35 pyrazol-5-yl)cyclopropane-1-carboxamide (P1, Ex.135), 100 mg, 0.21 mmol, 53% yield) and the regioisomer (5-amino-4-methyl-3-(pyridin-4-yl)-1H-pyrazol-1-yl)(2-(4- chlorophenyl)cyclopropyl)methanone (P2), 83 mg, 0.18 mmol, 44% yield) as a white and pale yellow solid respectively, trifluoroacetic acid salts. P1 (Ex. 135): LCSM: ESI-MS m/z: 353.1 [M+H]+; first eluting peak (retention time = 1.09 min). P2: LCMS: ESI-MS m/z: 353.1 [M+H]+; second eluting peak (retention time = 1.32 min). EXAMPLE 136 4-Chlorobenzyl (5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)carbamate
Figure imgf000137_0001
A vial was charged with 5-methyl-1-(pyridin-4-yl)-1H-pyrazole-4-carboxylic acid (100 mg, 0.49 mmol, 1.0 equiv). After dissolving in anhydrous toluene (3.0 mL, 0.16 M), triethylamine (120 mg, 1.2 mmol, 2.5 equiv) and DPPA (270 mg, 0.98 mmol, 2.0 equiv) were subsequently added and the mixture was heated to 50 °C. After 17 h, (4-chlorophenyl)methanol (84 mg, 0.59 mmol, 1.2 equiv) was added. The solution was heated to 60 °C and stirred for 4 h. The crude material was purified directly by RP-HPLC (Method A, 10–90 MeCN in H2O + 0.1% TFA). Fractions containing the desired mass were combined and concentrated by lyophilization. The material was subsequently recrystallized in hexanes to afford 4-chlorobenzyl (5- methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)carbamate (2.0 mg, 0.0044 mmol, 0.90% yield) as a white solid, trifluoroacetic acid salt. LCMS: ESI-MS m/z: 343.1 [M+H]+. EXAMPLE 137 3-(4-Chlorophenyl)-N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4- yl)propanethioamide 36
Figure imgf000138_0001
A vial was charged with 3-(4-chlorophenyl)-N-(5-methyl-1-(pyridin-4-yl)-1H- pyrazol-4-yl)propanamide (Example 86, 20 mg, 0.044 mmol, 1.0 equiv). After dissolving in THF (0.60 mL, 0.073 M), 2,4-bis(4-phenoxyphenyl)-1,3-dithia-2,4- diphosphetane 2,4-disulfide (67 mg, 0.13 mmol, 2.9 equiv) was subsequently added. The solution was heated to 40 °C and stirred for 2 h. The reaction mixture was quenched with water, filtered, and purified directly by RP-HPLC (Method A, 10–50% MeCN in H2O + 0.1% TFA). Fractions containing the desired mass were combined and concentrated by lyophilization to afford 3-(4-chlorophenyl)-N-(5-methyl-1- (pyridin-4-yl)-1H-pyrazol-4-yl)propanethioamide (1.4 mg, 0.0030 mmol, 6.7% yield) as a solid, trifluoroacetic acid salt. LCMS: ESI-MS m/z: 357.1 [M+H]+. EXAMPLE 138 4-(4-Chlorophenyl)-1-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)piperidin-2-one 37
Figure imgf000139_0001
Step 1: 3-(4-Chlorophenyl)-5-((4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)amino)-5-oxopentanoic acid. A vial was charged with 4-methyl-3-(pyridin-4-yl)- 1H-pyrazol-5-amine (160 mg, 0.94 mmol, 1.0 equiv) and 4-(4-chlorophenyl)dihydro- 2H-pyran-2,6(3H)-dione (210 mg, 0.94 mmol, 1.0 equiv). After dissolving in anhydrous THF (5.0 mL, 0.19 M), the mixture was heated to 65 °C. After 17 h, the reaction mixture was then concentrated in vacuo, re-dissolved in a minimal amount of DMSO and directly purified by RP-HPLC (Method A, 10–30% MeCN in H2O + 0.1% TFA). Fractions containing the desired mass were combined and concentrated by lyophilization to afford 3-(4-chlorophenyl)-5-((4-methyl-3-(pyridin-4-yl)-1H-pyrazol- 5-yl)amino)-5-oxopentanoic acid (P1, 180 mg, 0.35 mmol, 38% yield) and undesired regioisomer 5-(5-amino-4-methyl-3-(pyridin-4-yl)-1H-pyrazol-1-yl)-3-(4- chlorophenyl)-5-oxopentanoic acid (P2, 10 mg, 0.016 mmol, 1.7% yield) as white solids, trifluoroacetic acid salts. P1: 1H NMR (400 MHz, DMSO-d6) δ 12.1 (s, 1H), 9.89 (s, 1H), 8.76 (d, J = 5.8 Hz, 2H), 7.94 (s, 2H), 7.35 (d, J = 8.7 Hz, 2H), 7.32 (d, J = 8.7 Hz, 2H), 3.55 (quint, J = 38 7.2, 6.7 Hz, 1H), 2.79–2.54 (m, 4H), 1.91 (s, 3H). LCMS: ESI-MS m/z: 399.1 [M+H]+; first eluting peak (retention time = 0.77 min). P2: 1H NMR (400 MHz, DMSO-d6) δ 8.76 (d, J = 5.5 Hz, 2H), 7.89 (s, 2H), 7.36 (d, J = 8.7 Hz, 2H), 7.33 (d, J = 8.2 Hz, 2H), 6.45 (s, 1H), 3.72–3.50 (m, 2H), 3.41 (dd, J = 16.9, 5.8 Hz, 1H), 2.77 (dd, J = 16.0, 6.1 Hz, 1H), 2.63 (dt, J = 16.1, 8.2 Hz, 1H), 2.01 (s, 3H). LCMS: ESI-MS m/z: 399.1 [M+H]+; second eluting peak (retention time = 0.89 min). Step 2: 3-(4-Chlorophenyl)-5-hydroxy-N-(4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-yl)pentanamide. A vial was charged with 3-(4-chlorophenyl)-5-((4- methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)amino)-5-oxopentanoic acid (45 mg, 0.11 mmol, 1.0 equiv). After dissolving in anhydrous THF (3.0 mL, 0.038 M), the solution was cooled to 0 °C and LAH (1.0 M solution in THF, 42 mg, 1.1 mmol, 10 equiv) was added dropwise and the mixture was slowly warmed to rt and stirred for 2 h. The crude material was purified directly by RP-HPLC (Method A, 10–90% MeCN in H2O + 0.1% TFA). Fractions containing the desired mass were combined and concentrated by lyophilization to afford 3-(4-chlorophenyl)-5-hydroxy-N-(4-methyl-3-(pyridin-4- yl)-1H-pyrazol-5-yl)pentanamide (10 mg, 0.026 mmol, 23% yield) as a white solid, trifluoroacetic acid salt. LCMS: ESI-MS m/z: 385.2 [M+H]+. Step 3: 3-(4-Chlorophenyl)-5-((4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)amino)-5-oxopentyl methanesulfonate. A vial was charged with 3-(4- chlorophenyl)-5-hydroxy-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)pentanamide (9.0 mg, 0.023 mmol, 1.0 equiv). After dissolving in anhydrous THF (1.0 mL, 0.023 M), the solution was cooled to 0 °C and triethylamine (7.1 mg, 0.070 mmol, 3.0 equiv) was added. After 10 min, methanesulfonyl chloride (4.0 mg, 0.035 mmol, 1.5 equiv) was slowly added. The mixture was warmed to rt and stirred for 3 h. The reaction mixture was concentrated in vacuo to afford crude 3-(4-chlorophenyl)-5-((4- methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)amino)-5-oxopentyl methanesulfonate (10 mg, 0.022 mmol, >95% crude yield), which was used in the next step directly without purification. LCMS: ESI-MS m/z: 463.2 [M+H]+. Step 4: 4-(4-Chlorophenyl)-1-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)piperidin-2-one. A vial was charged with 3-(4-chlorophenyl)-5-((4-methyl-3- (pyridin-4-yl)-1H-pyrazol-5-yl)amino)-5-oxopentyl methanesulfonate (10 mg, 0.022 mmol, 1.0 equiv). After dissolving in anhydrous THF (1.0 mL, 0.022 M), the solution was cooled to 0 °C and NaH (60% w/w dispersion in mineral oil, 8.7 mg, 0.22 mmol, 10 equiv) was added. The suspension was warmed to rt and stirred for 3 h. The reaction mixture was quenched with water, filtered and purified directly by RP-HPLC (Method B, 10–90% MeCN in H2O + 0.1% FA). Fractions containing the desired mass were combined and concentrated by lyophilization to afford 4-(4-chlorophenyl)- 1-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)piperidin-2-one (1.6 mg, 0.0040 mmol, 18% yield) as a solid, formic acid salt. 1H NMR (400 MHz, CD3OD) δ 8.65 (d, J = 5.2 Hz, 2H), 8.52 (s, 1H), 7.66 (s, 2H), 7.37 (s, 4H), 3.91–3.79 (m, 1H), 3.71 (d, J = 12.2 Hz, 1H), 3.41–3.34 (m, 1H), 2.84 (dd, J = 17.7, 5.3 Hz, 1H), 2.72 (dd, J = 17.6, 10.9 Hz, 1H), 2.24 (td, J = 9.1, 8.4, 4.6 Hz, 2H), 2.14 (s, 3H). LCMS: ESI-MS m/z: 367.2 [M+H]+. EXAMPLE 139 3-(4-Chlorophenyl)-N-methyl-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide N
Figure imgf000141_0001
Step 2   Step 1: tert-Butyl 5-(3-(4-chlorophenyl)propanamido)-4-methyl-3- (pyridin-4-yl)-1H-pyrazole-1-carboxylate. To a solution of 3-(4- chlorophenyl)propanoic acid (340 mg, 1.8 mmol, 2.5 equiv) was added DCM (3 mL, 0.6 M) was added oxalyl chloride (2.0 M in DCM, 1.1 mL, 2.1 mmol, 3.0 equiv) and 1 drop of anhydrous DMF. The resulting mixture was stirred at rt for 4.5 h. The 40 mixture was concentrated in vacuo to afford a crude residue. In a separate flask, a solution of tert-butyl 5-amino-4-methyl-3-(pyridin-4-yl)-1H-pyrazole-1-carboxylate (Intermediate 28, 190 mg, 0.70 mmol, 1.0 equiv) in DCM (5.0 mL, 0.14 M) at 0 °C was treated with triethylamine (280 mg, 2.8 mmol, 4.0 equiv). The acid chloride was then dissolved in DCM (1.0 mL) and added to the cold solution. The mixture was warmed to rt and stirred for 16 h. It was then diluted with DCM (100 ml), washed with a saturated solution of NaHCO3, water, and brine. The organic fractions were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The resulting crude product was purified by silica gel column chromatography (5–55% EtOAc in DCM) to afford tert-butyl 5-(3-(4-chlorophenyl)propanamido)-4-methyl-3- (pyridin-4-yl)-1H-pyrazole-1-carboxylate (54 mg, 17% yield) as a white solid. LCMS: ESI-MS m/z: 441.2 [M+H]+. Step 2: 3-(4-Chlorophenyl)-N-methyl-N-(4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-yl)propenamide. To a solution of tert-butyl 5-(3-(4- chlorophenyl)propanamido)-4-methyl-3-(pyridin-4-yl)-1H-pyrazole-1-carboxylate (26 mg, 0.059 mmol, 1.0 equiv) in anhydrous DMF (2 mL, 0.030 M) at 0 °C was added NaH (60% w/w dispersion in mineral oil, 4.7 mg, 0.12 mmol, 2.0 equiv). The resulting suspension was stirred at 0 °C for 15 min. Then, methyl iodide (10 mg, 0.071 mmol, 1.2 equiv) was added and stirring was continued at 0 °C for a subsequent 40 min. After 40 min, the reaction was carefully quenched with water (0.20 mL) and the reaction was concentrated in vacuo. The resulting residue was then treated with a 1:6 solution of TFA:DCM (2.0 mL) and stirred at rt for 15 h. The mixture was again concentrated in vacuo and purified directly by RP-HPLC (Method A, 10–90% MeCN in H2O + 0.1% TFA) to afford 3-(4-chlorophenyl)-N-methyl-N-(4-methyl-3-(pyridin- 4-yl)-1H-pyrazol-5-yl)propenamide (3.7 mg, 13% yield) as a white solid, trifluoroacetic acid salt. LCMS: ESI-MS m/z: 355.2 [M+H]+. EXAMPE 140 3-(4-Ethynylphenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propenamide 41
Figure imgf000143_0001
Step 1: 3-(4-((Trimethylsilyl)ethynyl)phenyl)propanoic acid. A flask was charged with 3-(4-iodophenyl)propanoic acid (400 mg, 1.5 mmol, 1.0 equiv), which was azeotroped with toluene. Then CuI (28 mg, 0.15 mmol, 0.10 equiv), tetrakis(triphenylphosphine) palladium(0) (34 mg, 0.029 mmol, 0.020 equiv) and anhydrous THF (6.0 mL, 0.25 M) were added. The resulting mixture was degassed with nitrogen gas for 30 min, then triethylamine (6.1 mL, 4.4 g, 44 mmol, 30 equiv) and ethynyltrimethylsilane (0.24 mL, 170 mg, 1.7 mmol, 1.2 equiv) were added. The resulting mixture was stirred at rt for 17 h. Subsequently, the solution was diluted with EtOAc (140 ml) and washed with an aqueous solution of 1 N HCl (20 mL), and brine (20 mL). The organic layer was separated and dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to afford a crude residue. The crude product was purified by silica gel column chromatography (20–40% EtOAc in DCM) to afford 3-(4-((trimethylsilyl)ethynyl)phenyl)propanoic acid (210 mg, 58% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 12.2 (s, 1H), 7.40–7.32 (m, 2H), 7.28–7.17 (m, 2H), 2.82 (d, J = 7.6 Hz, 2H), 2.54 (d, J = 7.6 Hz, 2H), 0.22 (s, 9H). Step 2: N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4- ((trimethylsilyl)ethynyl)phenyl) propenamide. To a solution of 3-(4- ((trimethylsilyl)ethynyl)phenyl)propanoic acid (55 mg, 0.22 mmol, 1.0 equiv) in DMF (3 mL, 0.073 M) at 0 °C was added T3P (50 w/v % in DMF, 140 mg, 0.22 mmol, 1.0 equiv) and triethylamine (68 mg, 0.68 mmol, 3.0 equiv). The resulting solution was stirred at 0 °C for 10 min, followed then by the addition of 4-methyl-3- (pyridin-4-yl)-1H-pyrazol-5-amine (Intermediate 1, 43 mg, 0.25 mmol, 1.1 equiv). 42 The resulting mixture was stirred at rt for 3 h, then concentrated in vacuo and purified directly by RP-HPLC (Method A, 10–90% MeCN in H2O + 0.1% TFA) to afford N- (4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-((trimethylsilyl)ethynyl)phenyl) propenamide (41 mg, 46% yield) as a white solid, trifluoroacetic acid salt. LCMS: ESI-MS m/z: 403.2 [M+H]+. Step 3: 3-(4-Ethynylphenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide. To a solution of N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3- (4-((trimethylsilyl)ethynyl)phenyl) propenamide (37 mg, 0.092 mmol, 1.0 equiv) in THF (2 mL, 0.046 M) was added TBAF (1 M solution in THF, 0.18 mL, 0.18 mmol, 2.0 equiv). The resulting solution was stirred at rt for 30 min, then the reaction mixture was concentrated in vacuo and purified directly by RP-HPLC (Method A, 10–90% MeCN in H2O + 0.1% TFA) to afford 3-(4-ethynylphenyl)-N-(4-methyl-3- (pyridin-4-yl)-1H-pyrazol-5-yl)propenamide (22 mg, 54% yield), a white solid, trifluoroacetic acid salt.1H NMR (400 MHz, DMSO-d6)δ 9.93 (s, 1H), 8.76 (d, J = 5.7 Hz, 2H), 7.93 (s, 2H), 7.46–7.37 (m, 2H), 7.29 (d, J = 8.1 Hz, 2H), 4.13 (s, 1H), 2.94 (t, J = 7.6 Hz, 2H), 2.67 (t, J = 7.5 Hz, 2H), 2.04 (s, 3H). LCMS: ESI-MS m/z: 331.1[M+H]+. EXAMPLE 141 1-[(4-Cyanophenyl)methyl]-3-[4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl]urea H
Figure imgf000144_0001
, Step 1 Step 2 Step 1: 4-(Isocyanatomethyl)benzonitrile. To a stirred solution of 4- (aminomethyl)benzonitrile (150 mg, 1.2 mmol, 1.0 equiv) in EtOAc (10 mL, 0.12 M) at 0 °C was added triphosgene (400 mg, 1.3 mmol, 1.1 equiv). The reaction mixture was heated to reflux for 2 h. The reaction mixture was concentrated in vacuo and the residue was used in the next step without further purification. 43 Step 2: 1-[(4-Cyanophenyl)methyl]-3-[4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-yl]urea. To a stirred solution of crude 4-(isocyanatomethyl)benzonitrile (1.2 mmol, 1.0 equiv) in anhydrous DMF (2 mL, 0.60 M), was added DIPEA (390 mg, 3.1 mmol, 2.6 equiv) and 4-methyl-3-(pyridin-4-yl)-1-{[2- (trimethylsilyl)ethoxy]methyl}-1H-pyrazol-5-amine (Intermediate 2, 410 mg, 1.3 mmol, 1.1 equiv). The mixture was stirred for 16 h at rt. The mixture was diluted with water (10 mL) and extracted with EtOAc (10 mL). The organic layer was separated and washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude residue was dissolved in DCM (6 mL) and to this mixture was added TFA (2 mL). The reaction mixture was stirred for 2 h at rt then concentrated in vacuo and purified by RP-HPLC (Method C, 5–95 % MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3 ·H2O) to afford 1-[(4-cyanophenyl)methyl]-3-[4- methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl]urea (12 mg, 3.0% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 12.8 (d, J = 50.0 Hz, 1H), 8.65 (s, 4H), 7.81 (d, J = 8.2 Hz, 2H), 7.74–7.53 (m, 3H), 7.49 (d, J = 8.3 Hz, 2H), 4.42 (s, 2H), 2.10 (s, 3H). LCMS: ESI-MS: m/z: 333.1 [M+H]+. EXAMPLE 142 1-[(4-Fluorophenyl)methyl]-3-[4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl]urea
Figure imgf000145_0001
The product was prepared following the same procedure as Example #141to afford 1-[(4-fluorophenyl)methyl]-3-[4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl]urea in 10% yield (over two steps) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 12.9 (s, 1H), 8.66–8.58 (m, 2H), 8.44 (s, 1H), 7.64–7.56 (m, 3H), 7.35 (dd, J = 8.6, 5.7 Hz, 2H), 7.16 (t, J = 8.9 Hz, 2H), 4.33 (s, 2H), 2.09 (s, 3H). LCMS: ESI-MS m/z: 326.1 [M+H]+. 44 EXAMPLE 143 1-[(6-Chloropyridin-3-yl)methyl]-3-[4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl]urea
Figure imgf000146_0001
The product was prepared following the same procedure as Example #141 to afford 1-[(6-chloropyridin-3-yl)methyl]-3-[4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl]urea in 8.0% yield (over two steps) as a white solid.1H NMR (400 MHz, DMSO- d6) δ 12.9 (s, 1H), 8.64 (s, 2H), 8.49 (s, 1H), 8.35 (d, J = 2.2 Hz, 1H), 7.79 (dd, J = 8.2, 2.4 Hz, 1H), 7.58 (s, 2H), 7.50 (d, J = 8.2 Hz, 1H), 4.35 (d, J = 5.0 Hz, 2H), 2.08 (s, 3H). LCMS: ESI-MS m/z: 343.1 [M+H]+. EXAMPLE 144 1-(4-Chlorobenzyl)-3-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)urea
Figure imgf000146_0002
A solution of 5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-amine (Intermediate 6, 50 mg, 0.29 mmol, 1.0 equiv), (4-chlorophenyl)methanamine (41 mg, 0.29 mmol, 1.0 equiv) CDI (50 mg, 0.31 mmol, 1.1 equiv), and DIPEA (75 mg, 0.57 mmol, 2.0 equiv) in DCM (3.0 mL, 0.10 M) was stirred at rt for 16 h. The mixture was then washed with water and the organic fraction was separated and concentrated in vacuo. The crude material was purified directly by RP-HPLC (Method C, 15–40 % MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3·H2O) to afford 1-(4-chlorobenzyl)-3-(5- methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)urea (10 mg, 0.029 mmol, 10% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 8.66 (dd, J = 6.0 Hz, 2H), 7.98 (s, 1H), 7.85 (s, 1H), 7.63 (dd, J = 6.4 Hz, 2H), 7.41–7.38 (m, 2H), 7.32 (d, J = 8.4 Hz, 2H), 45 6.66 (t, J = 12.0 Hz, 1H), 4.28 (d, J = 6.0 Hz, 2H), 2.36 (s, 3H). LCMS: ESI-MS m/z: 342.0 [M+H]+. EXAMPLE 145 1-(4-Chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5-trifluorobenzyl)urea
Figure imgf000147_0001
Step 1.1-(3-(Pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5-trifluorobenzyl)urea. To a solution of (3,4,5-trifluorophenyl)methanamine (100 mg, 0.63 mmol, 1.0 equiv) and CDI (110 mg, 0.70 mmol, 1.2 equiv) in DCM (10 mL, 0.063 M) was added ethylbis(propan-2-yl)amine (120 mg, 0.94 mmol, 1.5 equiv), and the reaction mixture was stirred for 1 h at rt. 3-(Pyridin-4-yl)-1H-pyrazol-5-amine (100 mg, 0.63 mmol, 1.0 equiv) was then added and the reaction mixture was stirred for 8 h at rt. The reaction mixture was washed with water (20 mL), the layers were separated, and the organic layer was concentrated in vacuo. The resulting crude residue was then 15 purified RP-HPLC (Method C, 5–25 % MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3·H2O). Fractions containing the desired product were combined and concentrated by lyophilization to afford 1-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5- trifluorobenzyl)urea (20 mg, 0.31 mmol, 50% yield) as a colorless solid. 1H NMR (DMSO-d6, 400MHz) δ 13.01 (s, 1H), 9.12 (s, 1H), 8.61 (s, 2H), 7.68 (d, J = 5.8 Hz, 0 2H), 7.33–7.20 (m, 2H), 7.14 (s, 1H), 6.79 (s, 1H), 4.32 (d, J = 5.6 Hz, 2H). LCMS: ESI-MS m/z: 348 [M+H]+. Step 2.1-(4-Chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5- trifluorobenzyl)urea. A mixture of 1-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5- 146 trifluorobenzyl)urea (20 mg, 0.057 mmol, 1.0 equiv) and N-chlorosuccinimide (8.0 mg, 0.060 mmol, 1.1 equiv) in DCM (1 mL, 0.057 M) was stirred for 1 h at rt, and then concentrated in vacuo. The resulting residue was then purified RP-HPLC (Method C, 5–50 % MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3 ·H2O). Fractions containing the desired product were combined and concentrated by lyophilization to afford 1-(4-chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5- trifluorobenzyl)urea (5.0 mg, 0.013 mmol, 23% yield) as a colorless solid.1H NMR (DMSO-d6, 400MHz) δ 13.4 (s, 1H), 8.98 (s, 1H), 8.67 (s, 2H), 7.81 (d, J = 4.4 Hz, 2H), 7.27–7.20 (m, 3H), 4.31 (d, J = 6.0 Hz, 2H). LCMS: ESI-MS m/z: 348 [M+H]+. EXAMPLE 146 2,6-Difluoro-4-((2-oxo-1-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)pyrrolidin-3- yl)methyl)benzonitrile
Figure imgf000148_0001
Step 1: 3-(Pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol- 5-amine. To a solution of 3-(pyridin-4-yl)-1H-pyrazol-5-amine (Intermediate 13, 500 mg, 3.1 mmol, 1.0 equiv) in anhydrous DMF (10 mL, 0.31 M) was added sodium hydride (60 wt % dispersion in mineral oil, 190 mg, 4.7 mmol, 1.5 equiv) at 0 °C 47 under an atmosphere of nitrogen gas. After the addition, the mixture was stirred at 0 °C for 40 min. Next, SEM-Cl (780 mg, 4.7 mmol, 1.5 equiv) was added dropwise at 0 °C. After the addition, the mixture was stirred at 0 °C for 2 h. The mixture was then diluted with ethyl acetate (50 mL) and washed with a saturated solution of aqueous NH4Cl (2 × 30 mL). The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude residue was purified by silica gel column chromatography (5% DCM in MeOH) to afford 3-(pyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-amine (500 mg, 1.7 mmol, 55% yield) as a light yellow solid. LCMS: ESI-MS m/z: 291.1 [M+H]+. Step 2: 4-Chloro-N-(3-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)- 1H-pyrazol-5-yl)butanamide. To a solution of 3-(pyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-amine (200 mg, 0.69 mmol, 1.0 equiv) in DCM (4 mL, 0.17 M) was added 4-chlorobutanoyl chloride (120 mg, 0.83 mmol, 1.2 equiv) at 0 °C. DIPEA (110 mg, 0.83 mmol, 1.2 equiv) was then added dropwise and the reaction mixture was stirred at rt for 2 h. The reaction mixture was then concentrated in vacuo, and the resulting residue purified directly by RP-HPLC (Method C, 5–95 % MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3 ·H2O). The fractions containing the desired compound were concentrated by lyophilization to afford 4-chloro-N-(3-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol- 5-yl)butanamide (120 mg, 0.30 mmol, 36% yield) as a yellow oil. LCMS: ESI-MS m/z: 395.0 [M+H]+. Step 3: 1-(3-(Pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrazol-5-yl)pyrrolidin-2-one. To a solution of 4-chloro-N-(3-(pyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)butanamide (100 mg, 0.25 mmol, 1.0 equiv) in EtOH (4mL, 0.063 M) was added potassium tert-butoxide (85 mg, 0.76 mmol, 3.0 equiv) at rt and the reaction was stirred for 2 h. The reaction mixture was then concentrated in vacuo, and the resulting residue was purified by RP-HPLC (Method C, 5–95 % MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3·H2O). Fractions containing the desired product were concentrated by lyophilization to afford 1-(3-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)pyrrolidin- 2-one (50 mg, 0.14 mmol, 41% yield) as a yellow oil. LCMS: ESI-MS m/z: 359.0 [M+H]+. 48 Step 4: 2,6-Difluoro-4-(hydroxy(2-oxo-1-(3-(pyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)pyrrolidin-3- yl)methyl)benzonitrile. To a solution of 1-(3-(pyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)pyrrolidin-2-one (170 mg, 0.47 mmol, 1.0 equiv) in THF (3 mL, 0.16 M), was added LiHMDS (1.0 M in THF, 0.95 mL, 0.95 mmol, 2.0 equiv) dropwise at –78 °C. A solution of 2,6-difluoro-4- formylbenzonitrile (120 mg, 0.71 mmol, 1.5 equiv) in THF (2 ml) was then added at to the cold solution, and the resulting mixture was stirred at –78 °C for 1 h. Water (20 mL) was then added, and the mixture was extracted with DCM (3 × 30 mL). The combined organic fractions were washed with brine (2 × 20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by RP-HPLC (Method C, 5–95 % MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3 ·H2O) and fractions containing the desired product were concentrated by lyophilization to afford 2,6-difluoro-4-(hydroxy(2-oxo-1-(3-(pyridin-4-yl)-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)pyrrolidin-3-yl)methyl)benzonitrile (40 mg, 0.076 mmol, 16%) as a white solid. LCMS: ESI-MS m/z: 526.2 [M+H]+. Step 5: 2,6-Difluoro-4-((2-oxo-1-(3-(pyridin-4-yl)-1H-pyrazol-5- yl)pyrrolidin-3-yl)methyl)benzonitrile. A mixture of 2,6-difluoro-4-(hydroxy(2- oxo-1-(3-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5- yl)pyrrolidin-3-yl)methyl)benzonitrile (40 mg, 0.070 mmol, 1.0 equiv) and Zn dust (27 mg, 0.42 mmol, 6.0 equiv) in acetic acid (2 mL, 0.035 M) was stirred at 130 °C for 18 h. The mixture was filtered, and the filtrate was concentrated in vacuo. The residue was treated with NH3/MeOH (7 M) to adjust to pH 8–9 and further purified by RP-HPLC (Method C, 5–95 % MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3 ·H2O). The desired fractions were concentrated to afford 2,6-difluoro-4-((2-oxo- 1-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)pyrrolidin-3-yl)methyl)benzonitrile (2.0 mg, 0.0050 mmol, 7.5% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 13.3 (s, 1H), 8.64 (d, J = 5.5 Hz, 2H), 7.81–7.71 (m, 2H), 7.46 (d, J = 9.4 Hz, 2H), 7.28 (s, 1H), 3.86 (d, J = 9.1 Hz, 1H), 3.71 (dd, J = 17.1, 9.3 Hz, 1H), 3.24 (dd, J = 13.7, 5.2 Hz, 1H), 3.14–3.04 (m, 1H), 2.85 (dd, J = 13.7, 9.5 Hz, 1H), 2.13 (d, J = 4.5 Hz, 1H), 1.89–1.73 (m, 1H). LCMS: ESI-MS m/z: 380.0 [M+H]+. 49 EXAMPLE 147 N-(4-Bromo-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-chlorophenyl)propanamide N
Figure imgf000151_0001
Step 2 Step 1: 4-Bromo-3-(pyridin-4-yl)-1H-pyrazol-5-amine. To a stirred solution of 3-(pyridin-4-yl)-1H-pyrazol-5-amine (200 mg, 1.3 mmol, 1.0 equiv) in acetonitrile (3 mL, 0.43 M) was added NBS (250 mg, 1.4 mmol, 1.1 equiv) portionwise at 0 °C under an atmosphere of nitrogen gas. After the addition, the reaction was stirred at rt for 3 h. The reaction mixture was then concentrated in vacuo and the residue was purified by silica gel column chromatography (10% MeOH in DCM) to afford 4- bromo-3-(pyridin-4-yl)-1H-pyrazol-5-amine (160 mg, 0.66 mmol, 53% yield) as a light yellow solid. LCMS: ESI-MS m/z: 240.0 [M+H]+. Step 2. N-(4-Bromo-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4- chlorophenyl)propanamide. The product was prepared according to General Procedure #1 using 4-bromo-3-(pyridin-4-yl)-1H-pyrazol-5-amine and 3-(4- chlorophenyl)propanoic acid to afford N-(4-bromo-3-(pyridin-4-yl)-1H-pyrazol-5-yl)- 3-(4-chlorophenyl)propanamide (78 mg, 0.19 mmol, 46%) as a light yellow solid.1H NMR (400MHz, CDCl3) δ 8.71 (d, J = 4.4 Hz, 2H), 7.89 (d, J = 4.8 Hz, 2H), 7.56(s, 1H), 7.32 (d, J = 8.0 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H), 3.09 (t, J = 6.8 Hz, 2H), 2.84 (t, J = 7.2 Hz, 2H). LCMS: ESI-MS m/z: 405.0 [M+H]+. 50 EXAMPLE 148 (R)-1-(1-(4-Chlorophenyl)ethyl)-3-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)urea
Figure imgf000152_0001
A mixture of Intermediate 1 (50 mg, 0.28 mmol, 1.0 equiv), CDI (70 mg, 0.43 mmol, 1.5 equiv), triethylamine (0.16 mL, 1.2 mmol, 4.0 equiv), and DMF (1.5 mL, 0.19 M) was heated to 88 °C for 2 h. (R)-1-(4-Chlorophenyl)ethan-1-amine (45 mg, 0.29 mmol, 1.0 equiv) was then added and the reaction mixture was heated to 88 °C for 6 h. The crude material was purified by RP-HPLC (Method A, 40–45% MeCN in H2O + 0.1 % TFA) to give (R)-1-(1-(4-chlorophenyl)ethyl)-3-(4-methyl-3-(pyridin-4- yl)-1H-pyrazol-5-yl)urea (26 mg, 19% yield) as a pale white solid.1H NMR (400 MHz, DMSO-d6) δ 8.77 (d, J = 6.2 Hz, 2H), 8.47 (s, 1H), 7.96 (s, 2H), 7.60–7.12 (m, 4H), 4.84 (q, J = 7.0 Hz, 1H), 2.13 (s, 3H), 1.36 (dd, J = 24.9, 7.0 Hz, 3H). LCMS: ESI-MS m/z: 356.1 [M+H]+. EXAMPLE 149 (5-Chlorothiophen-2-yl)methyl (5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4- yl)carbamate
Figure imgf000152_0002
To a suspension of 5-methyl-1-(pyridin-4-yl)-1H-pyrazole-4-carboxylic acid (100 mg, 0.49 mmol, 1.0 equiv) in toluene (3.0 mL, 0.16 M) was added triethylamine (0.17 mL, 1.2 mmol, 2.5 equiv), and DPPA (0.21 mL. 0.98 mmol, 2.0 equiv). The reaction was heated to 70 °C. After 17 h, (5-chlorothiophen-2-yl)methanol (88 mg, 0.59 mmol, 1.2 equiv) was added. The solution was heated to 60 °C and stirred for 4 h. After cooling to rt, the crude material was purified directly by RP-HPLC (Method A, 10–90 MeCN in H2O + 0.1 % TFA). Fractions containing the desired mass were combined and concentrated by lyophilization. The material was subsequently 51 recrystallized in hexanes to afford (5-chlorothiophen-2-yl)methyl (5-methyl-1- (pyridin-4-yl)-1H-pyrazol-4-yl)carbamate (10 mg, 4.0% yield). LCMS: ESI-MS m/z: 349.1 [M+H]+. EXAMPLE 150 (rac)-3-(4-Chlorophenyl)-2-hydroxy-N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4- yl)propanamide
Figure imgf000153_0001
The product was prepared according to General Procedure #1 using Intermediate 6 and (rac)-3-(4-chlorophenyl)-2-hydroxypropanoic acid to afford (rac)- 3-(4-chlorophenyl)-2-hydroxy-N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4- yl)propanamide in 16% yield as a white solid.1H NMR (400 MHz, CDCl3) δ 8.96 (s, 0.34 H), 8.69 (d, J = 4 Hz, 1.34H), 8.57 (d, J = 4 Hz, 0.54H), 8.17-8.10 (m, 2H), 8.05 (s, 0.31H), 7.93 (s, 0.62H), 7.65–7.61 (m, 2H),7.34–7.21 (m, 4H), 5.00–4.95 (m, 0.3H), 4.56–4.53 (m, 0.62H), 3.28–3.22 (m, 1H), 3.11–2.98 (m, 1H), 2.33 (s, 1.90H), 2.22 (s, 1.1H). LCMS: ESI-MS m/z: 357.1 [M+H]+. EXAMPLE 151 (R)-2-Amino-3-(4-chlorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide H
Figure imgf000153_0002
, Step 3 152 Step 1: (R)-2-((tert-Butoxycarbonyl)amino)-3-(4-chlorophenyl)propanoic acid. To a solution of (R)-2-amino-3-(4-chlorophenyl)propanoic acid (500 mg, 2.5 mmol, 1.0 equiv) dissolved in a 1:1 mixture of dioxane:water (5.0 mL, 0.50 M) was added solid sodium hydroxide (200 mg, 5.0 mmol, 5.0 equiv). The resulting solution was cooled to 5 °C and Boc anhydride (160 mg, 3.8 mmol, 1.5 equiv) was slowly added as a solution in dioxane (2.0 mL). The resulting mixture was stirred at 0 °C for 1 h and then to rt and stirred for 15 h. Water was added and the aqueous layer was extracted with EtOAc (2 × 20 mL). The combined organic fractions were washed with a saturated solution of sodium bicarbonate (2 × 20 mL). The combined aqueous fractions were acidified with an aqueous solution of 10% HCl until pH ~ 1, then extracted with EtOAc (3 × 10 mL). The combined organic fractions were dried over anhydrous sodium sulfate and concentrated in vacuo to give (R)-2-((tert- butoxycarbonyl)amino)-3-(4-chlorophenyl)propanoic acid (750 mg, >95% yield) as a clear viscous oil. LCMS: ESI-MS m/z: 322.1 [M+Na]+. Step 2: tert-Butyl (R)-(3-(4-chlorophenyl)-1-oxo-1-((3-(pyridin-4-yl)-1H- pyrazol-5-yl)amino)propan-2-yl)carbamate. To a solution (R)-2-((tert- butoxycarbonyl)amino)-3-(4-chlorophenyl)propanoic acid (94 mg, 0.31 mmol, 1.0 equiv) in DCE (2.0 mL, 0.16 M) was added triethylamine (0.13 mL, 0.94 mmol, 3.0 equiv), then a solution of T3P (50% w/w in EtOAc, 0.11 mL, 0.38 mmol, 1.2 equiv). The reaction mixture was stirred at rt for 30 min then 3-(pyridin-4-yl)-1H-pyrazol-5- amine (50 mg, 0.31 mmol, 1.0 equiv) was added. The reaction mixture was stirred at rt for 15 h. The mixture was purified directly by RP-HPLC (Method A, 10–90% MeCN in H2O + 0.1% FA) to afford tert-butyl (R)-(3-(4-chlorophenyl)-1-oxo-1-((3- (pyridin-4-yl)-1H-pyrazol-5-yl)amino)propan-2-yl)carbamate (25 mg, 18% yield) as a white solid. LCMS: ESI-MS m/z: 442.2 [M+H]+. Step 3: (R)-2-Amino-3-(4-chlorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide. To a solution of tert-butyl (R)-(3-(4-chlorophenyl)-1-oxo-1-((3- (pyridin-4-yl)-1H-pyrazol-5-yl)amino)propan-2-yl)carbamate (100 mg, 0.23 mmol, 1.0 equiv) and anhydrous 1,4-dioxane (1.0 mL, 0.23 M) was added 4 M HCl in dioxane (0.57 mL, 2.3 mmol, 10 equiv). The reaction mixture was stirred at rt for 2 h. The reaction mixture was concentrated in vacuo to give (R)-2-amino-3-(4- chlorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (77 mg, >95% yield) as a light-yellow solid, hydrochloric acid salt.1H NMR (400 MHz, DMSO-d6) δ 13.3 (br s, 1H), 8.61 (d, J = 4 Hz, 2H), 7.71 (d, J = 4 Hz, 2H), 7.34 (d, J = 8 Hz, 2H), 7.28 (d, J = 8 Hz, 2H), 7.11 (br s, 1H), 3.65–3.60 (m, 1H), 3.04–2.97 (m, 1H), 2.76–2.65 (m, 1H). LCMS: ESI-MS m/z: 342.1 [M+H]+. EXAMPLE 152 (S)-5-(4-Chlorobenzyl)-2,2-dimethyl-3-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4- yl)imidazolidin-4-one H
Figure imgf000155_0001
Step 3 Step 4 Step 1: (S)-2-((tert-Butoxycarbonyl)amino)-3-(4-chlorophenyl)propanoic acid. To a solution of (S)-2-amino-3-(4-chlorophenyl)propanoic acid (500 mg, 2.5 mmol, 1.0 equiv) and a 1:1 mixture of 1,4-dioxane:water (10 mL, 0.25 M) was added solid sodium hydroxide (210 mg, 5.0 mmol, 2.0 equiv). The resulting solution was cooled to 5 °C and Boc anhydride (820 mg, 3.8 mmol, 1.5 equiv) in 1,4-dioxane (2.0 mL) was slowly added. The reaction mixture was stirred at 0 °C for 1 h, then warmed to rt and stirred for 15 h. Water was added and the aqueous layer was extracted with EtOAc (2 × 20 mL). The combined organic fractions were washed twice with a saturated solution of sodium bicarbonate. The combined aqueous fractions were acidified with an aqueous solution of 10% HCl until pH ~ 1, then extracted with EtOAc (3 × 10 mL). The combined organic fractions were dried over anhydrous sodium sulfate and concentrated in vacuo to afford (S)-2-((tert- butoxycarbonyl)amino)-3-(4-chlorophenyl)propanoic acid (810 mg, >95% yield) as a white solid. LCMS: ESI-MS m/z: 322.1 [M+Na]+. 54 Step 2: tert-Butyl (S)-(3-(4-chlorophenyl)-1-((5-methyl-1-(pyridin-4-yl)- 1H-pyrazol-4-yl)amino)-1-oxopropan-2-yl)carbamate. To a solution of (S)-2-((tert- butoxycarbonyl)amino)-3-(4-chlorophenyl)propanoic acid (270 mg, 0.90 mmol, 1.0 equiv) in DCM (3.0 mL, 0.30 M) at 0 °C was added DIPEA (0.47 mL, 2.7 mmol, 3.0 equiv) followed by dropwise addition of T3P (50% w/w in EtOAc, 0.69 mL, 1.2 mmol, 1.3 equiv). After 10 min, 5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-amine (Intermediate 6, 160 mg, 0.90 mmol, 1.0 equiv) in DCM (6.0 mL) was added and the reaction mixture was stirred at rt for 4 h. The reaction mixture was then concentrated in vacuo to afford a light orange residue. The crude product was purified by silica gel column chromatography (0–10% MeOH in DCM) to afford tert-butyl (S)-(3-(4- chlorophenyl)-1-((5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)amino)-1-oxopropan-2- yl)carbamate (160 mg, 39% yield) as a white solid. LCMS: ESI-MS m/z: 456.2 [M+H]+. Step 3: (S)-2-Amino-3-(4-chlorophenyl)-N-(5-methyl-1-(pyridin-4-yl)-1H- pyrazol-4-yl)propanamide. To a solution of tert-butyl (S)-(3-(4-chlorophenyl)-1-((5- methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)amino)-1-oxopropan-2-yl)carbamate (150 mg, 0.33 mmol, 1.0 equiv) and anhydrous 1,4-dioxane (3.0 mL, 0.11 M) was added 4 M HCl in dioxane (0.51 mL, 1.0 mmol, 3.0 equiv). After stirring for 30 min at rt, the reaction mixture was concentrated in vacuo to afford (S)-2-amino-3-(4-chlorophenyl)- N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)propanamide as a white solid. This material was moved forward with no further purification. LCMS: ESI-MS m/z: 356.2 [M+H]+. Step 4: (S)-5-(4-Chlorobenzyl)-2,2-dimethyl-3-(5-methyl-1-(pyridin-4-yl)- 1H-pyrazol-4-yl)imidazolidin-4-one. A solution of (S)-2-amino-3-(4-chlorophenyl)- N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)propanamide (30 mg, 0.084 mmol, 1.0 equiv) in acetone (0.025 mL) and methanol (1.0 mL) was heated to 75 °C for 15 h. The crude product was purified directly by RP-HPLC (Method A, 10–90% MeCN in H2O + 0.1% FA) to afford (S)-5-(4-chlorobenzyl)-2,2-dimethyl-3-(5-methyl-1- (pyridin-4-yl)-1H-pyrazol-4-yl)imidazolidin-4-one (2.0 mg, 6.0% yield) as a light yellow solid. 1H NMR (400 MHz, CD3OD) 8.70–8.64 (m, 2H), 7.82 (s, 1H), 7.70– 7.62 (m, 2H), 7.34–7.24 (m, 4H), 4.09–4.03 (m, 1H), 3.23–3.15 (m, 1H), 3.06–2.95 (m, 1H), 2.26 (s, 3H), 1.40 (s, 3H), 1.28 (s, 3H). LCMS: ESI-MS m/z: 396.2 [M+H]+. 155 EXAMPLE 153 (S)-2-Amino-3-(4-chlorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000157_0001
Step 1: tert-Butyl (S)-(3-(4-chlorophenyl)-1-oxo-1-((3-(pyridin-4-yl)-1H- pyrazol-5-yl)amino)propan-2-yl)carbamate. To a solution (S)-2-((tert- butoxycarbonyl)amino)-3-(4-chlorophenyl)propanoic acid (94 mg, 0.31 mmol, 1.0 equiv) in DCE (2.0 mL, 0.16 M) was added triethylamine (0.13 mL, 0.94 mmol, 3.0 equiv) then a solution of T3P (50% w/w in EtOAc, 0.11 mL, 0.38 mmol, 1.3 equiv). The reaction mixture was stirred at rt for 30 min then 3-(pyridin-4-yl)-1H-pyrazol-5- amine (50 mg, 0.31 mmol, 1.0 equiv) was added. The reaction mixture was stirred at rt for 15 h. The crude reaction mixture was directly purified by RP-HPLC (Method A, 10–90% MeCN in H2O + 0.1% FA) to afford tert-butyl (S)-(3-(4-chlorophenyl)-1- oxo-1-((3-(pyridin-4-yl)-1H-pyrazol-5-yl)amino)propan-2-yl)carbamate (25 mg, 18% yield) as a white solid. LCMS: ESI-MS m/z: 442.2 [M+H]+. Step 3: (S)-2-Amino-3-(4-chlorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide. To tert-butyl (S)-(3-(4-chlorophenyl)-1-oxo-1-((3-(pyridin-4-yl)- 1H-pyrazol-5-yl)amino)propan-2-yl)carbamate (25 mg, 0.057 mmol, 1.0 equiv) was added 4 M HCl in dioxane (1.0 mL, 4.0 mmol, 70 equiv). The reaction mixture was stirred at rt for 1 h. The reaction mixture was concentrated in vacuo to give (S)-2- amino-3-(4-chlorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (20 mg, >95% yield) as a light-yellow solid, hydrochloric acid salt.1H NMR (400 MHz, DMSO-d6) δ 13.3 (br s, 1H), 8.66–8.59 (m, 2H), 8.23 (s, 1H), 7.72 (d, J = 4Hz, 2H), 7.35 (d, J = 8Hz, 2H), 7.29 (d, J = 8Hz, 2H), 7.14 (br s, 2H), 3.63–3.59 (m, 1H), 3.05–2.96 (m, 1H), 2.76–2.66 (m, 1H). LCMS: ESI-MS m/z: 342.2 [M+H]+. EXAMPLE 154 (rac)-3-(4-Chlorobenzyl)-1-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)pyrrolidine-2,5-dione
Figure imgf000158_0001
A mixture of 4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine (Intermediate 1, 100 mg, 0.57 mmol, 1.0 equiv), 3-(4-chlorobenzyl)dihydrofuran-2,5-dione (130 mg, 0.57 mmol, 1.0 equiv) and THF (4.0 mL, 0.14 M) was heated to 75 °C and stirred for 1 h. After 1 h, the reaction mixture was cooled to rt and concentrated in vacuo. The resulting yellow solid was diluted with 2 mL of DCE then treated with thionyl chloride (68 mg, 0.57 mmol, 1.0 equiv). The reaction mixture was heated to 75 °C for 1 h. The reaction mixture was cooled to rt and filtered to afford (rac)-3-(4- chlorobenzyl)-1-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)pyrrolidine-2,5-dione (150 mg, 67% yield) as a tan colored solid. 1H NMR (400 MHz, DMSO-d6) δ 8.91 (d, J = 4Hz, 2H), 8.16–8.04 (br m, 2H), 7.44–7.31 (m, 4H), 3.21–3.12 (m, 2H), 3.05–2.99 (m, 2H), 2.74–2.65 (m, 1H), 2.03 (s, 3H). LCMS: ESI-MS m/z: 381.1 [M+H]+. 57 EXAMPLE 155 (rac)-4-(4-Chlorophenyl)-1-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)piperidine-2,6- dione
Figure imgf000159_0001
A mixture of 3-(pyridin-4-yl)-1H-pyrazol-5-amine (Intermediate 13, 100 mg, 0.62 mmol, 1.0 equiv), 4-(4-chlorophenyl)dihydro-2H-pyran-2,6(3H)-dione (140 mg, 0.62 mmol, 1.0 equiv) and THF (4.0 mL, 0.16 M) was heated to 75 °C for 1 h. The reaction mixture was cooled to rt and thionyl chloride (74 mg, 0.62 mmol) was added. The reaction mixture was heated to 75 °C for 1 h. The reaction mixture was cooled to rt then concentrated in vacuo. The resulting crude product was purified by RP-HPLC (Method A, 10–90% MeCN in H2O + 0.1% FA) to afford (rac)-4-(4-chlorophenyl)-1- (3-(pyridin-4-yl)-1H-pyrazol-5-yl)piperidine-2,6-dione (69 mg, 23% yield) as a tan colored solid.1H NMR (400 MHz, DMSO-d6) δ 13.9 (br s, 1H), 8.84–8.74 (m, 2H), 8.17–7.97 (m, 2H), 7.50–7.28 (m, 4H), 7.00 (br s, 1H), 3.22–3.10 (m, 2H), 3.04–2.94 (m, 2H). LCMS: ESI-MS m/z: 367.1 [M+H]+. EXAMPLE 156 (rac)-3-(4-Chlorobenzyl)-1-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)pyrrolidine-2,5- dione
Figure imgf000159_0002
A mixture of 3-(pyridin-4-yl)-1H-pyrazol-5-amine (Intermediate 13, 50 mg, 0.31 mmol, 1.0 equiv), 3-(4-chlorobenzyl)dihydrofuran-2,5-dione (70 mg, 0.31 mmol, 1.0 equiv) and THF (4.0 mL, 0.078 M) was heated to 75 °C for 1 hr. The reaction mixture was cooled to rt and a light-colored solid was filtered. The crude solid was 58 taken up in DCE (4.0 mL) and treated with thionyl chloride (37 mg, 0.31 mmol, 1.0 equiv). The reaction mixture was heated to 75 °C with stirring for 1 hr. The reaction mixture was cooled to rt and filtered to afford (rac)-3-(4-chlorobenzyl)-1-(3-(pyridin- 4-yl)-1H-pyrazol-5-yl)pyrrolidine-2,5-dione (55 mg, 48% yield) as a tan colored solid.1H NMR (400 MHz, DMSO-d6) δ 8.92–8.90 (m, 2H), 8.38–8.27 (m, 2H), 7.46– 7.32 (m, 4H), 7.23 (s, 1H), 3.24–3.13 (m, 2H), 3.03–2.84 (m, 2H), 2.69–2.59 (m, 1H). LCMS: ESI-MS m/z: 367.1 [M+H]+. EXAMPLE 157 (rac)- 4-(4-Chlorophenyl)-1-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)piperidine-2,6-dione
Figure imgf000160_0001
A solution of 4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine (Intermediate 1, 100 mg, 0.57 mmol, 1.0 equiv) and 4-(4-chlorophenyl)dihydro-2H-pyran-2,6(3H)- dione (130 mg, 0.57 mmol, 1.0 equiv) in anhydrous THF (2.0 mL, 0.29 M) was heated to 95 °C for 2 h. The mixture was cooled to rt and was directly purified by RP- HPLC (Method A, 10–90% MeCN in H2O + 0.1% TFA) to afford a viscous, light yellow oil. The purified intermediate (assume 0.57 mmol) was dissolved in DCE (4.0 mL, 0.14 M), treated with thionyl chloride (0.42 mL, 5.7 mmol, 1.0 equiv) and heated to 75 °C for 1 h. The mixture was again cooled to rt and purified directly by RP- HPLC (Method A, 10–90% MeCN in H2O + 0.1% TFA) to afford (rac)-4-(4- chlorophenyl)-1-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)piperidine-2,6-dione (56 mg, 20% yield) as a yellow solid, trifluoroacetic acid salt.1H NMR (400 MHz, DMSO-d6) δ 13.7 (br s, 1H), 8.85–8.77 (m, 2H), 8.00–7.84 (m, 2H), 7.51–7.43 (m, 4H), 3.83–3.59 (m, 1H), 3.31–3.14 (m, 2H), 3.08–2.93 (m, 2H), 2.09 (s, 1.5H), 1.96 (s, 1.5H). LCMS: ESI-MS m/z: 381.1[M+H]+. 59 EXAMPLE 158 1-(4-Chlorobenzyl)-3-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)imidazolidin-2-one N
Figure imgf000161_0001
Step 1: 1-(2-Chloroethyl)-3-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)urea. A mixture of 1-(pyridin-4-yl)-1H-pyrazol-4-amine (Intermediate 21, 50 mg, 0.31 mmol, 1.0 equiv), 1-chloro-2-isocyanatoethane (33 mg, 0.31 mmol, 1.0 equiv) and DCE (2.0 mL, 0.16 M) was stirred at rt for 15 h. After 15 h, a solid was filtered off and washed with DCE, then dried in vacuo to afford 1-(2-chloroethyl)-3-(1-(pyridin-4-yl)-1H- pyrazol-4-yl)urea (60 mg, 73% yield) as a tan solid. LCMS: ESI-MS m/z: 266.1 [M+H]+. Step 2: 1-(4-Chlorobenzyl)-3-(1-(pyridin-4-yl)-1H-pyrazol-4- yl)imidazolidin-2-one. To a solution of 1-(2-chloroethyl)-3-(1-(pyridin-4-yl)-1H- pyrazol-4-yl)urea (83 mg, 0.31 mmol, 1.0 equiv) and DMF (2.0 mL, 0.16 M) was added sodium hydride (60 wt % dispersion in mineral oil, 31 mg, 0.78 mmol, 2.5 equiv). The reaction was stirred at rt for 15 min. Subsequently, 1-chloro-4- (chloromethyl)benzene (50 mg, 0.31 mmol, 1.0 equiv) was added in one portion. The reaction was stirred at rt for 1 h. The reaction mixture was quenched carefully with water and purified directly by RP-HPLC (Method A, 10–90% MeCN in H2O + 0.1% TFA) to afford 1-(4-chlorobenzyl)-3-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)imidazolidin- 2-one (98 mg, 67% yield) as a white solid, trifluoroacetic acid salt. 1H NMR (400 MHz, DMSO-d6) δ 8.78 (d, J = 4 Hz, 2H), 8.69 (s, 1H), 8.28 (s, 1H), 7.45 (d, J = 8 Hz, 2H), 7.35 (d, J = 8 Hz, 2H), 4.40 (s, 2H), 3.79–3.73 (m, 2H), 3.49–3.43 (m, 2H). LCMS: ESI-MS m/z: 354.2 [M+H]+. 60 EXAMPLE 159 1-(4-Chlorobenzyl)-3-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)tetrahydropyrimidin- 2(1H)-one
Figure imgf000162_0001
Step 1: 1-(4-Chlorobenzyl)-3-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)urea. To a mixture of 1-(pyridin-4-yl)-1H-pyrazol-4-amine (Intermediate 21, 200 mg, 1.3 mmol, 1.0 equiv) and anhydrous DCE (4.0 mL, 0.33 M) was added 1-chloro-4- (isocyanatomethyl)benzene (410 mg, 2.5 mmol, 1.9 equiv) and the reaction mixture was stirred at rt for 15 h. After 15 h, the reaction mixture was concentrated in vacuo. The resulting solid was filtered and washed with hexanes to afford 1-(4- chlorobenzyl)-3-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)urea (370 mg, 87% yield) as a light tan solid. LCMS: ESI-MS m/z: 328.1 [M+H]+. Step 2: 1-(4-Chlorobenzyl)-3-(1-(pyridin-4-yl)-1H-pyrazol-4- yl)tetrahydropyrimidin-2(1H)-one. To a solution of 1-(4-chlorobenzyl)-3-(1- (pyridin-4-yl)-1H-pyrazol-4-yl)urea (35 mg, 0.079 mmol) in anhydrous THF (2.0 mL, 0.040 M) was added sodium hydride (60 wt % dispersion in mineral oil, 6.3 mg, 0.15 mmol). After stirring at rt for 5 min, 1,3-dibromopropane (8.0 uL, 0.079 mmol, 1.0 equiv) was added and the reaction mixture was stirred at rt for 1 h. After 1 h, the reaction mixture was carefully quenched with water and purified directly by RP- HPLC (Method A, 10–90% MeCN in H2O + 0.1% TFA) to afford 1-(4-chlorobenzyl)- 3-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)tetrahydropyrimidin-2(1H)-one (8.2 mg, 21% yield) as a tan solid, trifluoroacetic acid salt.1H NMR (400 MHz, DMSO-d6) δ 13.7 (br s, 1H), 8.85–8.77 (m, 2H), 8.00–7.84 (m, 2H), 7.51–7.43 (m, 4H), 3.83–3.59 (m, 61 1H), 3.31–3.14 (m, 2H), 3.08–2.93 (m, 2H), 2.09 (s, 1.5H), 1.96 (s, 1.5H). LCMS: ESI-MS m/z: 367.8 [M+H]+. EXAMPLE 160 1-(4-Chlorobenzyl)-3-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)thiourea
Figure imgf000163_0001
To a mixture of 1-(pyridin-4-yl)-1H-pyrazol-4-amine (Intermediate 21, 50 mg, 0.31 mmol, 1.0 equiv) and anhydrous DCE (4.0 mL, 0.078 M) was added 1-chloro-4- (isothiocyanatomethyl)benzene (57 mg, 0.31 mmol, 1.0 equiv). The heterogeneous reaction mixture was stirred at rt for 15 h. The reaction mixture was then concentrated in vacuo, and dissolved in 1.0 mL of DMSO. This solution was then purified by RP-HPLC (Method A, 10–90% MeCN in H2O + 0.1% TFA) to afford 1- (4-chlorobenzyl)-3-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)thiourea (50 mg, 35% yield) as a white solid, trifluoroacetic acid salt. LCMS: ESI-MS m/z: 344.1 [M+H]+. EXAMPLE 161 1-(4-Chlorobenzyl)-3-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)urea
Figure imgf000163_0002
To a solution of tert-butyl 5-amino-4-methyl-3-(pyridin-4-yl)-1H-pyrazole-1- carboxylate (Intermediate 28, 100 mg, 0.37 mmol, 1.0 equiv) in anhydrous DCE (1.0 mL, 0.37 M) was added 1-chloro-4-(isocyanatomethyl)benzene (61 mg, 0.37 mmol, 1.0 equiv). The reaction mixture was stirred at rt for 15 h, then concentrated in vacuo. The resulting residue was diluted with DCM (0.5 mL) and TFA (0.1 mL) was added. After stirring at rt for 1 h, the reaction mixture was concentrated in vacuo and purified directly by RP-HPLC (Method A, 10–90% MeCN in H2O + 0.1% TFA) to afford 1- 62 (4-chlorobenzyl)-3-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)urea (15 mg, 9.3 % yield) as a white solid, trifluoroacetic acid salt. LCMS: ESI-MS m/z: 342.1 [M+H]+. EXAMPLE 162 3-(4-Chlorophenyl)-N-(5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)propanamide
Figure imgf000164_0001
Step 1: tert-Butyl 3-amino-5-(pyridin-4-yl)-4H-1,2,4-triazole-4- carboxylate. To a solution of 5-(pyridin-4-yl)-4H-1,2,4-triazol-3-amine (200 mg, 1.2 mmol, 1.0 equiv) in DCM (3.0 mL, 0.40 M) was added triethylamine (250 mg, 2.5 mmol, 2.0 equiv), followed by Boc anhydride (270 mg, 1.2 mmol, 1.0 equiv). The resulting solution was stirred at rt for 3 h. The reaction mixture was then concentrated in vacuo and the crude residue was purified by silica gel column chromatography (50–100% EtOAc in hexanes) to afford tert-butyl 3-amino-5-(pyridin-4-yl)-4H-1,2,4- triazole-4-carboxylate (130 mg, 40% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ 8.69–8.68 (m, 2H), 7.84–7.82 (m, 2H), 7.49 (br s, 2H), 1.60 (s, 9H). LCMS: ESI-MS m/z: 262.1 [M+H]+. Step 2: 3-(4-Chlorophenyl)-N-(5-(pyridin-4-yl)-4H-1,2,4-triazol-3- yl)propanamide. A solution of 3-(4-chlorophenyl)propanoic acid (110 mg, 0.59 mmol, 1.2 equiv) in DMF (2.5 mL, 0.20 M) was treated with DIPEA (0.17 mL, 0.98 mmol, 1.7 equiv) at rt for 5 min. The mixture was cooled to 0 °C and HATU (220 mg, 0.59 mmol, 2.0 equiv) was added and the mixture was stirred for 10 min at rt. Subsequently, tert-butyl 3-amino-5-(pyridin-4-yl)-4H-1,2,4-triazole-4-carboxylate (130 mg, 0.49 mmol, 1.0 equiv) was added at 0 °C and the mixture was slowly warmed to rt and stirred for 3 h. After 3 h, the reaction mixture was purified directly by RP-HPLC (Method A, 10–90% MeCN in H2O + 0.1% TFA) to afford 3-(4- chlorophenyl)-N-(5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)propanamide (1.3 mg, 0.81% yield) as a white solid, trifluoroacetic acid salt. LCMS: ESI-MS m/z: 328.1 [M+H]+. 63 EXAMPLE 163 1-(4-Chloro-3,5-difluorobenzyl)-3-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)urea N
Figure imgf000165_0001
A solution of 3-(pyridin-4-yl)-1H-pyrazol-5-amine (Intermediate 13, 50 mg, 0.31 mmol, 1.0 equiv), DIPEA (81 mg , 0.63 mmol, 2.0 equiv) and CDI (100 mg, 0.63 mmol, 2.0 equiv) in DCM (3.0 mL, 0.10 M) was stirred at rt for 30 min. Subsequently (4-chloro-3,5-difluorophenyl)methanamine (55 mg, 0.31 mmol, 1.0 equiv) was added. The resulting mixture was stirred at rt for 1 h then heated to 50 °C for a subsequent 3 h. The reaction mixture was cooled to rt and concentrated in vacuo, then purified directly by RP-HPLC (Method C, 15–40 % MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3 ·H2O) to afford 1-(4-chloro-3,5-difluorobenzyl)-3-(3-(pyridin-4-yl)-1H- pyrazol-5-yl)urea (20 mg, 0.055 mmol, 18% yield) as a white solid.1H NMR (400 MHz, CDCl3) δ 8.71 (d, J = 9.2 Hz, 2H), 7.52 (s, 1H), 7.42 (d, J = 4.8 Hz, 2H), 7.01– 6.99 (m, 3H), 6.79 (s, 1H), 6.22 (s, 1H), 4.52 (d, J = 6.4 Hz, 2H). LCMS: ESI-MS m/z: 364.1 [M+H]+. EXAMPLE 164 1-(3-(Pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5-trifluorobenzyl)urea N
Figure imgf000165_0002
, 2 , , The product was prepared according to the same procedure as Example #163 to afford 1-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5-trifluorobenzyl)urea in 18% yield.1H NMR (400 MHz, DMSO-d6) δ 13.0 (s, 1H), 9.12 (s, 1H), 8.61 (s, 2H), 7.68 (d, J = 5.8 Hz, 2H), 7.33–7.20 (m, 2H), 7.14 (s, 1H), 6.79 (s, 1H), 4.32 (d, J = 5.6 Hz, 2H). LCMS: ESI-MS m/z: 348.1 [M+H]+. 64 EXAMPLE 165 1-(4-Chlorobenzyl)-3-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)urea
Figure imgf000166_0001
The product was prepared according to the same procedure as Example #163 to afford 1-(4-chlorobenzyl)-3-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)urea in 20% yield. 1H NMR (400 MHz, DMSO-d6) δ 13.0 (s, 1H), 9.04 (s, 1H), 8.61 (s, 2H), 7.68 (d, J = 5.6 Hz, 2H), 7.47–7.29 (m, 4H), 7.09 (s, 1H), 6.77 (s, 1H), 4.33 (d, J = 6.0 Hz, 2H). LCMS: ESI-MS m/z: 328.1 [M+H]+. EXAMPLE 166 3-(4-Chloro-3,5-difluorophenyl)-N-(4-chloro-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide
Figure imgf000166_0002
A solution of 3-(4-chloro-3,5-difluorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol- 5-yl)propanamide (Example 101, 30 mg, 0.082 mmol, 1.0 equiv) and N- chlorosuccinimide (22 mg, 0.17 mmol, 2.0 equiv) in DMF (1.5 mL, 0.055 M) was stirred at rt for 5 h. The reaction mixture was then concentrated in vauco and purified directly by RP-HPLC (Method C, 15–40 % MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3 ·H2O) to afford 3-(4-chloro-3,5-difluorophenyl)-N-(4-chloro-3-(pyridin- 4-yl)-1H-pyrazol-5-yl)propanamide (13 mg, 0.034 mmol, 41% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 13.4 (br s, 1H), 9.08 (br s, 1H), 8.68 (s, 2H), 7.81 (d, J = 4.8 Hz, 2H), 7.26–7.24 (m, 3H), 4.34 (d, J = 6.0 Hz, 2H). LCMS: ESI-MS m/z: 398.1 [M+H]+. 65 EXAMPLE 167 N-(4-Chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5- trifluorophenyl)propanamide N
Figure imgf000167_0001
The product was prepared according to the same procedure as Example #166 to afford N-(4-chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5- trifluorophenyl)propanamide in 42% yield. 1H NMR (400 MHz, CD3OD) δ 7.09 (d, J = 4.7 Hz, 2H), 6.37 (s, 2H), 5.57–5.49 (m, 2H), 1.46 (dd, J = 18.2, 11.0 Hz, 2H), 1.24 (t, J = 7.4 Hz, 2H). LCMS: ESI-MS m/z: 381.1 [M+H]+. EXAMPLE 168 1-(4-Chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-chlorobenzyl)urea
Figure imgf000167_0002
The product was prepared according to the same procedure as Example #166 to afford 1-(4-chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-chlorobenzyl)urea in 45% yield.1H NMR (400 MHz, DMSO-d6) δ 13.4–13.2 (m, 1H), 8.95 (s, 1H), 8.67 (s, 2H), 7.82 (s, 2H), 7.38 (dd, J = 29.7, 8.5 Hz, 4H), 7.17 (s, 1H), 4.33 (d, J = 6.0 Hz, 2H). LCMS: ESI-MS m/z: 362.1 [M+H]+. 66 EXAMPLE 169 3-(4-Chlorophenyl)-N-(3-(3-methoxypyridin-4-yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000168_0001
A mixture of N-(3-bromo-1H-pyrazol-5-yl)-3-(4-chlorophenyl)propanamide (Intermediate 29, 50 mg, 0.15 mmol, 1.0 equiv), (3-methoxypyridin-4-yl)boronic acid (25 mg, 0.16 mmol, 1.1 equiv), Pd(dppf)Cl2 (11 mg, 0.015 mmol, 0.1 equiv), and sodium carbonate (32 mg, 0.30 mmol, 2.0 equiv) in a solution of 4.0 mL of 1,4-dioxane and 1.0 mL water (0.030 M) was stirred at reflux under an atmosphere of nitrogen gas for 3 h. The reaction mixture was then cooled to rt and diluted with EtOAc (10 mL), filtered, the filtrate was concentrated in vacuo and purified directly by RP-HPLC (Method C, 15–40 % MeCN in H2O + 10 mM NH4HCO3 + 0.025% NH3 ·H2O) to afford 3-(4-chlorophenyl)-N-(3-(3-methoxypyridin-4-yl)-1H-pyrazol-5-yl)propanamide (15 mg, 0.042 mmol, 28% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 12.8 (s, 1H), 10.49 (s, 1H), 8.49 (s, 1H), 8.26 (d, J = 4.8 Hz, 1H), 7.66 (d, J = 5.2 Hz, 1H), 7.35 (d, J = 8.4 Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H), 7.13(s, 1H), 4.02 (s, 3H), 2.90 (t, J = 7.6 Hz, 2H), 2.63 (t, J = 7.6 Hz, 2H). LCMS: ESI-MS m/z: 357.1 [M+H]+. EXAMPLE 170 3-(4-Chlorophenyl)-N-(3-(3-fluoropyridin-4-yl)-1H-pyrazol-5-yl)propanamide
Figure imgf000168_0002
The product was prepared following the same procedure as Example #169 to afford 3-(4-chlorophenyl)-N-(3-(3-fluoropyridin-4-yl)-1H-pyrazol-5-yl)propanamide in 30% yield.1H NMR (400 MHz, DMSO-d6) δ 8.66 (s, 1H), 8.47 (s, 2H), 7.87 (t, J = 12.0 Hz, 1H), 7.34 (d, J = 8.8 Hz, 2H), 7.27 (d, J = 8.4 Hz, 2H), 2.89 (t, J = 15.2 Hz, 2H), 2.63 (t, J = 15.2 Hz, 2H). LCMS: ESI-MS m/z: 345.1 [M+H]+. 67 Example A Biological Assay Each reaction was run at a volume of 20 µL containing 50 µM compound (dissolved in DMSO; final concentration of DMSO is 1% v/v), 40 nM human SARM1(50-724), 0.3 mM NMN, 20 µM NAD, 1 mM TCEP, 25 mM HEPES pH 7.4, 10 mM KCl and 10 mM MgCl2. The reaction was incubated at room temperature for 60 minutes and quenched with 20 µL of 0.4% formic acid. The samples were run on Agilent HPLC 1260 Infinity II with Synergi 2.5 µM Fusion-RP 100Å (100 x 3.0 mm) LC column from Phenomenex. Total run time for each sample was 4 minutes. The run was isocratic with 1.5% methanol in 40 mM ammonium acetate pH 6.0. Samples were run at a flow rate of 0.8 mL/min at 55 °C. Peak areas of NAD and NAM were determined using OpenLAB CDS (Chem Station edition) software. For dose- response, the compound was diluted serially 1:3 in DMSO and added to the reaction starting at a final compound concentration of 100 µM in 1% DMSO. IC50 data according to the assay described above is provided in Table 1 below. IC50 <1 (+); 1≤IC50<10 (++); and 10≤ IC50≤ 100 (+++) ^M for the exemplified compounds. Table 1
Figure imgf000169_0001
68
Figure imgf000170_0001
Figure imgf000171_0001
Figure imgf000172_0001
Figure imgf000173_0001
Figure imgf000174_0001
Figure imgf000175_0001
Figure imgf000176_0001
Example B Assessment of the Protective Effect of SARM1 Inhibitors in Multiple Sclerosis To evaluate the ability of a SARM1 inhibitor to delay, prevent, or treat multiple sclerosis, a preclinical mouse model of experimental autoimmune encephalomyelitis (EAE) may be used (Lyons JA et al., Eur J of Immunology,1999 29(11):3432-9). To induce EAE, female mice, 9-13 weeks old, may receive 0.1 ml subcutaneous injection (s.c.) of myelin oligo glycoprotein peptide (MOG35-55) suspension in complete Freund’s adjuvant (CFA) in the upper and lower back, followed by intraperitoneal injection (i.p.) of pertussis toxin (100 ng) within 3 hours of MOG injection and again within 24 hours of MOG injection. Weight and clinical 75 score of paralysis may be recorded daily starting at day 7 until day 28 post-MOG injection. A SARM1 inhibitor can be dosed orally (p.o.) daily or with the use of osmotic pumps implanted s.c. or i.p. as a stand-alone treatment, or in conjunction with current standard of care medication(s) either on the same day as MOG treatment or at the start of symptoms. Effective compounds will slow the development of disease and/or to decrease the severity of the symptoms. Example C Assessment of the Protective Effect of SARM1 Inhibitors in Chemotherapy- induced Peripheral Neuropathy (CIPN) To evaluate the ability of a SARM1 inhibitor to prevent CIPN, a mouse model of CIPN may be used. To induce peripheral neuropathy, mice may be treated with a specific chemotherapeutic known to cause peripheral neuropathy in humans (e.g., vincristine, paclitaxel, or oxaliplatin) (Geisler et al., Brain 2016, 139(Pt 12):3092- 3108; Wang MS et al., Ann. Neurol., 2002, 52(4)442-7; Sprowl et al., Proc Natl Acad Sci 2013, 110(27):11199). Peripheral neuropathy may be assessed with behavior tests of mechanical allodynia by measuring sensitivity in the footpad by increasing applied force of Von Frey filament, cold or heat sensitivity by measuring escape/pain behavior (e.g., jumping, paw licking or paw lifts) on a thermally controlled enclosed platform. Furthermore, behavior may be correlated with biomarkers of neuropathy (e.g., plasma neurofilament light) and by histologically examining intra-epidermal nerve fiber density in hind paw pad biopsies. SARM1 inhibitors may be dosed orally (p.o.) daily, or with the use of osmotic pumps implanted s.c. or i.p. at the start of the experiment. Effective compounds will prevent allodynia, prevent the increase of the neuropathy biomarker and/or prevent the decrease in IENF density relative to vehicle treated cohorts. 76 Example D Assessment of the Protective Effect of SARM1 Inhibitors in Amyotrophic Lateral Sclerosis (ALS) To evaluate the ability of a SARM1 inhibitor to delay, prevent, or treat ALS, a genetic mouse model of the disease may be used. Transgenic mice with the mutation TDP43Q331K have been shown to develop progressive motor deficits as measured by performance on the accelerating rotarod and by progressive hind limb weakness as measured by hind paw grip strength. Furthermore, plasma NfL levels may appear to be increased in the mutants. SARM1 inhibitors may be dosed with the use of osmotic pumps implanted s.c. or i.p. Effective compounds will protect from the neurodegeneration and show a decrease in plasma NfL, as well as delay and/or prevent progression of the motor deficits and hind limb weakness. Example E Assessment of the Protective Effect of SARM1 Inhibitors in Glaucoma To evaluate the ability of SARM1 inhibitor to prevent glaucoma, several mouse models of the disease are utilized. The optic nerve crush (ONC) model of glaucoma is generated by applying transient pressure to the optic nerve with forceps to induces retrograde retinal ganglion cell death and replicate many of the changes observed in glaucomatous retinas, excluding increased ocular pressure. Other models of glaucoma mimic increased intraocular pressure and are generated by blockade of the trabecular network by injection of exogenous oil/microbeads or by laser-induced coagulation. At select time points in all of the aforementioned glaucoma models, eyes and optic nerves are harvested for histology to evaluate ocular damage. Retinal cross sections or flatmounts stained with markers of retinal ganglion cells, such as RBPMS or BRN2A, are used to determine the number of surviving cells. Optic nerve sections stained with neuronal specific markers such as SMI32 are used to determine surviving axon number and morphology. In both histological sample types, markers of neuroinflammation, such as GFAP or IBA1, are used to assess injury extent. SARM1 inhibitors will be dosed orally (p.o.) everyday with the use of osmotic pumps implanted s.c. or i.p. at the start of the experiment. Additionally, SARM1 inhibitors may be dosed via topical eye drops or by intravitreal, subconjunctival, subtenon, or retrobulbar injection. We expect our compounds to prevent degeneration of retinal ganglion cells and their axons in the optic nerve, attenuate neuroinflammatory responses, and preserve visual function relative to vehicle treated cohorts. Example F Assessment of the Protective Effect of SARM1 Inhibitors in Traumatic Brain Injury (TBI) To evaluate the ability of a SARM1 inhibitor to protect against TBI, a genetic mouse model of the disease may be used. Closed head TBI will be produced using a weight drop device as previously described in detail and as adapted for use in mice (Henninger et al., Brain 2016, 139(Pt 4):1094). SARM1 inhibitors will be dosed orally (p.o.) everyday with the use of osmotic pumps implanted s.c. or i.p. at the start of the experiment. Effective compounds will be evaluated using multiple endpoints, primary endpoint being βAPP immunohistology after TBI. Secondary outcomes will include neurobehavioral deficits measured throughout the 4-week observation period using the NSS scale (Flierl et al., 2009, 4(9):1328), plasma phosphorylated neurofilament heavy chain (pNFH) and plasma neurofilament light chain (NfL) levels and cerebral neurochemical profiling. Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including all patent, patent applications, and publications, cited in the present application is incorporated herein by reference in its entirety. 78

Claims

What is claimed is: 1. A compound of Formula Ia, Ib, Ic, or Id:
Figure imgf000180_0001
Id or a pharmaceutically acceptable salt thereof, wherein: A is N or N+-O-; Q1 and Q2 are each independently selected from CH and N; W is O, S, or NRN;
Figure imgf000180_0002
is a single, double, or triple bond; wherein when the
Figure imgf000180_0004
bond between X and Y is a single bond, then: X is CR5R6, NR7, or O and Y is CR8R9, NR10, O, S, SO, or SO2, wherein when X is NR7 or O, then Y is CR8R9; wherein when the
Figure imgf000180_0003
bond between X and Y is a double bond, then: X is CR5 and Y is CR8; and wherein when the bond between X and Y is a triple bond, then: X is C and Y is C; Ring Z is C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, or 4-10 membered heterocycloalkyl; RN is H, C1-4 alkyl, or CN; R1 is halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy; R2 , R2A, and R2B are each independently selected from H, halo, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 cyanoalkyl, C1-4 alkoxy, C1-4 alkoxy-C1-4 alkyl, C1-4 haloalkoxy, and C3-7 cycloalkyl; R2C is selected from H, C1-4 alkyl, C1-4 hydroxyalkyl, C1-4 cyanoalkyl, and C3-7 cycloalkyl; R3 is H, C1-4 alkyl, -C(=O)-(C1-6 alkyl), -S(=O)2-(C1-6 alkyl), or a group of Formula (ii):
Figure imgf000181_0001
or R3 and R5, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; or R3 and R7, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; or R3 and R8, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents 80 independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; or R3 and R10, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; each R4 is independently halo, nitro, cyano, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy; or two adjacent R4 together with the atoms to which they are attached form a fused phenyl ring, C3-7 cycloalkyl ring, 5-7 membered heteroaryl ring, or 4-7 membered heterocycloalkyl ring, each optionally substituted with 1, 2, or 3 substituents independently selected from oxo, halo, nitro, cyano, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; or R4 and R9, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring fused with ring Z or a 5-7 membered heterocycloalkyl ring fused with ring Z, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; R5, R6, R7, R8, R9, and R10 are each independently selected from H, halo, NH2, OH, C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; or R5 and R9 together with the atoms to which they are attached form a C3-7 cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted with 1, 2 or 3 substituents independently selected from oxo, halo, NH2, OH, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; or R5 and R10 together with the atoms to which they are attached form a 5-7 membered heterocycloalkyl ring optionally substituted with 1, 2 or 3 substituents independently selected from oxo, halo, NH2, OH, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; W1 is O, S, or NRN; wherein when the bond between X1 and Y1 is a single bond, then: X1 is CR5R6, NR7, or O and Y1 is CR8R9, NR10, O, S, SO, or SO2, wherein when X1 is NR7 or O, then Y1 is CR8R9; wherein when the bond between X1 and Y1 is a double bond, then: X1 is CR5 and Y1 is CR8; and wherein when the bond between X1 and Y1 is a triple bond, then: X1 is C and Y1 is C; Ring Z1 is C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, or 4-10 membered heterocycloalkyl; R4A is halo, nitro, cyano, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy; or two adjacent R4A together with the atoms to which they are attached form a fused phenyl ring, fused C3-7 cycloalkyl ring, fused 5-7 membered heteroaryl ring, or fused 4-7 membered heterocycloalkyl ring, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, nitro, cyano, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; m is 0, 1, or 2; n is 0, 1, 2, 3, 4, or 5; and n1 is 0, 1, 2, 3, 4, or 5, with the proviso that the compound is other than
Figure imgf000183_0001
.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having Formula Ia.
3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having Formula Ib.
4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having Formula Ic.
5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having Formula Id.
6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein A is N.
7. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein A is N+-O-.
8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein W is O or S.
9. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein W is O.
10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein is a single bond.
11. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein is a double bond.
12. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein is a triple bond.
13. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein X is CR5R6.
14. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein X is NR7.
15. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein X is O.
16. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein Y is CR8R9.
17. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein Y is NR10.
18. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein Y is O.
19. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein Y is S, SO, or SO2.
20. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, wherein Ring Z is C6-10 aryl or 5-10 membered heteroaryl.
21. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, wherein Ring Z is C6-10 aryl.
22. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, wherein Ring Z is phenyl.
23. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, wherein Ring Z is 5-10 membered heteroaryl.
24. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, wherein Ring Z is 5-6 membered heteroaryl.
25. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, wherein Ring Z is pyridyl, pyrimidinyl, thienyl, thiazolyl, isoxazolyl, or pyrazolyl.
26. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, wherein Ring Z is C3-7 cycloalkyl.
27. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, wherein Ring Z is cyclohexyl or cyclopentyl.
28. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, wherein Ring Z is selected from the following (a)-(k): ( (
Figure imgf000186_0001
.
29. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1.
30. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein m is 0.
31. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt thereof, wherein R1 is halo, C1-4 alkyl, or C1-4 alkoxy.
32. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R2 , R2A, and R2B are each independently selected from H, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxy, and C3-7 cycloalkyl.
33. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R2 , R2A, and R2B are each independently selected from H, Cl, Br, methyl, ethyl, trifluoromethyl, methoxy, cyclopropyl, and hydroxymethyl.
34. The compound of any one of claims 1-33, or a pharmaceutically acceptable salt thereof, wherein R3 is H, C1-4 alkyl, -C(=O)-(C1-6 alkyl), or -S(=O)2-(C1-6 alkyl).
35. The compound of any one of claims 1-33, or a pharmaceutically acceptable salt thereof, wherein R3 is a group of Formula (ii):
Figure imgf000187_0001
36. The compound of any one of claims 1-35, or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, or 3.
37. The compound of any one of claims 1-35, or a pharmaceutically acceptable salt thereof, wherein n is 1.
38. The compound of any one of claims 1-37, or a pharmaceutically acceptable salt thereof, wherein each R4 is independently halo, nitro, cyano, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy.
39. The compound of any one of claims 1-37, or a pharmaceutically acceptable salt thereof, wherein each R4 is independently F, Cl, Br, I, CN, NO2, methyl, ethyl, CF3, CHF2, OCF3, or OCHF2.
40. The compound of any one of claims 1-37, or a pharmaceutically acceptable salt thereof, wherein each R4 is independently F or Cl.
41. The compound of any one of claims 1-37, or a pharmaceutically acceptable salt thereof, wherein two adjacent R4 together with the atoms to which they are attached form a fused phenyl ring, C3-7 cycloalkyl ring, 5-7 membered heteroaryl ring, or 4-7 membered heterocycloalkyl ring, each optionally substituted with 1, 2, or 3 substituents independently selected from oxo, halo, nitro, cyano, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy.
42. The compound of any one of claims 1-37, or a pharmaceutically acceptable salt thereof, wherein two adjacent R4 together with the atoms to which they are attached form a fused phenyl ring or 4-7 membered heterocycloalkyl ring.
43. The compound of any one of claims 1-42, or a pharmaceutically acceptable salt thereof, wherein R5 and R6 are each independently selected from H, F, NH2, and OH.
44. The compound of any one of claims 1-43, or a pharmaceutically acceptable salt thereof, wherein each R7 is independently selected from H and methyl.
45. The compound of any one of claims 1-44, or a pharmaceutically acceptable salt thereof, wherein R8 and R9 are each independently selected from H and methyl.
46. The compound of any one of claims 1-45, or a pharmaceutically acceptable salt thereof, wherein R3 and R5, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring or a 5- 187 7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy.
47. The compound of any one of claims 1-45, or a pharmaceutically acceptable salt thereof, wherein R3 and R7, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring or a 5- 7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy.
48. The compound of any one of claims 1-45, or a pharmaceutically acceptable salt thereof, wherein R3 and R8, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring or a 5- 7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy.
49. The compound of any one of claims 1-45, or a pharmaceutically acceptable salt thereof, wherein R3 and R10, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring or a 5- 7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy.
50. The compound of any one of claims 1-45, or a pharmaceutically acceptable salt thereof, wherein R4 and R9, together with the atoms to which they are attached and together with any intervening atoms, form a C5-7 membered cycloalkyl ring fused with ring Z or a 5-7 membered heterocycloalkyl ring fused with ring Z, each optionally substituted by 1, 2, or 3 substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy.
51. The compound of any one of claims 1-45, or a pharmaceutically acceptable salt thereof, wherein R5 and R9 together with the atoms to which they are attached form a C3-7 cycloalkyl ring or a 5-7 membered heterocycloalkyl ring, each optionally substituted with 1, 2 or 3 substituents independently selected from oxo, halo, NH2, OH, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy.
52. The compound of any one of claims 1-45, or a pharmaceutically acceptable salt thereof, wherein R5 and R10 together with the atoms to which they are attached form a 5-7 membered heterocycloalkyl ring optionally substituted with 1, 2 or 3 substituents independently selected from oxo, halo, NH2, OH, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy.
53. The compound of any one of claims 1-52, or a pharmaceutically acceptable salt thereof, wherein R8, R9, and R10 are each independently selected from H and C1-4 alkyl.
54. The compound of any one of claims 1-53 having Formula IIa:
Figure imgf000190_0001
IIa or a pharmaceutically acceptable salt thereof.
55. The compound of any one of claims 1-53 having Formula IIb:
Figure imgf000190_0002
or a pharmaceutically acceptable salt thereof.
56. The compound of any one of claims 1-53 having Formula IIIa:
Figure imgf000191_0001
IIIa or a pharmaceutically acceptable salt thereof.
57. The compound of any one of claims 1-53 having Formula IIIb:
Figure imgf000191_0002
IIIb or a pharmaceutically acceptable salt thereof.
58. The compound of claim 1 selected from: N-Acetyl-3-(4-chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide (1); 3-(4-Chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-N- propionylpropanamide (2); 3-(4-Chlorophenyl)-N-(3-(4-chlorophenyl)propanoyl)-N-(4-methyl-3-(pyridin- 4-yl)-1H-pyrazol-5-yl)propanamide (3); 3-(3-Chlorophenyl)-N-(3-(4-chlorophenyl)propanoyl)-N-(4-methyl-3-(pyridin- 4-yl)-1H-pyrazol-5-yl)propanamide (4); 3-(2-Chlorophenyl)-N-(3-(4-chlorophenyl)propanoyl)-N-(4-methyl-3-(pyridin- 4-yl)-1H-pyrazol-5-yl)propanamide (5); 3-(4-Chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-N-(3- phenylpropanoyl)propanamide (6); N-(3-(4-Chlorophenyl)propanoyl)-4-methyl-N-(4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-yl)pentanamide (7); 3-(4-Chlorophenyl)-N-(3-cyclopentylpropanoyl)-N-(4-methyl-3-(pyridin-4- yl)-1H-pyrazol-5-yl)propanamide (8); 3-(4-Chloro-3,5-difluorophenyl)-N-(3-(4-chloro-3,5- difluorophenyl)propanoyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (9); N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5-trifluorophenyl)-N-(3- (3,4,5-trifluorophenyl)propanoyl)propanamide (10); 3-(4-Chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-N- (methylsulfonyl)propanamide (11); 3-(4-Chlorophenyl)-N-isobutyryl-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (12); 3-(4-Chloro-3,5-difluorophenyl)-N-(4-ethyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (13); 3-(4-Chlorophenyl)-N-(4-ethyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (14); 3-(4-Cyano-3,5-difluorophenyl)-N-(4-ethyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (15); 3-(4-Cyano-3-fluorophenyl)-N-(4-ethyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (16); 3-(5-Chlorothiophen-2-yl)-N-(4-ethyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide (17); (rac)-3-(4-chlorophenyl)-2-fluoro-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (18); 3-(4-Chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (19); 3-(Benzo[d][1,3]dioxol-5-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (20); 3-(3,5-Dichlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (21); N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-phenylpropanamide (22); 3-(2-Chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (23); N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(p-tolyl)propanamide (24); N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(m-tolyl)propanamide (25); N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(o-tolyl)propanamide (26); 3-(4-Methoxyphenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (27); N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(naphthalen-2- yl)propanamide (28); N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(naphthalen-1- yl)propanamide (29); 3-(3-Chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (30); 3-(3,4-Dichlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (31); N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4- (trifluoromethyl)phenyl)propanamide (32); 3-(4-Fluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (33); 3-(4-Ethylphenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (34); 3-(4-Bromophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (35); 3-(4-Cyanophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (36); N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-nitrophenyl)propanamide (37); 3-(6-Chloropyridin-3-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (38); 3-(5-Chloropyridin-2-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (39); 3-(4-Chloro-2,5-difluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (40); 3-(4-Chloro-2-fluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (41); 3-(4-Chloro-2-methylphenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (42); 3-(4-Chloro-3-methylphenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (43); 3-(3,4-Difluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (44); 3-(2,4-Difluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (45); 3-(4-Iodophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (46); N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5- trichlorophenyl)propanamide (47); 3-(4-Chloro-3,5-difluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (48); 3-(4-Chloro-2,3-difluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (49); N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5- trifluorophenyl)propanamide (50); N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(2,3,4- trifluorophenyl)propanamide (51); N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(2,4,5- trifluorophenyl)propanamide (52); 3-(4-Cyano-3-fluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (53); N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4- (trifluoromethoxy)phenyl)propanamide (54); 3-(4-(Difluoromethoxy)phenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (55); 3-(4-(Fluoromethyl)phenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (56); 3-(4-(Difluoromethyl)phenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (57); N-(4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3- (perfluorophenyl)propanamide (58); 3-(6-Fluoropyridin-3-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (59); 3-(2-Fluoropyrimidin-5-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (60); 3-(2-Chloropyrimidin-5-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (61); 2-(4-Chlorophenoxy)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)acetamide (62); 2-((4-Chlorophenyl)thio)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)acetamide (63); 3-(4-Chloro-3-fluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (64); 3-(4-Cyano-3,5-difluorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (65); N-[4-Methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl]-2-(1,2,3,4- tetrahydronaphthalen-1-yl)acetamide (66); 2-(5-Chloro-2,3-dihydro-1H-inden-1-yl)-N-[4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-yl]acetamide (67); 2-(6-Chloro-1,2,3,4-tetrahydronaphthalen-1-yl)-N-[4-methyl-3-(pyridin-4-yl)- 1H-pyrazol-5-yl]acetamide (68); (E)-3-(4-chlorophenyl)-2,3-difluoro-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol- 5-yl)acrylamide (69); (rac)-3-(4-Cyano-3-fluorophenyl)-2-fluoro-N-(4-methyl-3-(pyridin-4-yl)-1H- pyrazol-5-yl)propanamide (70); (rac)-3-(4-Chloro-3,5-difluorophenyl)-2-fluoro-N-(4-methyl-3-(pyridin-4-yl)- 1H-pyrazol-5-yl)propanamide (71); 3-(4-Chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propiolamide (72) 3-(4-Chlorothiophen-2-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide (73);; 3-(5-Chlorothiophen-2-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide (74); 3-(2-Chlorothiazol-5-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (75); 3-(5-Chlorothiazol-2-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide (76); 3-(4-Chloro-1H-pyrazol-1-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide (77); 3-(3-Chloroisoxazol-5-yl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (78); 2-((4-Chlorophenyl)amino)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)acetamide (79); 3-(4-Chlorophenyl)-2,2-difluoro-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (80); 2-((4-Chlorophenyl)thio)-N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4- yl)acetamide (81); 3-(6-Chloropyridin-3-yl)-N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4- yl)propenamide (82); 3-(4-Chloro-3,5-difluorophenyl)-N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4- yl)propanamide (83); N-(5-Methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)-3-(3,4,5- trifluorophenyl)propanamide (84); 2-(4-Chlorophenoxy)-N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4- yl)acetamide (85); 3-(4-Chlorophenyl)-N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4- yl)propenamide (86); 2-(4-Chlorophenoxy)-N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4- yl)acetamide (87); 3-(4-Chloro-3,5-difluorophenyl)-N-[1-(pyridin-4-yl)-1H-pyrazol-4- yl]propanamide (88); 3-(4-Chlorophenyl)-N-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)propanamide (89); N-(5-Chloro-1-(pyridin-4-yl)-1H-pyrazol-4-yl)-3-(4- chlorophenyl)propenamide (90); N-(5-Chloro-1-(pyridin-4-yl)-1H-pyrazol-4-yl)-3-(4-chloro-3,5- difluorophenyl)propanamide (91); N-(5-Chloro-1-(pyridin-4-yl)-1H-pyrazol-4-yl)-3-(3,4,5- trifluorophenyl)propanamide (92); N-(5-Chloro-1-(pyridin-4-yl)-1H-pyrazol-4-yl)-3-(4-cyano-3,5- difluorophenyl)propanamide (93); N-(5-Chloro-1-(pyridin-4-yl)-1H-pyrazol-4-yl)-3-(4-cyano-3- fluorophenyl)propanamide (94); 3-(4-Chlorophenyl)-N-(1-(pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4- yl)propanamide (95); N-(4-Chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4- chlorophenyl)propanamide (96); 3-(4-Chloro-3,5-difluorophenyl)-N-(4-chloro-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (97); 3-(4-Chlorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (98); 3-(Benzo[d][1,3]dioxol-5-yl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (99); 3-(3-Chlorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)propanamide (100); 3-(4-Chloro-3,5-difluorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (101); N-(3-(Pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5-trifluorophenyl)propanamide (102); 3-(4-Cyano-3-fluorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide (103); 3-(4-Cyano-3,5-difluorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (104); 3-(4-Chlorophenyl)-N-(1-methyl-2-(pyridin-4-yl)-1H-imidazol-5- yl)propanamide (105); 3-(4-Chlorophenyl)-N-(3-(3-methylpyridin-4-yl)-1H-pyrazol-5- yl)propanamide (106); 3-(4-Chlorophenyl)-N-(3-methyl-1-(pyridin-4-yl)-1H-pyrazol-4- yl)propenamide (107); 3-(4-Chlorophenyl)-N-(4-(pyridin-4-yl)-1H-imidazol-2-yl)propenamide (108); 3-(4-Chlorophenyl)-N-(1-(3-methylpyridin-4-yl)-1H-pyrazol-4- yl)propanamide (109); 3-(4-Chlorophenyl)-N-(4-methyl-3-(3-methylpyridin-4-yl)-1H-pyrazol-5- yl)propenamide (110); 3-(4-Chloro-3,5-difluorophenyl)-N-(4-methyl-3-(3-methylpyridin-4-yl)-1H- pyrazol-5-yl)propanamide (111); 3-(4-Cyano-3-fluorophenyl)-N-(4-methyl-3-(3-methylpyridin-4-yl)-1H- pyrazol-5-yl)propanamide (112); 3-(4-Cyano-3,5-difluorophenyl)-N-(4-methyl-3-(3-methylpyridin-4-yl)-1H- pyrazol-5-yl)propenamide (113); 3-(4-Bromophenyl)-N-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)propanamide (114); 3-(4-Fluorophenyl)-N-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)propenamide (115); 3-(4-Chlorophenyl)-N-(4-(hydroxymethyl)-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (116); 3-(4-Chloro-3,5-difluorophenyl)-N-(4-(hydroxymethyl)-3-(pyridin-4-yl)-1H- pyrazol-5-yl)propanamide (117); 3-(4-Chloro-3-fluorophenyl)-N-(4-(hydroxymethyl)-3-(pyridin-4-yl)-1H- pyrazol-5-yl)propenamide (118); N-(4-(Hydroxymethyl)-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5- trifluorophenyl)propenamide (119); 2-((4-chlorophenyl)sulfinyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)acetamide (120) ; 2-((4-chlorophenyl)sulfonyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)acetamide (121); 3-(4-Chlorophenyl)-N-(4-methoxy-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (122); 97 3-(4-Chlorophenyl)-N-(4-cyclopropyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (123); 3-(4-Chlorophenyl)-N-[4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl]propanethioamide (124); 3-(4-Chlorophenyl)-N-[3-(pyridin-4-yl)-4-(trifluoromethyl)-1H-pyrazol-5- yl]propanamide (125); N-[5-Chloro-1-(pyridin-4-yl)-1H-pyrazol-4-yl]-3-(3- chlorophenyl)propanamide (126); N-[5-Bromo-1-(pyridin-4-yl)-1H-pyrazol-4-yl]-3-(4-chloro-3,5- difluorophenyl)propanamide (127); N-(4-Chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-cyano-3,5- difluorophenyl) propenamide (128); N-(4-Chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-cyano-3- fluorophenyl)propenamide (129); 4-Chlorobenzyl (4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)carbamate (130); 1-(4-Chlorobenzyl)-1-methyl-3-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)urea (131); 3-(4-Chlorophenyl)-N-(1-methyl-5-(pyridin-4-yl)-1H-imidazol-2- yl)propenamide (132); 3-(4-chlorophenyl)-N-methyl-N-(1-methyl-5-(pyridin-4-yl)-1H-imidazol-2- yl)propanamide (133); 3-(4-Chlorophenyl)-N-methyl-N-(1-(pyridin-4-yl)-1H-pyrazol-4- yl)propanamide (134); 2-(4-Chlorophenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)cyclopropane-1-carboxamide (135); 4-Chlorobenzyl (5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)carbamate (136); 3-(4-Chlorophenyl)-N-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4- yl)propanethioamide (137); 4-(4-Chlorophenyl)-1-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)piperidin-2- one (138); 3-(4-Chlorophenyl)-N-methyl-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide (139); 3-(4-Ethynylphenyl)-N-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propenamide (140); 1-[(4-Cyanophenyl)methyl]-3-[4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl]urea (141); 1-[(4-Fluorophenyl)methyl]-3-[4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl]urea (142); 1-[(6-Chloropyridin-3-yl)methyl]-3-[4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl]urea (143); 1-(4-Chlorobenzyl)-3-(5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4-yl)urea (144); 1-(4-Chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5-trifluorobenzyl)urea (145); 2,6-Difluoro-4-((2-oxo-1-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)pyrrolidin-3- yl)methyl)benzonitrile (146); N-(4-Bromo-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4- chlorophenyl)propanamide (147); (R)-1-(1-(4-Chlorophenyl)ethyl)-3-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)urea (148); (5-Chlorothiophen-2-yl)methyl (5-methyl-1-(pyridin-4-yl)-1H-pyrazol-4- yl)carbamate (149); (rac)-3-(4-Chlorophenyl)-2-hydroxy-N-(5-methyl-1-(pyridin-4-yl)-1H- pyrazol-4-yl)propanamide (150); (R)-2-Amino-3-(4-chlorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (151); (S)-5-(4-Chlorobenzyl)-2,2-dimethyl-3-(5-methyl-1-(pyridin-4-yl)-1H- pyrazol-4-yl)imidazolidin-4-one (152); (S)-2-Amino-3-(4-chlorophenyl)-N-(3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (153); (rac)-3-(4-Chlorobenzyl)-1-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)pyrrolidine-2,5-dione (154); (rac)-4-(4-Chlorophenyl)-1-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)piperidine-2,6- dione (155); (rac)-3-(4-Chlorobenzyl)-1-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)pyrrolidine-2,5- dione (156); (rac)- 4-(4-Chlorophenyl)-1-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5- yl)piperidine-2,6-dione (157); 1-(4-Chlorobenzyl)-3-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)imidazolidin-2-one (158); 1-(4-Chlorobenzyl)-3-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)tetrahydropyrimidin- 2(1H)-one (159); 1-(4-Chlorobenzyl)-3-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)thiourea (160); 1-(4-Chlorobenzyl)-3-(4-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)urea (161); 3-(4-Chlorophenyl)-N-(5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)propanamide (162); 1-(4-Chloro-3,5-difluorobenzyl)-3-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)urea (163); 1-(3-(Pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5-trifluorobenzyl)urea (164); 1-(4-Chlorobenzyl)-3-(3-(pyridin-4-yl)-1H-pyrazol-5-yl)urea (165); 3-(4-Chloro-3,5-difluorophenyl)-N-(4-chloro-3-(pyridin-4-yl)-1H-pyrazol-5- yl)propanamide (166); N-(4-Chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(3,4,5- trifluorophenyl)propanamide (167); 1-(4-Chloro-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-(4-chlorobenzyl)urea (168); 3-(4-Chlorophenyl)-N-(3-(3-methoxypyridin-4-yl)-1H-pyrazol-5- yl)propanamide (169); and 3-(4-Chlorophenyl)-N-(3-(3-fluoropyridin-4-yl)-1H-pyrazol-5-yl)propanamide (170), or a pharmacuetically acceptable salt of any of the aforementioned.
59. A pharmaceutical composition comprising a compound of any one of claims 1-58, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
60. A method of inhibiting SARM1 comprising contacting the SARM1 with a compound of any one of claims 1-58, or a pharmaceutically acceptable salt thereof.
61. The method of claim 60 wherein the contacting is carried out in vitro.
62. The method of claim 60 wherein the contacting is carried out in vivo.
63. A method of inhibiting axonal degeneration in a patient in need thereof comprising administering to the patient an inhibiting amount of a compound of any one of claims 1-58, or a pharmaceutically acceptable salt thereof.
64. The method of claim 63 wherein the axonal degeneration is caused by abnormal reduction or depletion of NAD+ in the axons.
65. A method of treating or preventing a neurological disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of any one of claims 1-58, or a pharmaceutically acceptable salt thereof.
66. The method of claim 65 wherein the neurological disorder is a neurodegenerative disease.
67. The method of claim 66 wherein the neurological disorder is selected from: spinal muscular atrophy (SMA), Chemotherapy Induced Peripheral Neuropathy, multiple sclerosis (MS), traumatic brain injury (TBI), spinal cord injury, stroke, Parkinson’ disease, glaucoma, Huntington’s disease, Alzheimer’s disease, Charcot- Marie-Tooth disease (CMT), retinitis pigmentosa (RP), age-related macular degeneration (AMD), small fiber neuropathies, peripheral neuropathy (e.g., viral neuropathy), spinocerebellar ataxias, cystic fibrosis, familial amyloidotic polyneuropathy, spongiform encephalopathies, spinal and bulbar muscular atrophy, hereditary dentatorubral-pallidoluysian atrophy, adrenoleukodystrophy, adrenomyeloneuropathy, Alexander’s disease, amyotrophic lateral sclerosis (ALS), Bassen-Kornzweig syndrome, Bell’s palsy, progressive supra nuclear palsy (PSP), central pontine myelolysis, cluster headache, congenital hypomyelination, corticobasal degeneration, Creutzfeldt-Jakob disease, epilepsy, dementia (e.g., frontotemporal dementia and Lewy body dementia), demyelination disorders (e.g., ischemic demyelination), encephalomyelitis, Friedrich’s ataxia, Gaucher’s disease, hereditary sensory and autonomic neuropathy (HSAN), Hurler syndrome, Krabbe’s disease, metachromatic leukodystrophy, migraine and tension headaches, mild cognitive impairment, motor spinoneuron disease, neuromyelitis optica, Niemann- Pick disease, optic neuritis, Pelizaeus Merzbacher disease, peripheral neuropathy, periventricular leukomalacia, post-herpetic neuralgia, prion disease, progressive supranuclear palsy, progressive multifocal leukoencephalopathy, Tay-Sacks disease, thoracic disc herniation, traverse myelitis, trigeminal neuralgia, wallerian degeneration, cerebellar degeneration, chiari malformation, dystonia, encephalitis (e.g., pediatric viral encephalitis and La Crosse virus encephalitis), hyperekplexia, multifocal motor neuropathy, muscular dystrophy, myasthenia gravis, myopathy, neurofibromatosis, neuronal ceroid lipofuscinosis, neuropathies (e.g., peripheral neuropathy), pseudobulbar affect, restless legs syndrome, spina bifida, syringomyelia, thoracic outlet syndrome, and transverse myelitis.
PCT/US2021/044389 2020-08-04 2021-08-03 Substituted pyridine derivatives as sarm1 inhibitors WO2022031736A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US18/019,452 US20230339913A1 (en) 2020-08-04 2021-08-03 Substituted pyridine derivatives as sarm1 inhibitors
EP21763435.1A EP4192828A1 (en) 2020-08-04 2021-08-03 Substituted pyridine derivatives as sarm1 inhibitors
US18/481,173 US11970481B1 (en) 2023-10-04 Substituted pyridine derivatives as SARM1 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063060790P 2020-08-04 2020-08-04
US63/060,790 2020-08-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US18/019,452 A-371-Of-International US20230339913A1 (en) 2020-08-04 2021-08-03 Substituted pyridine derivatives as sarm1 inhibitors
US18/481,173 Continuation US11970481B1 (en) 2023-10-04 Substituted pyridine derivatives as SARM1 inhibitors

Publications (1)

Publication Number Publication Date
WO2022031736A1 true WO2022031736A1 (en) 2022-02-10

Family

ID=77595618

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/044389 WO2022031736A1 (en) 2020-08-04 2021-08-03 Substituted pyridine derivatives as sarm1 inhibitors

Country Status (3)

Country Link
US (1) US20230339913A1 (en)
EP (1) EP4192828A1 (en)
WO (1) WO2022031736A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220056013A1 (en) * 2020-08-24 2022-02-24 Disarm Therapeutics, Inc. Inhibitors of SARM1
US11629136B1 (en) 2021-07-28 2023-04-18 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
WO2024026368A1 (en) * 2022-07-27 2024-02-01 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
WO2024020188A3 (en) * 2022-07-21 2024-03-14 Amylyx Pharmaceuticals, Inc. Oligonucleotide compositions and methods thereof
WO2023240084A3 (en) * 2022-06-06 2024-03-21 Denali Therapeutics Inc. Compounds, compositions, and methods
US11945796B2 (en) 2020-09-16 2024-04-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
US11970481B1 (en) 2023-10-04 2024-04-30 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105780A2 (en) * 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2010093849A2 (en) * 2009-02-13 2010-08-19 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
WO2016187324A1 (en) * 2015-05-18 2016-11-24 Td2, Inc. Heterocyclic compounds as kinase inhibitors
WO2018094362A1 (en) * 2016-11-21 2018-05-24 Translational Drug Development, Llc Heterocyclic compounds as kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105780A2 (en) * 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2010093849A2 (en) * 2009-02-13 2010-08-19 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
WO2016187324A1 (en) * 2015-05-18 2016-11-24 Td2, Inc. Heterocyclic compounds as kinase inhibitors
WO2018094362A1 (en) * 2016-11-21 2018-05-24 Translational Drug Development, Llc Heterocyclic compounds as kinase inhibitors

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
"Journal of Pharmaceutical Science", vol. 66, 1977, pages: 2
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418
COLEMAN M.P. ET AL., PNAS USA, vol. 5, no. 17, 9 August 1998 (1998-08-09), pages 9985 - 90
ESSUMAN K. ET AL., NEURON, vol. 3, no. 6, 9 March 2017 (2017-03-09), pages 1334 - 43
ESSUMAN, K. ET AL., NEURON, vol. 93, no. 6, 22 March 2017 (2017-03-22), pages 1334 - 43
GERDTS ET AL., SCIENCE, vol. 48, no. 6233, 3 April 2015 (2015-04-03), pages 453 - 57
GERDTS, J. ET AL., NEURON, vol. 89, 2016, pages 449 - 60
HENNINGER ET AL., BRAIN, vol. 139, 2016, pages 1094 - 3108
KANAMORI A. ET AL., AM. J. PATHOL., vol. 181, no. 1, July 2012 (2012-07-01), pages 62 - 73
KUROWSKA, Z. ET AL., J. PARKINSON'S DIS, vol. 6, 2016, pages 703 - 07
LYONS JA ET AL., EUR J OF IMMUNOLOGY, vol. 29, no. 11, 1999, pages 3432 - 9
SALVADORES, N. ET AL., FRONT. NEUROSCI., vol. 11, 2017, pages 451
SPROWL ET AL., PROC NATL ACAD SCI, vol. 110, no. 27, 2013, pages 11199
SUMMERS D. W. ET AL., PNAS USA, vol. 113, no. 41, 11 October 2016 (2016-10-11), pages E6271 - E6280
SUMMERS, D.W ET AL., J NEUROSCI., vol. 34, no. 28, 9 July 2014 (2014-07-09), pages 9338 - 50
WANG MS ET AL., ANN. NEUROL., vol. 52, no. 4, 2002, pages 442 - 7
YANG J. ET AL., CELL, vol. 160, no. 1-2, January 2015 (2015-01-01), pages 161 - 76

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220056013A1 (en) * 2020-08-24 2022-02-24 Disarm Therapeutics, Inc. Inhibitors of SARM1
JP7349046B2 (en) 2020-08-24 2023-09-21 ディスアーム セラピューティクス， インコーポレイテッド Inhibitor of SARM1
US11945796B2 (en) 2020-09-16 2024-04-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
US11629136B1 (en) 2021-07-28 2023-04-18 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
WO2023240084A3 (en) * 2022-06-06 2024-03-21 Denali Therapeutics Inc. Compounds, compositions, and methods
WO2024020188A3 (en) * 2022-07-21 2024-03-14 Amylyx Pharmaceuticals, Inc. Oligonucleotide compositions and methods thereof
WO2024026368A1 (en) * 2022-07-27 2024-02-01 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
US11970481B1 (en) 2023-10-04 2024-04-30 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors

Also Published As

Publication number Publication date
EP4192828A1 (en) 2023-06-14
US20240116901A1 (en) 2024-04-11
US20230339913A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
EP4192828A1 (en) Substituted pyridine derivatives as sarm1 inhibitors
US9783501B2 (en) Substituted quinolines as modulators of sodium channels
EP3027604B1 (en) Novel quinazolinones as bromodomain inhibitors
JP5966014B2 (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of diseases
JP5140577B2 (en) Hydroxysteroid dehydrogenase inhibitor
EP2519515B1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
US11724989B2 (en) MCT4 inhibitors for treating disease
JP6054868B2 (en) LSD1 arylcyclopropylamine based demethylase inhibitors and their medical use
US11945796B2 (en) Substituted pyridine derivatives as SARM1 inhibitors
WO2009117421A2 (en) Heterocyclic modulators of gpr119 for treatment of disease
EA016948B1 (en) Nicotinic acetylcholine receptor modulators
JP2009544625A (en) Benzothiophene inhibitors of RHO kinase
US20130045948A1 (en) Azocyclic inhibitors of fatty acid amide hydrolase
BG108070A (en) New pyrimidines
US11629136B1 (en) Substituted pyridine derivatives as SARM1 inhibitors
WO2019178324A1 (en) Amino-benzoisothiazole and amino-benzoisothiadiazole amide compounds
US11970481B1 (en) Substituted pyridine derivatives as SARM1 inhibitors
WO2024026368A1 (en) Substituted pyridine derivatives as sarm1 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21763435

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2021763435

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE